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The aims of this project were to (i) examine the extent and nature of pharmacy 
services for drug misusers in the south west of England; and (ii) to investigate the 
views and experiences of pharmacists who provide and clients who use such services 
with a view to describe the opportunities for improving and extending pharmacy based 
drug misuse services.
Methods
The extent of pharmacy based drug misuse services, pharmacist attitude and 
knowledge on aspects of drug misuse were examined using a self-completion 
questionnaire that was sent to 903 community pharmacies in the south west of England. 
The views and experiences of pharmacists’ (n=31) and service users (n=15) were 
examined using qualitative semi-structured in depth interviews.
Results
The response rate to the postal questionnaire was 78.3% (n=707). 19.1% 
(n=135) respondents were prepared to sell injecting equipment and currently did so. 
One hundred and seven respondents (15.1%) participated in a needle/ syringe exchange 
scheme. 69.2% (n=489) reported dispensing methadone with 70.1% of these (n=434) 
reporting that they supervised consumption.
Pharmacists who provided drug misuse services had a more positive attitude 
score, than those who did not, and pharmacists who sold injecting or who participated 
in a needle exchange scheme tended to have a higher level of knowledge on aspects of 
drug misuse.
Interviews with pharmacists’ revealed that important factors in the delivery of 
drug misuse services were the sharing of information with other health care 
professionals, support to provide services, and training. The prescribing of controlled 
drugs by pharmacists was identified as a possible extension to their current role.
The provision of adequate training to pharmacists was viewed as an important 
facilitator to the provision of drug misuse services whilst the lack of training and 
understanding of the area was seen as a potential barrier.
Service users tended to view pharmacists a ‘dispensers of medication’ rather 
than potential experts in the field of drug misuse. They described strong mixed 
experiences of pharmacy services. Pharmacist prescribing was generally welcomed as a 
way of increasing the availability of treatment with the reassurance that such 
pharmacists were adequately trained.
Conclusions
The project has provided an assessment of the extent and nature of drug misuse 
services provided by pharmacists in south west England. It is clear that pharmacists are 
contributing much to the provision of community-based drug misuse services, however 
they could be better supported and more integrated. Negative attitudes were still 
apparent and service users shared mixed views of pharmacists.
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Chapter One - Introduction
1.1. THE ROLE OF THE PHARMACIST IN THE MANAGEMENT OF DRUG 
MISUSE
The importance of the community pharmacist in the delivery of care to drug users has 
been highlighted in the current clinical guidelines for the treatment of drug dependence 
(Department of Health, 1999) and in the Working Party on Pharmaceutical Services to 
Drug Misusers (RPSGB, 1998) as well as in other key documents including Advisory 
Council on the Misuse of Drugs (1988), Polkinghome (1996) and Nakajima and 
Steinbach (1997).
Community pharmacists dispense methadone and other drugs on prescription to people 
dependent on opioids and if required by the prescriber, may supervise consumption of 
these drugs. Attending the pharmacy on a regular basis means that clients have regular 
access to a healthcare professional who can provide support and advice. As the 
pharmacist will often see the client more than the prescriber, a suitably trained and 
motivated pharmacist is in an excellent position to provide feedback on an individual’s 
progress and may be able to provide brief interventions to aid a client through their 
treatment.
The aim of this thesis is to explore the extent of community pharmacy involvement (in 
the South West of England) in the care of people who misuse drugs with a view as to 
how this involvement could be extended, therefore this introduction will examine the 
extent of illicit drug misuse in England, and the strategies employed to manage the
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harm associated with problematic drug use, with particular regard to the role of the 
pharmacist.
Chapter One - Introduction
1.2. ILLICIT DRUG USE
1.2.1. Prevalence of Illicit Drug Use in England and Wales
The use of illicit drugs in England and Wales appears to be an increasing problem; 
however estimating the extent of the problem is difficult because of the illegal nature of 
illicit drug use. The British Crime Survey (BCS) is a self-completed survey carried out 
by the Home Office which asks respondents about their experiences of crime. Since 
1996 it has also contained a comparable self-completion section on illicit drug use. In 
2003/2004, 24,442 people respondent to this section with a further 2332 young people 
aged 16-24 who were also interviewed as part of the BCS.
The survey reports that cannabis is the most frequently used illicit drug in England and 
Wales. There was a significant increase in Class A drug use since 1998, mainly due to 
an increase in the use of cocaine and ecstacy, and an increase in the number of people 
aged 25-59 who take Class A drugs. It estimates that of all 16-59 year olds, 35.6% had 
(ever) taken an illicit drug and 12.3% had taken one or more illicit drugs within the last 
year. By extrapolating the data to the whole population, it was estimated that 500,000 
people had used one or more ‘Class A’ drugs in the month before responding to the 
survey with 28,000 of all Class A users reporting using heroin in the last month.
The BCS has some limitations in its ability to reliably report rates of drug use.
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As a household survey, the BCS does not cover some small groups, potentially 
important given that they may have relatively high rates of drug use, for example, the 
homeless, and those living in certain institutions such as prisons or student halls of 
residence. Nor, in practice, will any household survey necessarily reach those 
problematic drug users whose lives are so busy or chaotic that they are hardly ever at 
home.
Extrapolation of the results to the entire population is difficult, as a subsequent analysis 
of the BCS suggested that there was an inverse relationship between household income 
level and response rate with lower income households being less likely to respond. 
Extrapolation may therefore dilute the potential influence of lower income households 
on the prevalence of illicit drug use. (Elliot, 1997)
The National Drug Treatment Monitoring System (NDTMS) provides information on 
the numbers of people in treatment, and the percentage of these who were retained in 
treatment in a given month. In 2005-2006 there were 181,390 users in contact with 
treatment services in England compared with 85,000 in 1988-89.
By definition, the NDTMS data gives information about the number of individuals in 
treatment at a point in time. It does not therefore give information about those people 
using drugs but not receiving treatment. However, taken together, the results of the 
British Crime Survey and the statistics provided by the NDTMS suggest that the
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prevalence of illicit drug misuse is increasing with a rise in the number of people 
receiving treatment for their problematic drug use.
1.2.2. Illicit Opioid Use
The term opioid refers to a substance that mimics the effects of ‘natural’ opioids in the 
brain. Most of the commonly misused opioids are derived from the opium poppy 
Papaver somniferum. Morphine and diamorphine (heroin) are examples of such 
substances. Pharmacologically, morphine and diamorphine are agonists at the p-opioid 
receptor and are used medicinally for their potent analgesic properties. Other effects of 
these drugs include euphoria and a feeling of relaxation.
1.2.3. Consequences of Heroin Misuse
1.2.3.1. Consequences fo r the Individual
Regular use of heroin can lead to tolerance of its euphoric effects with increasing doses 
needed to get the same effect. Heroin is addictive and may cause physical dependence 
if used regularly. Withdrawal after regular use can produce unpleasant flu like 
symptoms and may include aches, tremor, sweating and chills and muscular spasms. 
These fade after 7-10 days but feelings of weakness and feeling ill may last longer. 
Whilst many people do successfully give up long term heroin use, coming off and 
staying off heroin can be very difficult.
Fatal overdoses can happen, especially when users take their initial dose after a break 
during which tolerance has faded, or when opiate use is combined with use of other
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depressant drugs such as an alcohol, tranquillisers or other opiates (Darke and Zador, 
1996) as regular heroin users may use other opiates or depressant drugs when they 
cannot get hold of heroin.
These consequences are not, however, inevitable, some individuals use heroin in an 
occasional and controlled manner, and in this way limit the harm associated with 
chaotic use. (Warburton et al, 2005)
It is often difficult to know exactly what is being taken because the purity of street 
heroin varies and it is often mixed with adulterants, however, street heroin purity in the 
United Kingdom has been estimated at approximately 50%. (source: IDMU.co.uk)
Injecting increases the risk of overdose and also puts users at risk of a range of 
infections including hepatitis B and C, and HIV if injecting equipment is shared. The 
physical effects of long term heroin use may include chronic constipation, irregular 
periods for women and possibly pneumonia and decreased resistance to infection. This 
can be made worse by poor nutrition, self neglect and bad housing. Regular injectors 
may suffer more health problems including damaged veins, heart and lung disorders.
I.2.3.2. Consequences fo r Society
Much has been made of the link between drug use and acquisitive crime. Actual rates 
are hard to ascertain, but results from the National Treatment Outcomes Research 
Study (NTORS) suggest that once individuals are in treatment, rates of acquisitive
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crime drop. Gossop et al (1999) report that their cohort of 753 patients reported more 
than 17,000 offences in the 90-day period before the start of the study, with 10% 
committing 76% of the reported crimes. The majority of the crime committed was in 
the form of shoplifting. In a comparable 90-day period, one year after commencing 
treatment 5632 crimes were committed representing a reduction of 67% from the 
number reported at intake, with the majority of these crimes being carried out by just 
10% of the sample.
The results of the National Treatment Outcomes Research Study are discussed in more 
detail in section 2.4.2 on page 29.
It is clear, then that the consequences of drug misuse reach beyond that of the 
individual and that where the treatment of individuals with problem drug use occurs, 
there is a benefit to society from the reduction in crime associated with drug use.
Whilst it is acknowledged that treatment of all problematic drug use will result in 
benefit to the individual and society as a whole, this study concentrates on the 
treatment of individuals who have become dependent on opioids.
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1.3. DRUG TREATMENT
1.3.1. Structure of Treatment Services in England
In 2001, in response to an increase in the prevalence of drug misuse in England, and a 
lack of a central co-ordinated approach to treatment, the Government created the 
National Treatment Agency (NTA), which is a special health authority, established to 
improve the availability, capacity and effectiveness of treatment for drug misuse in 
England.
The central aims of the NTA are to double the number of people in effective, well- 
managed treatment from 85,000 in 1998 to 170,000 in 2008 and to increase the 
proportion of people who successfully complete or, if appropriate, continue treatment. 
(Home Office, 2002)
At a local level, services to drug misusers are co-ordinated and purchased by Drug 
Action Teams (DAT). DATs are local consortiums that bring together representatives 
of some the local agencies involved in tackling the misuse of drugs, including primary 
care trusts, local authority, police and probation services. There are 149 DATs in 
England covering all local authorities, (source: www.nta.nhs.uk)
The NTA is responsible for monitoring the effectiveness of the DATs, for example, all 
DATs should be able to provide drug misusers with access to advice and information,
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needle exchanges, counselling, community based prescribing, inpatient detoxification 
and residential rehabilitation.
This system of local agencies providing a local response to a central target should result 
in resources being targeted to the needs of the community which the DAT serves. 
However, as DATs are made up of a variety of local agencies (criminal justice and 
medical) it could be argued that the priorities of tackling drug misuse in the local area 
will vary depending on the over-riding structure of the DAT. Thus if a DAT is 
primarily made up of representatives with a medical background then the focus may be 
on treatment. If however, as is sometimes the case, a DAT has mainly criminal justice 
focus then it may concentrate more on crime and crime reduction initiatives rather than 
treatment.
1.3.2. Primary Care Services for Drug Misusers
The majority of services for drug users are based in the primary care sector, as has been 
advocated by the National Treatment Agency in the document ‘Models of Care for 
Substance Misuse Treatment’ (Department of Health, 2002) and in the current Clinical 
Guidelines for the Management of Drug Dependence (Department of Health, 1999). 
One of the key principles of this document is that “Medical practitioners should not 
prescribe in isolation, but should seek to liaise with other professionals who will be 
able to help with factors contributing to an individual’s drug misuse. A 
multidisciplinary approach to treatment is therefore essential.”
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Drug users seeking treatment may receive assistance from their GP who may undertake 
to prescribe substitute medication alone, or in conjunction with a ‘shared care’ 
agreement. Support and the development of a treatment plan may be provided by a 
‘liaison worker’ who will see the client on a regular basis. Alternatively, the GP may 
refer a drug user seeking treatment to a secondary care ‘specialist’ service which is 
overseen by a consultant. The type and availability of drug treatment is monitored by 
the NTA, and varies throughout the country, with a wide variation in the waiting times 
for treatment. For example, the waiting time for a ‘specialist’ clinic in Bristol was 1.9 
weeks in September 2005 or 3.0 weeks for a GP-led service whilst in Torbay, the wait 
for a ‘specialist’ clinic was 15.8 weeks with no GP-led services available. (NTA, 2005)
1.3.3. Drug Treatment of Opioid Dependence
In the United Kingdom, substitution therapy with methadone is the most common form 
of treatment for opioid dependence. The aim of methadone treatment is to improve the 
quality of life of opioid dependent people and to reduce the potential harm from using 
illicit drugs. (Ford et al, 2005) The evidence for methadone and other treatments for 
opioid dependence are reviewed in sections 2.3,2.4 and 2.5 on pages 26-36.
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1.3.4. Prescriptions for the Treatment of Opioid Dependence
Analysis of Prescribing Analysis and Cost (PACT) data shows that the number of 
prescriptions for methadone issued by General Practitioners in England has increased 
by a factor of over 25% between 2002 and 2004 (770,453 in 2002 and 1,047,118 in 
2004) although it is acknowledged that a small proportion of these prescriptions may 
have been for conditions other than opiate dependence. The number of prescriptions 
issued for buprenorphine has increased by over 50% (207,915 in 2002 and 432,304 in 
2004) however it is similarly acknowledged that a proportion of this total is the 
prescription of low dose buprenorphine for pain relief.
As increasing number of prescriptions for methadone and buprenorphine are being 
issued for dispensing in a community pharmacy, it follows that more community 
pharmacists are becoming involved in the care of drug misusers. In 1998, a Working 
Party on Pharmaceutical Services for Drug Misusers (RPSGB, 1998) made 59 
recommendations on improving community pharmaceutical services to drug misusers. 
The Party recommended that the way forward was to ensure that better use was made 
of the existing network of community pharmacies.
However, at the time that this work was started, there was little acknowledgement by 
the NTA of the importance of the role of the pharmacist in the care of drug users in 
their key ‘Models of Care’ document. Although the NTA frequently refers to the 
dispensing of methadone, supervision of consumption and the provision of needle
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exchange it does not pay any specific attention to pharmaceutical care service models 
or development.
It is suggested that as the community pharmacist will often see the client more 
frequently that the prescriber, they are vital to ensuring that the National Treatment 
Agency’s 10 year drug strategy is implemented. Other models of providing treatment, 
for example, nurse dispensing within specialist drugs services do not have the capacity 
to meet the needs of the entire population. With a network of primary care prescriptions 
for methadone being written by GP’s and dispensed by community pharmacists, with 
additional counselling and feedback provided by the pharmacists to support the care 
given by the GP and drugs worker, the secondary care ‘Specialist’ teams can focus on 
more complex needs cases.
1.3.5. Clinical Governance
Clinical governance provides a framework through which the quality of service 
provision and standards of care continuously improve. The clinical governance 
guidelines for community pharmacy clearly see community pharmacy services as part 
of the NHS and community pharmacists as being accountable for the publicly funded 
services that they provide (Department of Health, 2001). An important part of clinical 
governance is reviewing current standards of service provision and identifying 
opportunities for service development. This may include quantifying the extent of 
service provision with the aim of identifying if levels of service provision are sufficient 
to meet need, and improving quality of care e.g. implementing risk management
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strategies, ensuring staff are appropriately trained. The identification and sharing of 
good practice is a fundamental principle of clinical governance. It is therefore 
somewhat surprising that the Models of Care document produced by the NTA lacks 
information on the standard of care provided by pharmacists to drug misusers.
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1.4. THE EXTENT OF PHARMACY INVOLVEMENT IN THE CARE OF 
DRUG MISUSERS
The extent to which pharmaceutical services in England are provided to drug misusers 
was last quantified in 1995 (Sheridan et al, 1996). Since this time there have been 
many developments in drug misuse treatment provision with the establishment of the 
NTA, so a consequent increase in pharmaceutical involvement is predicted e.g. 
supervised consumption, although the extent of this has not been quantified. In a 
recently published study from Scotland this increase has been quantified. Matheson et 
al (2002) found the number people receiving methadone through pharmacies had 
increased by 259% between 1995 and 2000. The mean number of methadone clients 
per pharmacy had increased from 7.3 in 1995 to 13.2 in 2000 with 65% of all 
methadone clients under pharmacist supervision of consumption. The proportion of 
pharmacies that provide a supervised consumption service had increased from 37% to 
83%. Such large increases suggest that the 1995 data for England will now be out of 
date.
Detailed review of these studies can be found in section 2.7.2 on pages 42-54.
1.4.1. Quality of Pharmacy Services
As described briefly above, the majority of published work has concentrated on 
quantitative (numerical) measures of pharmacy services to drug misusers. Little work 
has been carried out on the quality of these services and how they are perceived by
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service users. Qualitative studies in this area are reviewed in section 2.8 and 2.9 on 
pages 55-66.
1.4.2. The Expanding Role of the Pharmacist
It is recognized that pharmacy services in areas other than drug misuse are expanding, 
for example cholesterol and blood pressure testing and Medication Use Reviews are 
being carried out by community pharmacists, with some setting up structured services 
to enable weight loss and smoking cessation. Recent changes in legislation now enable 
suitably qualified pharmacists to act as supplementary prescribers, and as pharmacists 
are often the healthcare professional in most regular contact with people who misuse 
drugs, there may well be the potential to expand and develop the range of services 
provided to drug misusers. However, to enable service development the views of the 
providers and users should be further researched.
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1.5. THE CURRENT STUDY
1.5.1. Motivation
The motivation for this study was three-fold. Firstly, as the last estimation of the extent 
of pharmacy services in England was over a decade ago, this study sought to update the 
literature of the extent and nature of services provided by community pharmacists to 
drug misusers. Secondly, at the projects conception in 2002, it was recognised that the 
NTA’s ‘Models of Care’ document lacked specific description, detailing the expected 
quality of pharmacy services, and finally it was recognized that in order for pharmacy 
services to drug misusers to be expanded and developed, the views of service providers 
and services users on the current service and future expansion should be considered 
with the addition of qualitative work to the literature.
1.5.2. Location of the study
The study was based in the South West of England with the whole population of 
community pharmacies in the three Strategic Health Authority areas of Avon, 
Gloucestershire and Wiltshire; Dorset and Somerset and the South West Peninsula 
included in the research.
The South West is made up of large urban, small urban, suburban, small town and rural 
areas with a diverse urban population and is home to nearly 5 million people from a 
total population of 49 million in England. There are 903 community pharmacies in the 
South West which is 8.6% of the total number of pharmacies in England. The most
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recent statistics from the National Treatment Agency indicate that there are nearly 
17,000 drug users in treatment in the South West, which is approximately 10% of the 
total number of drug misusers in treatment in England (160,450 in 2004/2005). English 
national drug policy and funding systems apply, as do national pharmaceutical practice 
guidance so whilst extrapolation of the data to the whole of England will not be 
attempted, the figures quoted above suggest that approximately 10% of the total 
population of community pharmacies have potential contact with approximately 10% 
of the total number of drug misusers in treatment.
1.5.3. The Literature Review
The following chapter contains a review of the literature on pharmacy based drug 
misuse services and on previous surveys that have attempted to quantify these services. 
At the end of the literature review a series of research questions are generated which 
form the objectives for the research conducted in this thesis.
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2.1. SEARCH STRATEGY
The bibliographic database EMBASE was used to assist this literature review. 
EMBASE includes journals with a bioscience and pharmacy background and includes 
journals with a psychiatric focus. The database was searched in a systematic manner, 
and the searches described below were carried out bi-monthly to ensure that any new 
articles were picked up.
The results of the final search (conducted in May 2006) are summarised in the tables
below.
Keyword Number of Articles
Drug Abuse 28708
Drug Misuse 2213
Drug Dependence/ addiction 20883
Substance Abuse 14686












Table 1; Results o f keyword search from  Embase 1980-2006 (week 23)
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Next, the keywords above were combined in a systematic manner to obtain articles 
most relevant to the review. These combined searches are summarized in the following
table.
Combination of Keywords Used Number of Articles
Drug Abuse AND Pharmacist 150
Drug Misuse AND Pharmacist 140
Drug Dependence AND Pharmacist 134
Substance Abuse AND Pharmacist 42
Heroin Dependence AND Pharmacist 22
Methadone AND Pharmacist 170
Methadone Treatment AND Pharmacist 28
Harm Reduction AND Pharmacist 3
Drug Abuse AND Pharmacist AND Attitude 3
Heroin Dependence AND Pharmacist AND Attitude 1
Methadone AND Pharmacist AND Attitude 3
Harm Reduction AND Pharmacist AND Attitude 0
Methadone AND Users Views 4
Supervised Consumption OR Pharmacist AND Users Views 1
Methadone AND Pharmaceutical Care 6
Table 2: Results o f  combination search from  Embase 1980-2006 (Week 23)
Following the keyword and combination search, a search of names of known important 
authors in the subject was performed. The results of the search are summarised below.





Table 3: Results o f author search from  Embase 1980-2006 (Week 23)
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The results of the combined and author searches were then studied-on a citation-by- 
citation basis, and from this the reference list was obtained. Criteria for exclusion from 
the primary reference list were as follows:
1. Citation was not based on human studies.
2. Citation did not have drug misuse as its focus.
3. Drug misuse was the focus, but the drugs mentioned were not illicit or Over the 
Counter (OTC) medications.
The primary reference list was added to Reference Manager, a computer database 
program. At this stage those references that were deemed to be most relevant were read 
in detail.
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2.2. DRUG TREATMENT OF OPIOID DEPENDENCE
2.2.1. Drugs licensed in the United Kingdom
The British National Formulary (BNF-51) lists four drugs that are licensed to treat 
opioid dependence in the United Kingdom. These drugs can be classified as follows.
2.2.1.L Substitute Medication
This term refers to the use of these drugs as a substitute for the illicit drug on which the 
individual is dependent. The aim is, therefore, to prevent the onset of withdrawal 
symptoms. These drugs are also opioids and as such have the potential to cause 
dependence. The two drugs licensed for substitution therapy are methadone and high 
dose buprenorphine.
2.2.1.2. Adjunctive Medication
This term refers to those drugs which are used as an add on to substitute treatment to 
alleviate symptoms of withdrawal in those whose opioid use is under control and who 
are undergoing detoxification (lofexidine), or to block the actions of opioids and 
precipitate withdrawal in opioid dependent individuals (naltrexone). The latter drug is 
often given to recovered addicts as an aid to prevent relapse.
2.2.2. Drugs not licensed in the United Kingdom
Diamorphine and lambda-alpha-acetylmethadol (LAAM) are both substitute 
medications which are not licensed for the treatment of opioid dependence in the UK,
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however, diamorphine (in the injectable form) is used by some treatment centres in the 
UK.
There now follows a more detailed review of substitute medication.
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2.3. METHADONE
Dole and Nyswander pioneered methadone maintenance therapy (MMT) in 1965. Since 
then a number of articles have reviewed MMT based on a number of outcomes. Such 
review articles are Farrell et al (1994), Ward et al (1999) and Marsch (1998).
The effectiveness of MMT has been judged on the following criteria,
1. Reduction in illicit opiate use
2. Reduction in crime
3. Reduction in HIV risk behaviours
These criteria will now be discussed in more depth.
2.3.1. Reduction in Opiate Use
An early trial (Dole et al, 1969) comparing MMT to a no treatment control suggested 
that subjects in the control group were 92 times more likely to be using heroin daily 
than those in the methadone group. More recently, Hutchinson et al (2000) reported 
that in a one-year cohort study of a group of 204 opiate injectors, 29% of the initial 
group remained on methadone for the 12-month period, and in that group, self-reported 
opiate injecting reduced from 78% to 2%. Lewis and Beilis (2001) found that 56% of 
clients being treated in a general practice setting still had some form of illicit drug use 
compared with 100% at the start of treatment (mean length of treatment was 15 
months).
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In a meta-analysis of 11 studies investigating the effect of MMT on reducing opiate 
use, Marsch (1998) found that all 11 studies reported that MMT significantly reduced 
illicit drug use (r=0.35), although the margins by which this occurred varied greatly, 
and were dependent on sample size. Taking the results of this statistical analysis into 
account, Marsch derived that, based on a sample size of 200, approximately 135 (67%) 
may be expected to reduce their illicit drug use.
2.3.2. Reduction in Crime
Dole et al (1969) found that subjects in the control (no treatment) group were 53 times 
more likely to have been reincarcerated than those in the MMT group. Hutchinson et al 
(ibid) reported that in those drug users who remained on the program for 12 months, 
mean daily drug spend reduced from £50 to £4, and the mean number of monthly 
acquisitive crimes reduced from 13 to three.
A meta-analysis study that looked at the ability of MMT to reduce criminal behaviour 
(Marsch, 1998) revealed that overall; MMT had a small to moderate effect (r=0.25). 
However, the 24 studies to which the meta-analysis was applied differed in the type of 
criminal behaviour studied. Those studies looking at the reduction in drug related 
criminal behaviour revealed a significant large effect size (r=0.70), but a small effect 
(r=0.17) on non-drug related crimes. Marsch concluded that MMT treatment effects are 
restricted to reducing drug related crime, and that even whilst in treatment, some 
opiate-dependent individuals have the inclination to engage in crime that is not related
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to their drug use. Based on a sample of 200 people undergoing MMT, Marsch deduced 
that 170 (85%) would be expected to reduce their drug related criminal behaviour.
2.3.3. Reduction in HlV Risk Behaviours
Marsch’s meta-analysis of 8 studies also looked at the ability of MMT to reduce HTV 
risk behaviours, and revealed a small overall effect size of 0.22. However, when 
compared to the reduction in risky behaviour that would have occurred by chance 
(r=0.5), based on a sample of 200, it was calculated that 122 (61%) may be expected to 
reduce HIV risk behaviours whilst on MMT.
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2.4. EFFECTIVENESS OF METHADONE
2.4.1. US Trials
There have been a number of large scale US-based treatment outcome studies including 
the Drug Abuse Reporting Program (DARP), the Treatment Outcome Prospective 
Study (TOPS) and the Drug Abuse Treatment Outcome Study (DATOS). These studies 
have shown that patients who enter methadone programs can make significant 
reductions in their use of heroin and other illicit drugs (Hubbard et al. 1997;Simpson & 
Sells 1983)
There are differences between drug treatment programs in the US and those in England 
and Wales. There are cross national differences in the patterns of drug misuse, the types 
of treatment services provided and socio-economic factors. It is unclear, therefore how 
results from studies in the US can be generalised to England. For this reason the 
National Treatment Outcome Research Study (NTORS) was commissioned by the 
Department of Health, and it is this study which is focussed upon in this review.
2.4.2. National Treatment Outcome Research Study (NTORS)
NTORS was a large-scale longitudinal study of more than 1000 people in 31 
methadone programmes who entered these services in England during 1995. The 31 
treatment programmes were divided according to the goals of the service, either 
methadone maintenance or methadone detoxification. The study was designed to test 
whether methadone treatment was an effective means of reducing levels of illicit drug
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use and other problem behaviours such as intravenous injecting and acquisitive crime 
as has been demonstrated in previous studies in the USA.
Gossop et al (1998) reported that at intake, NTORS clients reported extensive problems 
related to long-term drug misuse. As well as heroin, many clients reported the use of 
other drugs such as benzodiazepines and non-prescribed methadone. Many clients also 
reported regular use of alcohol.
2.4.2.L NTORS Outcomes - Drug and Alcohol Use
At the one-year follow up stage, Gossop et al (1998) reported that clients had indeed 
reduced their consumption of heroin, stating that regular use (weekly or more frequent) 
reduced from 81% at intake to 49% after one year. Regular use of benzodiazepines and 
non-prescribed methadone was reported by approximately one-third of clients at the 
start of treatment and was reduced to under 20% after one year of methadone treatment.
At the two year follow up, there were further significant reductions in the use of heroin 
and other drugs, with no increases in the average frequency of use reported between the 
two follow-ups. (Gossop et al, 2002).
2.4.2.2. NTORS Outcomes - Injecting Behaviour
NTORS showed a reduction in the proportion of clients injecting drugs. This reduced 
from nearly two-thirds at the start of treatment, dropping to less than one half after one
- 3 0 -
Chapter Two -  Literature Review
year. There was also a reported reduction in the rates of sharing needles, from 13% to 
5% after one year.
2.4.2.3. NTORS Outcomes - Reduction in crime
Clients reported a high level of crime at the start of treatment. The authors of the study 
estimated that the cost of this drug related crime for the NTORS cohort totalled £12 
million in the year preceding treatment. After one year the levels of reported criminal 
behaviour were greatly reduced, with the proportion of methadone clients committing 
acquisitive offences reduced by half. In particular, shoplifting and burglary offences 
were reduced by 70%. These reductions in acquisitive crime were associated with 
reductions in the frequency of heroin use. After two years, there was a further (slight) 
reduction in acquisitive crime.
2.4.2.4. Interpreting the results o f  NTORS
NTORS concluded that clients treated in methadone programs showed improvements 
in their drug use, as well as a reduction in intravenous use of drugs and a reduction in 
acquisitive crime. These results are consistent with other US based studies. A welcome 
finding from the NTORS data is that reduction in drug use occurred in the early stages 
of treatment and appeared to be maintained after one and two year follow up.
However, any large scale multi-site study such as NTORS has shortcomings. The 
NTORS cohort was recruited by the treatment agency in which they started treatment. 
Fifty-four such agencies participated in the study and staff from those agencies were
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responsible for conducting interviews at the intake of clients, at one month and six 
month follow up stages. There was likely to have been considerable differences in the 
way the interviews were conducted, and as treatment agency staff carried out the 
interviews, the clients may have felt under pressure to give positive responses to 
questions in order that their treatment continued. Although participation in the study 
and subsequent responses to questions in no way jeopardised continuing therapy, the 
effect on the participant of being interviewed by a member of the agency staff cannot 
be ignored.
NTORS compared four treatment modalities: (i) inpatient units, (ii) residential 
programmes, (iii) outpatient/community based methadone reduction programmes and 
(iv) outpatient methadone maintenance programs. Patients were not randomised to the 
treatment options due to the way in which the study participants were recruited. 
Because of this there were differences in client characteristics between the four groups, 
for example clients in the inpatient and methadone maintenance programs had used 
heroin for longer than those in the methadone reduction services. Clients in the 
residential agencies tended to drink more heavily than those in other treatment 
modalities and tended to have more complex health problems than those in the 
community setting.
This makes overall comparison between the different treatment modalities difficult, and 
whilst clients treated in each of the four modalities showed improvement at one year it
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would not be possible to conclude that all clients would have improved after treatment 
in any of the four modalities.
There were no ‘control’ clients in any of the four treatment groups, so no conclusions 
could be made regarding the effectiveness of treatment intervention of any kind versus 
no intervention.
There was no mention in the NTORS study as to how the community programmes were 
organised. We do not know if all the clients’ treatment in the community modalities 
were expected to attend the clinic every day for a dose of methadone, or if some of 
these programmes involved community pharmacies. We also do not know if the clients 
in the community modalities were given methadone to take away of if they were 
required to consume their dose in front of the drugs worker or pharmacist.
After one year, the NTORS study stated that there ‘was considerable inter-agency 
variation in drug use outcomes with clients from the best performing agencies showing 
far greater improvement than those at the worst performing services.’ There is, 
however, no discussion about the characteristics of a service that yielded good results. 
This information would have been useful to inform treatment programmes how to best 
structure their approach to treatment.
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2.5. OTHER OPIOIDS USED IN THE MANAGEMENT OF DEPENDENCE
As the weight of the evidence is behind methadone, it has remained the mainstay of 
treatment of opioid dependence in the UK; however, other alternative agents have been 
used. These will be briefly discussed below.
2.5.1. Buprenorphine
Buprenorphine is a mixed opioid receptor agonist/ antagonist. As a partial antagonist, it 
reduces the risk of overdose, and its long half-life means that every-other day dosing is 
possible. This is less time-consuming for the patient, and helps to reduce treatment 
costs. Johnson et al (2000) reported that the percentage of patients with 12 or more 
consecutive opiate-negative urine samples was equivalent when comparing patients 
treated with buprenorphine and those treated with an adequate dose of methadone.
2.5.2. Injectable-Diamorphine Maintenance
Injectable-diamorphine maintenance treatment has been proposed as a way of attracting 
heroin users into treatment through the provision of their preferred drug, heroin (Ward 
et al, 1999). Some drug users already on a MMT program would rather use injectable- 
heroin as a way of stabilising their drug use, (P.Anson, personal communication). 
Reasons for this include the perceived difficultly in breaking the ‘needle habit’ 
associated with long-term intravenous drug use. (McBride, 2001)
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Perenger et al, 1998 reported on a randomised trial of a heroin maintenance program 
for addicts who had failed in at least two previous drug treatments. Eligible patients 
were randomised into two groups. The first group received maintenance doses of 
heroin (usually three times a day) at doses established by a psychiatrist. The control 
group were enrolled onto other conventional drug treatment programs, with the option 
of transferring to the heroin maintenance program after six months. Both groups were 
followed up after six months. Those in the ‘heroin’ group reported less use of ‘street 
heroin’ that the control group, and the mental health status of those in the heroin group 
improved significantly more than the control group. The authors suggested that a 
heroin maintenance program may be a feasible alternative for severely addicted opiate 
users, although they did note that after the six month trial only 38% of the control 
group decided to change to heroin maintenance.
This study was on a very small scale (57 participants) and the authors concede that this 
threatens the reliability of the findings. The outcomes measured in this trial were all 
self-reported which can introduce bias.
Injectable-heroin maintenance is unlikely to gain much ground on traditional forms of 
treatment for drug addicts (i.e. methadone). It is likely to be more costly than MMT, as 
in the trial reported above, clients went to the clinic up to three times a day, and were 
observed for thirty minutes before being allowed to leave. In contrast methadone is 
usually given as a single daily dose, as it has a longer half-life than heroin.
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Luty (2003) argues that prescribing injectable heroin to addicts is ‘unproven, unpopular 
and unbelievable.’
It may, however, be an alternative for those addicts who are resistant to conventional 
treatment.
2.5.3. Lambda-alpha-acetylmethadol (LAAM)
LAAM is a longer acting opioid agonist than methadone and has the same advantages 
of buprenorphine in terms of alternate day dosing and cost effectiveness. Johnson et al 
(ibid) found LAAM was equally effective at reducing illicit opiate use, measured by 
urine testing. However, continued participation in the trial was significantly more 
frequent in those patients receiving adequate doses of methadone than those patients 
being treated with LAAM.
The EU licence for LAAM was withdrawn in April 2001 following evidence that the 
drug prolongs the QTc interval.
Chapter Two -  Literature Review
2.6. CHARACTERISTICS OF TREATMENT PROGRAMMES
2.6.1. Maintenance or Abstinence?
Dole and Nyswander’s original model of methadone maintenance treatment called for 
high doses of methadone coupled with a long duration of treatment and intensive 
rehabilitation therapy, however, the goal of many programmes has moved from 
maintenance towards abstinence from all opioid drugs (Ward et al, 1999).
The decision to detoxify the client is based on a number of factors, such as evidence of 
positive behaviour change and low levels of ‘life stress’. However, it should only be 
considered after at least one year in maintenance treatment. (Law and Dean, 1997).
Ward et al (1999) suggest that the effectiveness of MMT is reduced when there is a 
reduction in the dose of methadone, and when clients are under pressure to become 
abstinent.
Farrell et al suggest that methadone maintenance programmes vary substantially in 
their effectiveness. In a study of six methadone clinics, illicit drug use was reduced to 
10% in the most effective clinic, to just 56% in the least effective. Effective clinics 
were generally prescribing higher doses of methadone and had a treatment goal of 
maintenance rather than abstinence.
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2.6.2. Dosage of Prescribed Methadone
Johnson et al (2000) reported that high doses of methadone (60-100mg) were 
significantly more effective at reducing illicit drug use, measured by urine analysis and 
self-reporting, than the control group (low dose, 20mg methadone). Retention in the 
trial was significantly greater for the high dose methadone group (105 ± 4 days) than in 
the low dose group (70 ± 4 days).
Law and Dean (ibid) suggest that program factors that include a low average level of 
methadone dosage, shorter duration of methadone maintenance and low levels of 
ancillary services such as counselling and employment help are associated with a poor 
prognosis for the client. They also argue that some clients may never be suitable for 
detoxification from opiates, but should continue to receive treatment on the basis of a 
harm reduction stand.
Newman (1996) argues that addiction to opiates is a chronic disease, and should be 
managed thus. He argues that ‘methadone is simply a medication and should be used 
like one’ He states that most diseases we treat defy cure (e.g. schizophrenia) but even 
so, long term treatment are still provided. Newman also states that there are too many 
rules, regulations and negative attitudes imposed on those clients in MMT and that this 
‘degrades’ the process of methadone treatment. However, Newman does not take into 
account the characteristics of drug users that sometimes prompt ‘rules and regulations’ 
regarding methadone treatment. Nevertheless, it does prompt an interesting debate as to 
whether opiate dependent users should be ‘detoxed’ at all.
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2.6.3. General Practice or Drug Clinic?
Lewis and Beilis (2001) compared the outcomes of MMT patients treated in general 
practice or a drug clinic over a two-year period. They found that patients in general 
practice were more likely to be in treatment at the end of the study than those treated by 
the clinic (71% and 27% respectively) and patients in general practice were more likely 
to be tested for and immunised against hepatitis B.
The general practitioners (GPs) in this study worked closely with community 
psychiatric nurses (CPNs) and were all interested in drug dependence, and were 
supported by the local health authority to provide treatment to drug users. This is an 
example of a ‘shared care’ agreement which suggests that general practice is as good as 
drug clinics at keeping drug users in MMT. However, differences in the client profile 
may have influenced these results as drug clinics are more likely to see the more 
difficult to treat client, such as a chaotic or poly drug user or with co-morbid 
psychiatric disorders.
The authors do however point out that not all GPs wish to treat drug users and some do 
not consider primary care as an appropriate setting. This suggests that in other areas, 
where the existence of shared care guidelines is limited, the drug clinic may be better at 
keeping clients in treatment.
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In the UK, the Royal College of General Practitioners has recently updated it’s 
guidance on the use of methadone for the management of drug dependence in the 
primary care setting (Ford et al, 2005).
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2.7. PHARMACEUTICAL CARE OF DRUG MISUSERS
2.7.1. Definition of Pharmaceutical Care
The term ‘Pharmaceutical Care’ was defined by Hepler and Strand (1990) as the 
‘responsible provision of drug therapy for the purpose of achieving definite outcomes 
that improve a patient's quality of life. These outcomes are (i) cure of a disease; (ii) 
elimination or reduction of a patient's symptomatology; (iii) arresting or slowing of a 
disease process; or (iv) preventing a disease or symptomatology.’
Challenges to this original definition have been made; Barber (2001) argues that Hepler 
and Strand’s original definition is focussed on the patient’s disease rather than the 
patient. He suggests that this definition of pharmaceutical care is no different to that of 
medicines management, since the outcomes are all related to the provision of drug 
therapy.
2.7.1.1. Pharmaceutical Care o f Drug Misusers
Pharmacists dispense methadone and other opioid substitutes to opioid dependent drug 
misusers and if requested by the prescriber, may supervise the consumption of the daily 
dose. These services fall within the criteria of Hepler and Strand’s definition of 
pharmaceutical care.
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However, providing clean injecting equipment and advice to drug users are activities 
that are outside the original definition, as they are not related to the provision of drug 
therapy.
2.7.2. Survey of Pharmacists: Provision of Pharmaceutical Services to Drug Users
There have been a number of studies that have attempted to quantify the level of 
community pharmacy involvement in the care of drug misusers in the UK. These are 
now reviewed in detail below.
2.7.2,1. England and Wales -  National surveys
The first major study of community pharmacists’ involvement in the provision of 
pharmaceutical services to drug users was carried out by Glanz et al (1989). The study 
set out to determine the current and potential roles of community pharmacists in the 
prevention of AIDS among injecting drug users (IDU). Glanz surveyed a one in four 
random sample of registered pharmacies in England and Wales and a response rate of 
79% was achieved after three mailings. As this fell short of the target sample of 1 in 4 
pharmacies, Glanz choose to correct for non-response by applying weighting to his 
results. The assumption was therefore made that non-responding pharmacies would 
respond in a similar manner to responding pharmacies.
The study found that 23% of pharmacies surveyed were dispensing controlled drugs to 
an estimated 7700 injecting drug users. 75% of pharmacies surveyed would be 
prepared to sell clean injecting equipment to known or suspected IDUs, and that 28%
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of pharmacies surveyed were currently selling clean injecting equipment. This was 
then extrapolated to the whole population of pharmacies in England and Wales and 
Glanz suggested that some 7000 pharmacies could be outlets for injecting equipment 
whilst some 2700 already were.
Glanz also measured the pharmacists’ attitude to some statements concerning the 
pharmacist’s role in the prevention of AIDS. He found that those pharmacists who were 
already supplying injecting equipment to drug users and those who were willing to 
supply had a more positive attitude score that those who were not willing to supply. For 
example the proportions agreeing or strongly agreeing to the statement that drug 
misusers visiting the premises would have a damaging effect on business were 61% 
(current suppliers), 63% (willing suppliers) and 90% for those pharmacists who were 
not willing to supply.
A significant assumption was made in this study; this was that non-respondents would 
reply in a similar manner to those who chose to respond to the study. This assumption 
is flawed. One must consider why an individual may choose not to respond. As Glanz 
acknowledges in the appendix of the paper, analysis by mailing wave showed a 
tendency for response to be more negative in later response waves, with 76% of first 
mailing respondents prepared to sell clean injecting equipment compared to 64% of 
third mailing respondents. Perhaps those pharmacists who did not respond had no 
interest in the prevention of HTV or felt that the questions being asked were not 
relevant to them, and therefore did not respond. An understanding of the effect of ‘non­
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response bias is important, especially as the authors decided to extrapolate their 
findings to the whole population. Such extrapolation of the results of a 1 in 4 sample to 
the whole population of pharmacies presents some difficulties. The differing 
demographic profile of England and Wales means that there are likely to be areas of 
high involvement, such as in the London area where an average of 36% of pharmacies 
survey were selling injecting equipment, as well as areas of low involvement such as 
Wales where only 11% of pharmacies were selling injecting equipment. Bearing these 
differing levels of involvement in mind, it is therefore impossible to make assumptions 
about the whole of England and Wales based on this sample.
In 1996, Sheridan et al (1996) published the results from the second such survey of 
community pharmacists, eight years on from Glanz’s original work. The questionnaire 
used was based on that of Glanz (1989), using the same one in four sample size. The 
response rate obtained was 74.8% after four mailings, slightly less than Glanz (79%) 
eight years previously. Sheridan, however, did not apply weightings in an attempt to 
correct for non-response.
Sheridan found that 50.1% of pharmacies were dispensing to an estimated 30,000 drug 
users, compared with 23.0% in 1988, and that 34.4% of pharmacies surveyed were 
currently selling injecting equipment to users compared with 28.0% in 1988. The 
number of pharmacies willing to sell injecting equipment remained unchanged (73.9% 
in 1995 and 74.0% in 1988).
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Sheridan did not attempt to extrapolate these results to the entire population of 
community pharmacies, but at the same time did not acknowledge that comparison of 
these latest figures with those of Glanz (1988) should be treated with caution because 
of the data manipulation required due to the weightings applied to the 1988 data.
This caution was however acknowledged in a later paper, Sheridan et al (1997) where 
the attitude component of the questionnaire was reported. The attitude statements used 
in the 1995 survey were similar to that of the 1988 survey and a cautious comparison 
was made. Sheridan (1997) noted that there was very little shift in attitude in the eight 
years between the two surveys. More respondents in 1995 tended to agree that they 
needed training in areas around drug misuse, and that they had a positive role to play in 
the prevention of HTV and AIDS, however, slightly more pharmacists in 1995 agreed 
with the statement that drug misusers have a damaging effect on business. Sheridan 
does however acknowledge that it is uncertain to what extent these small shifts in 
attitude are due to the questionnaire differences. A direct comparison should only be 
made if the questionnaire remains the same.
The use of attitude data in this paper was limited, and there was no attempt to correlate 
attitude with service provision.
The extent of non-response bias in this survey was investigated by Sheridan and Strang 
(1998). In the original 1988 survey, Glanz followed up his initial mail shot with two 
further reminders sent out at weekly intervals. In the survey carried out eight years
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later, Sheridan used an additional mail shot to further increase the response rate. As has 
already been discussed, the missed responses from those who chose not to respond to 
the questionnaire are of important consideration if the intention is to extrapolate the 
results of a sample to the entire population.
To examine the non-response bias in the 1995 postal survey of community pharmacists, 
Sheridan (1998) followed up non respondents with a short telephone interview. They 
found that significantly less of the ‘telephone’ group dispensed controlled drugs for the 
treatment of addiction when compared to the ‘postal group’ (60.8% and 49.9% 
respectively). Interestingly, significantly more of the telephone group were selling 
clean injecting equipment than those in the postal group. (51.2% and 34.5% 
respectively). The authors concluded that on the basis of the statistical difference 
between the postal responders and non-responders (telephone follow-up) it would have 
been misleading to extrapolate the results of the postal survey to the entire population 
of community pharmacies.
Sheridan and Barber (1998) also looked at the addition of a fourth mail shot as a means 
of increasing the response rate to the postal questionnaire used in the 1995 survey. 
They compared the results of mail shots 1-3 to the fourth and final mail shot. They 
found no statistical difference between the two groups either on demographics or 
service provision and concluded that the addition of this fourth mail shot had no effect 
on the overall results. They stated that the addition of this final mail shot only increased 
the overall response rate by 4.8% and that in this particular study did not particularly
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improve the representativeness of the results, as a high response rate (70%) had already 
been achieved after three mail shots. However, in a study where a poor initial response 
has been obtained, further mail shots may be required in order to reach a reasonable 
response rate of 60-70%.
2.7.2.2. England and Wales -  Local Surveys
The difficulty in extrapolating national survey results such as those from Glanz (1989) 
and Sheridan (1996) is highlighted by the following two studies.
McBride et al (2001) reported the results of a small scale survey of a population of 
community pharmacists in the Bro Taf health authority. This postal based questionnaire 
study achieved a response rate of 89% after an initial mail shot followed by telephone 
reminders and additional mailings to non-responders.
In this survey, 23% of respondents participated in a needle exchange scheme, with 55% 
of pharmacists willing to sell injecting equipment. 55% of respondents currently 
dispensed controlled drugs for the treatment of drug misusers, with 25% supervising 
methadone consumption in the pharmacy. A further 31% of respondents reported that 
they did not currently have any clients on supervised consumption.
The results of this survey were compared to a study carried out 10 years previously, 
(McBride et al, 1993). The authors recognise that the study carried out in 1990 and 
1991 was different, both in areas covered and details of the questionnaire. However, a
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comparison was made, and the authors reported that there has been little change in the 
level of pharmacy based service provision for drug users in the Bro Taf health authority 
area.
Luger et al (2000) published the results of a small scale study which looked at the 
involvement of community pharmacists in the supervision of methadone consumption 
in a pilot scheme in Camden, London. The aim of the study was to assess the feasibility 
and acceptability of providing a supervised consumption of methadone service from 
local community pharmacies. A number of social research methods were employed 
during the study, semi-structured questionnaires, focus groups, in-depth interviews and 
telephone interviews. This study has a number of flaws.
Firstly, clients with a history of alcohol and/ or chaotic drug use were excluded from 
the scheme. Later, the authors report that “While bad experiences, such as verbal abuse, 
theft or violence, were reported from non-supervised methadone clients or other illicit 
drug users, the supervised clients were generally considered as well selected, well 
informed as to regimes, well behaved, more stable than some other drug using clients.” 
This observation is inevitable as the exclusion criteria of the study selected only those 
clients who were reasonably well adjusted.
MMT and supervised consumption are methods by which a drug users life can be made 
less chaotic and therefore one could argue that this study has selected against those 
clients for whom supervised consumption may have a positive benefit.
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Secondly, it would appear that the researchers made an apparent attempt to triangulate 
the responses of the client and their respective drugs worker and pharmacist was made 
during the in-depth interview section, however there is no mention of this triangulation 
in the results.
Thirdly, the small scale of this study made it difficult to include any meaningful 
descriptive statistics, and none were attempted in this report. Instead, vague statements 
such as “On the whole....”, “The majority of....” and “The great majority of.....” were 
used to describe the data.
The 17 pharmacists who were recruited for this study were done so on the basis of their 
experience in dispensing for drug users, their geographical location and proving 
acceptable facilities for dispensing at their premises. The pharmacists were given a 
days training on many aspects of drug misuse, in order to fully equip them with the 
necessary skills to deal with drug using client. In spite of this training, ‘a third’ of 
pharmacists found it difficult to cope with methadone patients. The authors did not 
however question the suitability of the training, nor did they question the feasibility of 
such training should the scheme be adopted across the whole of the Trust area. It is 
uncertain what ‘acceptable facilities’ means, what it does not mean is a private area for 
consumption of methadone since this was later reported as being an issue for 60% of 
the clients in the study.
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The conclusions drawn from these limited results were that supervised consumption of 
methadone was an effective use of resources and a viable method of substitute drug 
treatment for opiate users.
This paper reported on a very small study, and one which could not be analysed by 
anything but the most basic statistics. Any conclusions drawn from these results should 
be treated with caution.
2.7.2,3. Scottish Surveys
Matheson et al (1999) reported on a postal survey of the entire population of Scottish 
pharmacies. The survey was carried out in 1995, and contained demographic 
information as well as questions about provision of services to drug users and a 
significant section on attitude.
A response rate of 79.1% was achieved with two reminders. Questions around the 
provision of sterile injecting equipment revealed that only 8.8% of those pharmacists 
who replied provided a needle exchange service. 17% of those surveyed sold needles 
and syringes with a further 36.9% willing to do so but reporting that there was no 
demand.
Methadone was dispensed by 53.2% of respondents, and of these 35.4% supervised 
consumption, with the mean number of clients per pharmacy at 7.3.
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Matheson used the results obtained form the survey to correlate service provision with 
attitude. The responses to twenty-seven statements on the theme of drug misuse, 
pharmacists attitudes towards drug misusers and service strategy were measured using 
a five point Likert scale from ‘strongly agree’ to ‘strongly disagree’. Each response was 
assigned a value from -2  to 2. This allowed the researchers to compute a score for each 
respondent by adding the response to each statement (from -2 to +2). The higher the 
score, the more positive the attitude.
Those pharmacists with a high attitude score (15.7) were more likely to provide a 
needle exchange service. Those with a lower attitude score (3.1) tended not to provide 
such a service. Similarly, those pharmacists prepared to supervise consumption of 
methadone had a significantly higher attitude score than those who were not prepared 
to supervise consumption, (14.5 and -6.8 respectively). Those pharmacists who had 
received training on drug misuse had significantly higher attitude scores than those who 
had not had training (7.8 and 2.4 respectively). Similarly those pharmacists wanting 
further training had significantly higher attitude scores that those not wanting training 
(6.9 and -4.0 respectively).
What is not possible to deduce from the results of this attitude measure is whether the 
high attitude scores seen in those pharmacists who had received training are because of 
the fact that they have received training or whether these pharmacists already had a 
positive attitude towards drug misuse and that this was the reason for carrying out 
further training on the subject.
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This is an important issue as showing that training positively influences a pharmacists’ 
attitude towards drug misuse would provide a powerful argument to policy makers for 
making pharmacists’ training in drug misuse a part of the undergraduate program and 
carrying on into their professional career.
This paper highlighted that the pharmacists surveyed did not fully understand the 
rational of maintenance therapy as 69.9% of respondents ‘strongly agreed’ or ‘agreed’ 
to the statement ‘I believe drug misusers should only be prescribed controlled drugs if 
it is in reducing doses to help them ‘come off drugs’
This study (Matheson et al, 1999) was the first of its kind to test pharmacists’ attitude 
and to demonstrate a link between attitude and service provision. It may have been of 
interest to ask some clinical questions around methadone pharmacokinetics and some 
scenarios around intoxicated clients to test the hypothesis that those pharmacists’ with 
high attitude scores have a high level of clinical knowledge.
Matheson et al (2002) have recently reported on a second postal questionnaire of 
Scottish pharmacists carried out in 2000. They compared the results of this survey with 
those reported in Matheson et al (1999). Levels of needle exchange provision had not 
changed significantly (9.7% in 2000 compared with 8.6% in 1995). However, 71.5% of 
respondents dispense drugs for the management of drug misuse (53.2% in 1995) with 
an average of 13.2 clients per pharmacy (7.3 in 1995). The majority of methadone
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clients consume their dose on the premises (65.1%) and the proportion of respondents 
who provide a supervised methadone service rose from 37% in 1995 to 82.8% in 2000.
It is clear from this research that the use of pharmacy based services for drug misusers 
has increased significantly in the period between 1995 and 2000. The major increases 
are in the areas of dispensing drugs for the management of drug misuse and the 
supervised consumption of methadone. This is likely to be due to the increased 
occurrence of ‘shared care’ schemes, which advocate daily methadone dispensing with 
supervised consumption.
Matheson et al (2002) also reported that pharmacists were now more proactive at 
providing advice and information to drug misusers and suggested that this may be due 
to the increased level of training that pharmacists in the latest survey report. This paper 
did not repeat the attitude questionnaire that was reported in Matheson et al (1999). 
This is unfortunate as a repeat of the attitude scores would have given die author 
greater insight into the reasons why more pharmacists are now providing a service in 
2000 than were in 1995. It is not possible to deduce from the results of this survey 
whether an increase in positive attitude is the reason for more pharmacists now 
providing services to drug users or whether it is simply a result of an increasing 
demand for services that is forcing otherwise reluctant pharmacists to provide services. 
This is an important consideration. It is very clear form the literature generated in 
Scotland that demands for a community pharmacy based service for drug misusers is 
on the increase, and that these services are the mainstay of treatment for drug misusers.
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(There is no comparison data for England and Wales as Sheridan et al (1996) is the 
most up to date survey available).
One must be mindful of the quality of the services provided by community 
pharmacies. If there are a proportion of ‘reluctant’ pharmacists supplying these services 
then one should consider the impact of this reluctance on the client using the pharmacy. 
There are a number of papers looking at the clients’ view of a ‘good’ and ‘bad’ 
pharmacy service; some of these will be reviewed in section 2.9.2 on page 64.
- 54 -
Chapter Two -  Literature Review
1.8. PHARMACISTS’ ATTITUDE TOWARDS DRUG MISUSERS
A number of published articles have sought to explore the pharmacists’ attitude 
towards drug misuse and drug users, recognising that negative perceptions by health 
professionals of drug misusers and addiction may be a barrier to their effective 
involvement with this patient group.
Harding et al (1992) surveyed 362 community pharmacists using a postal questionnaire 
containing 23 attitudinal statements. This was at a time when pharmacists in the UK 
had been encouraged to develop and extend the range of services that they offered to 
the public, including drug misusers. In 1986, the Royal Pharmaceutical Society of 
Great Britain issued guidelines to pharmacists who wished to sell sterile injecting 
equipment to intravenous drug users. Against this backdrop, pharmacists were asked to 
rate their agreement on a five point Likert scale to a number of statements.
Encouragingly, the majority of pharmacists (77%) in this survey believed they should 
be more active in community-based strategies to reduce the spread of HIV and AIDS. 
However, pharmacists were split over the statement that ‘Drug addiction is a vice, not 
an illness’ indicating that many pharmacists do not understand the nature of addiction. 
More than half of the respondents believed that ‘there is no excuse for intravenous drug 
misuse’, and 40% agreed that people who take drugs are anti-social
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A factor analysis of the results identified four factors that underlie pharmacists’ 
attitudes and practices towards intravenous drug users. These were:
1. Pharmacists’ views on extent of their professional role in serving IDUs -  in 
particular problems and considerations of pursuing such a role.
2. Societal responses and perceived seriousness of injecting drug use in respect of HTV/ 
AIDS.
3. Pharmacists’ perception of the effects of drugs on IDUs.
4. Pharmacists’ role in reducing the transmission of HTV as part of an inter-professional 
strategy.
The authors discussed that the majority of the responses to the questionnaire indicate 
that pharmacists do not hold attitudes that are likely to be a barrier to the development 
of services to drug users, however a noteworthy proportion of pharmacists agreed with 
those statements aimed at under covering negative attitudes, with 40% of pharmacists 
stating that they do not have the knowledge to handle problem drug users.
This suggests that whilst some pharmacists have genuinely negative attitudes towards 
drug users, others may feel that they do not have the skills to handle this patient group 
and that this is the barrier to providing services.
The letters section of the ‘Pharmaceutical Journal’ provides an additional insight into 
the attitudes of pharmacists to drug users and methadone treatment. The experiences of 
one pharmacist and his staff who were subjected to muggings seems to have spurred
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him on to providing supervised methadone consumption to benefit the greater 
community, by reducing drug related crime (Diamond, 2000). In a reply to Diamond, 
Bennett, (2000) writes to highlight the benefits of supervised methadone consumption 
in reducing crime and drug related deaths in Sheffield, where the supervision of 
methadone consumption has been aided by the development of a coordinated pharmacy 
service for drug users.
In a letter to the Pharmaceutical Journal, Jackson (2002) describes his frustration with 
the Pharmaceutical Society, stating that (in his opinion) pharmacists are the 
professionals qualified to speak about all drugs, including drugs of abuse, and the 
physiological and psychological effects of drug addiction. He states that the RPSGB 
should have a ‘direct line* to the media to put forward the pharmaceutical facts
whenever drugs and drug addiction are discussed. He argues that the profession must
!
raise its profile as experts in this area.
The ‘Letters’ page also shows pharmacists’ frustration at the apparent failure of 
supervised consumption of methadone. Crabbe (2000) feels that methadone treatment 
alone is inadequate. He is concerned that the continuing exposure to drug using friends 
and relatives means that the newly detoxed patient has little chance of abstinence from 
drugs, and states that: ‘It might be the greatest service that we could provide for anyone 
following detox treatment is to insist that they move away from home’.
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Another pharmacist, Finberg (2000) writes about his confusion surrounding the Misuse 
of Drugs Act legislation and advice from the Law and Ethics Committee regarding the 
supply of citric acid and similar products to injecting drug users, and asks for firm 
guidance for all pharmacists.
2.8.1. Barriers and Motivation to Providing Services
Matheson and Bond (1999) reported the findings of 45 telephone interviews conducted 
with community pharmacists in Scotland. This research aimed to qualify barriers and 
motivations of pharmacists to providing services for drug users.
2.8.1.1. Selling Clean Injecting Equipment
The singular motivation for the two-thirds of respondents who were prepared to sell 
clean injecting equipment was to reduce the need to share needles and hence limit the 
spread of HIV/AIDS. A third of those interviewed were not prepared to sell clean 
injecting equipment and the most common barrier to this was the negative effect on 
other customers, perhaps implying that ‘other’ customers were more valuable to the 
pharmacist than the drug user.
2.8.1.2. Participation in Needle/Syringe Exchange
Several different motivations for providing a needle/ syringe exchange scheme are 
apparent from this data. The reduction in the spread of HTV and AIDS was one such 
motivation. Two pharmacists interviewed were concerned about the effect of discarded 
injecting equipment on the public at large and for this reason decided to take part in the
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scheme. One pharmacist indicated that it was his ‘professional duty’ to provide such a 
service and the other indicated that participating in a needle exchange was a means of 
extending the professional role of the pharmacist. Barriers to providing such a service 
included the perceived risk to staff both from needle stick injuries and the threat posed 
by the drug user themselves. Others mentioned insufficient remuneration and sheer 
numbers as a barrier to providing a needle/ syringe exchange service.
2.8.1.3. Dispensing Controlled Drugs and Supervised Methadone Consumption
A few pharmacists’ had considered the needs of the community when deciding to 
dispense methadone to drug users. “If you don’t offer help and support to them (drug 
users), what are they going to do to the rest of the community”. Some pharmacists’ 
mentioned that reduction in the crime committed by an addicted person as being a 
motivation to dispense controlled drugs. Those respondents who were prepared to 
supervise consumption of methadone did so because they believed that it would help 
reduce leakage of prescribed methadone onto the black market.
Pharmacists who did not dispense methadone stated that there was no demand in their 
locality. Those who had made a conscious decision not to dispense to drug users cited 
the perceived negative effect on other customers, as a reason for not wishing to take 
part. Those pharmacists who did not supervise consumption of methadone reasoned 
that they did not have a private area in which to do so.
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The overwhelming theme of these results is that pharmacists seem more concerned 
about the effect of service provision on other customers rather than the effect on not 
providing services on drug users. This may be the effect of an in-grained attitude that 
drug users are in some ways second-class citizens. (Sheridan and Barber, 1996)
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2.9. DRUG MISUSERS’ ATTITUDES
1.9.1. ...Towards Pharmacy Services and Pharmacists.
An early study of drug users’ views and experiences of community pharmacists was 
conducted by Sheridan and Barber (1996). From this pilot study two main themes 
emerged. The stigmatisation of drug misusers either real or perceived, and secondly, 
the perception of the pharmacist as a provider of ‘goods’ such as medicines and 
injecting equipment, and not as a source of advice and information.
The respondents to this study felt that pharmacists made them feel like second-class 
patients, being made to wait, whilst other patients were served first. Some of the 
respondents felt that pharmacists were motivated by money “When you’re paying 
they’re really nice” as opposed to “I’ve had linctus, but they’re (pharmacists) not very 
nice then because it was National Health”
Some of the drug users interviewed in the study felt that it was the pharmacists’ 
responsibility to take control of and stop the leakage of methadone on to the black 
market.
Regarding attitudes towards drug users, the majority of the comments made by the drug 
users in this study were around the theme that pharmacists have a ‘low opinion’ of drug 
users.
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Matheson (1998) interviewed 124 illicit drug users using a semi-structured interview 
technique.
Once again, the personality aspects of the pharmacist and pharmacy staff were most 
frequently mentioned. A polite and friendly attitude and being treated like any other 
customer was the most important aspect of a ‘good’ pharmacy service reported in this 
paper. One service user interviewed suggested that a good rapport helps to get over any 
perceived stigma.
Several interviewees commented on the need for privacy whilst consuming their daily 
dose of methadone, the time spent waiting for their dose was also an important factor 
with two interviewees suggesting that pharmacists deliberately kept them waiting in an 
attempt to aggravate them.
Some users specified that a ‘good’ pharmacy service was one where the pharmacist 
showed some flexibility with regard to picking up methadone, although this may 
require the pharmacist to go against legislation. Others, however, preferred a ‘strict’ 
pharmacist to prevent a prescription getting into the wrong hands.
Some users interviewed thought that the pharmacist could provide other services, such 
as advice and information on safer injecting, however, information requirements were 
often met elsewhere.
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Most users seemed satisfied with the current level of service provision i.e. supervised 
consumption of methadone and needle/ syringe exchange. The authors suggested that 
this may be because of the low expectations of pharmacy service and the perception of 
the pharmacy as a place where drugs are dispensed and little more. It was suggested 
that this attitude of drug users differs little from that of other pharmacy clients and 
indicates the need for a publicity campaign aimed at illicit drug users to highlight the 
professional service that a pharmacist can provide.
These two studies highlight that illicit drug users would appear to want to be treated no 
differently from other pharmacy clients, and that a good rapport with the pharmacist 
and pharmacy staff helps to eliminate the apparent stigma attached to illicit drug 
misuse.
The apparent mistrust of pharmacists by drug using clients is likely to be historical. In 
the past pharmacist have seen themselves in a policing role where drugs of abuse are 
concerned, and the current Misuse of Drugs Act reinforces this. The legislation 
regarding handwriting requirements requires the pharmacist to have a ‘legal’ 
prescription before he is able to dispense to the client. If the prescription is missing any 
of its ‘legal requirements’ the pharmacist is placed in a difficult situation if he then 
decides to dispense it. A decision not to dispense may be viewed by the drug user as the 
pharmacist being ‘difficult’ or ‘picky’.
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2.9.2. ...Towards Methadone and Supervised Consumption
Lovell et al (1999) interviewed 86 clients attending a treatment service in South 
London. Over half of the clients interviewed agreed that the supervised consumption of 
methadone helped them to regulate their lives. Interestingly a larger proportion (58.8%) 
of those who agreed that supervised consumption helped to regulate their lives picked 
up from a community pharmacy. Similarly, those clients who picked up from a 
pharmacy felt less inconvenienced than those who visited the clinic each day.
The majority of clients (88.1%) felt that supervised methadone was a ‘Good’ or ‘Very 
good’ idea, with community pharmacy attendees being slightly more in favour, when 
asked if they (the interviewees) felt that supervised consumption reduced the amount of 
methadone on the street, 70.9% thought that it would.
This study found that in general, supervised consumption of methadone was acceptable 
to this client group, although it is difficult to extrapolate these results to the wider 
supervised methadone community, since all the clients in this study attended a clinic 
where supervised consumption was the ‘norm’ and therefore were not able to compare 
their experience of supervised consumption with anything else.
The authors of this study also noted that this sample of clients had some concerns over 
the lack of privacy in community pharmacies and a lack of trust of the pharmacist, this 
is a similar finding to that of Matheson (1998) in Scotland, and once again highlights 
the need for pharmacists to achieve a good rapport with the clients to alleviate some of 
this mistrust.
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Some of Lovell et aV s findings are strengthened by the results of a qualitative study of 
124 illicit drug users carried out by Neale (1999). Many interviewees declared that they 
would prefer not to be supervised, although some actually want the arrangement. A 
large number of interviewees reported that they did not mind, provided that there was 
somewhere private for them or if the shop was empty.
Interviewees in this study regarded supervised consumption to be beneficial for a 
number of reasons. Firstly that it afforded them a degree of personal safety as some 
users had in the past been mugged for their methadone, secondly that it was ‘proof that 
they were taking their medication and it prevented individuals form selling their 
prescription or abusing the system in another way. Others felt that supervised 
consumption helped them to stick to the programme.
Disadvantages mentioned were that supervised consumption limited the control an 
individual has over their medication such as the timing of the dose and amount taken. 
The main reason for not wanting to be supervised was the embarrassment of having to 
take their medication in a public place. Some described supervised consumption as an 
infringement of privacy and degrading. Others were worried about seeing people that 
they knew whilst in the pharmacy.
Overall, however, the majority of users interviewed felt that supervised methadone 
consumption was a positive requirement of their treatment, however others pointed out
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that supervision was not for everyone, and that there should be a degree of flexibility 
when decided how and when a person should be supervised.
Two common themes run through the research summarized above.
1. Drug users want to be treated as ‘normal’ members of the public.
2. There is some ‘distrust’ of the pharmacist, which if overcome results in a 
positive relationship between client and pharmacist.
3. Most drug users who have their methadone supervised by the pharmacist would 
prefer a degree of privacy.
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2.10. INTERNATIONAL LITERATURE ON PHARMACY SERVICES TO 
DRUG MISUSERS
The extent to which community pharmacy are involved in the care of drug misusers 
varies from country to country. This section will briefly review the international 
literature on services provided by pharmacists outside of the United Kingdom.
2.10.1. USA and Canada
Methadone as a treatment for opioid dependence was pioneered by Dole and 
Nyswander (1965) in New York City. However, there are less than 1000 methadone 
clinics providing treatment to approximately one-eighth of USA’s opioid addicts, and 
some states do not permit methadone maintenance treatment (MMT). (Peterson, 1999) 
Those individuals who are in treatment tend to receive MMT in a hospital or outpatient 
setting. However, community pharmacies are not involved in the dispensing or supply 
of substitute medication, as it is illegal for them to do so in the USA.
In Canada, the availability of methadone in Ontario was severely limited until policy 
changes in 1996 increased the availability of treatment. (Strike et al, 2005) However, it 
is suggested by the authors that more efforts are needed to increase the proportion of 
opiate users that are in treatment. As in the USA, community pharmacists in Canada 
have limited involvement in service provision to drug misusers.
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2il0.2. Australia and New Zealand
In Australia, pharmacies issue over half the total number of sterile needles and syringes 
distributed to intravenous drug users and there are approximately 23,000 patients in 
methadone maintenance programs, most of whom receive their methadone under the 
supervision of a pharmacist (Peterson, 1999). In two states, Queensland and Victoria, 
community pharmacy provision of methadone is virtually the only means of obtaining 
substitute medication. (Roberts, 2003) In 1996, Koutroulis et al (2000) conducted a 
postal questionnaire and focus group study of 188 community pharmacies in Victoria. 
The aim of the study was to understand how pharmacists would respond to clients who 
presented intoxicated. They found that male pharmacists and those pharmacies with 
more than 10 clients were more likely to dispense methadone to an intoxicated client. 
‘Insufficient communication between pharmacists and prescribers’ and ‘Fear of 
retribution from the client’ were amongst the reasons cited for doing this. Although not 
mentioned in the paper, ‘workload’ appears to have an impact on the decision of 
whether or not to supply methadone to an intoxicated patient, perhaps suggesting that 
some of Victoria’s pharmacies are unable to cope with the demand of dispensing and 
supervising consumption.
In New Zealand, people with opioid dependency are most commonly treated in 
community based methadone programmes, with the community pharmacist dispensing 
and supervising the consumption of methadone. McCormick et al, (2006) recently 
surveyed a sample of 898 community pharmacists in New Zealand (from a total of 
2437 on the register of Pharmaceutical Society of New Zealand) in order to explore
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levels of training and attitudes towards providing services to drug users. They found 
that 26% of respondents had undertaken training about the management of opioid 
dependence and that training (either that had had training or those who desired it) was 
positively associated with attitude. This finding provides further evidence that training 
is a factor in influencing a pharmacist’s attitude to drug misusers. In contrast to 
Matheson (1999) who found her attitude scale to be uni-dimensional, McCormick el al 
describe an attitude scale that had four factors (dimensions) and suggest that attitudes 
to service provision may not be as simple as first perceived. However, it is difficult to 
compare these two studies as the attitude questionnaires are different.
A response was obtained from 557 pharmacists which was approximately 23% of the 
population of community pharmacists in New Zealand. In his discussion, McCormick 
suggests that the results from these respondents are generalizable (page 572) to New 
Zealand community pharmacists as a whole, on the basis that the age and gender of the 
respondents of the respondents were similar to the 2001 register. Here it could be 
suggested that McCormick has misused the term generalizability and is in fact talking 
about representativeness.
Despite this, the conclusions from the paper are broadly the same as Matheson’s in that 
providing training to pharmacists should help to both improve the quality of the service 
and the attitudes of the pharmacists who provide them.
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2.10.3. Europe
The extent of involvement of community pharmacies in the provision of drug misuse 
services varies across Europe. For example in Spain, whilst methadone is available to 
be dispensed by pharmacies, few do so. However, more Spanish pharmacies are 
involved in providing needle exchange. Italian pharmacies can sell injecting equipment 
and can also sell naloxone to opioid users without a prescription. This reflects the fact 
that treatment in Italy is primarily aimed at detoxification rather than maintenance. 
(Berbatis, 2003)
In France, pharmacies dispense methadone, buprenorphine and codeine to opioid 
addicts and participate in needle exchange programs. Bonnet (2006) describes a study 
in which it was demonstrated that the provision of free injecting equipment via 
pharmacies can reduce the number of times that a syringe is reused. The pharmacists in 
the study were asked to advise clients of the risks of sharing injecting equipment. The 
dialogue that this created allowed the pharmacists to signpost injecting drug users to 
local drug treatment programs.
Bonnet’s research in France clearly provides evidence that the community pharmacist 
is a vital resource for both drug misusers seeking harm reduction measures and those 
who desire treatment.
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2.10.4. Final Comment
Whilst the majority of the literature on pharmacy services to drug misusers is based in 
the UK, the international literature on the provision of pharmacy services to drug 
misusers clearly highlights the different approaches that individual countries have to 
the treatment of opioid dependence. In the USA, community pharmacies have no 
involvement whilst in some states in Australia; attendance at a community pharmacy is 
the only way of obtaining substitute medication.
As is the case in the UK, in countries where community pharmacies are involved, 
research has highlighted the importance of the pharmacist in the provision of harm 
reduction services such as methadone dispensing and needle exchange, but also the 
ability of the pharmacist to encourage dialogue with the drug misuser that enables them 
to signpost the individual to appropriate treatment services, which Bonnet describes as 
an 'unexpected and happy result. ' This finding suggests that the role of the pharmacist 
in the care of drug misusers goes beyond dispensing methadone and supplying clean 
injecting equipment.
Koutroulis’ study of the provision of methadone to intoxicated clients (Koutroulis, 
2000) suggested that some pharmacists in his study felt that there was inadequate 
communication between the prescriber and the pharmacist. This is an important 
finding, which suggests that inadequate communication between healthcare 
professionals involved in the care of drug misusers may result in harm to the client.
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This research has relevance in the UK, and suggests that the nature and extent of 
communication and information sharing between doctors and pharmacists in the drug 
misuse team should be examined to ensure that a high quality, safe service is provided 
to the clients.
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2.11. RESEARCH QUESTIONS ARISING FROM THE LITERATURE 
REVIEW
The review of the literature on the pharmaceutical care of drug misusers has prompted 
a number of research questions which form the basis of the research conducted for this 
thesis. These research questions and the objectives arising from them will now be 
described.
2.11.1. What is the current level of community pharmacy involvement in the 
provision of services to drug misusers in the South West of England?
The last survey of community pharmacy service provision to drug misusers in England 
and Wales was carried out in 1995. However, more recent figures from Scotland 
suggest that the English figures are now out of date. (Matheson, 2002)
Furthermore, Sheridan (1996) did not attempt to quantify the level of supervised 
consumption in English pharmacies and since this survey was conducted there have 
been a number of developments in drug policy in England, including the establishment 
of the National Treatment Agency and the publication of key Department of Health 
documents on the management of drug misuse.
It is therefore important to re-assess the extent of community pharmaceutical care to 
drug misusers in the light of these developments.
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2.11.2. What is the range of attitude and knowledge of pharmacists who provide 
services to drug misusers?
Matheson (1999) suggested that the attitude of Scottish pharmacists towards drug 
misusers was influenced by whether or not they had received training on issues around 
the management of drug misuse with those pharmacists who had received training 
having a more positive attitude score than those who had not had training.
Glanz (1989) conducted a small assessment of attitude as part of his national survey; 
however, few conclusions could be drawn from this survey of English pharmacists’. 
Therefore, the research conducted for this thesis will include a more comprehensive 
assessment of pharmacists’ attitude towards drug misusers.
There has been no attempt to quantify the level of a pharmacist’s knowledge on aspects 
of drug misuse. This will, therefore, be attempted in the research conducted for this 
thesis.
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2.11.3. What are the views and experiences of pharmacists, who provide drug 
misuse services, and service users who use pharmacy based drug misuse services 
and how services can be improved and developed?
There has been little qualitative assessment of the experiences of pharmacists who 
provide drug misuse services with the majority of the work in this area focussing on 
quantitative assessment of the level of pharmacy involvement.
In order to improve and develop services, it is important to understand the experiences 
of service providers, to ensure that recommendations for extending services are 
relevant and feasible.
The views of service users should also be taken into consideration when deciding how 
to develop or extend a service. The experiences of service users of pharmacy drug 
misuse services and their views on the extension of such services will be sought.
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2.11.4. What are the barriers and opportunities to developing community 
pharmacy services to drug misusers?
Matheson and Bond (1999) described the motivations and barriers to providing 
pharmacy services to drug misusers and they found, amongst other motivations, that 
pharmacists wanted to provide services to drug misusers in order to expand their 
professional services. At this time, professional services to drug misusers included 
needle exchange and dispensing and supervision of consumption of controlled drugs 
used to manage opioid dependence.
Once ways to extend these current services have been sought, it is necessary to explore 
some of the potential barriers and opportunities to developing these ideas into practice. 
These barriers and opportunities will be researched from the point of view of both 
service provider and service user.
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2.12. SUMMARY OF RESEARCH QUESTIONS AND RESULTING 
OBJECTIVES OF THE THESIS
The study is divided into three key areas.
1. A quantitative description of the extent of pharmacy services to drug misusers 
provided by community pharmacists in the South West of England. This 
includes a description of the practical aspects of service provision, a study of 
the attitudes of the pharmacists who provide such services and quantification of 
the depth of knowledge of these pharmacists in key areas of drug treatment.
2. A qualitative investigation of the views and experiences of community 
pharmacists who provide services to drug misusers, including a description of 
the how service may be extended and improved.
3. A qualitative investigation of the views and experiences of users of pharmacy- 
based services with comment on suggested improvements and extension to 
existing services.
The following pages summarises the research questions that resulted from the literature 
review and the corresponding objectives of the thesis.
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Objective One
‘Ascertain the level of community 
pharmacy involvement in the 
provision of services to drug 
misusers in the South West of 
England.’
Research Question 1
What is the current level of 
community pharmacy 
involvement in the provision of 
services to drug misusers in the 
South West of England?
Research Question 2
What is the range of attitude and 
knowledge of the pharmacists 
providing such services?
Objective Two
‘Describe the range of attitudes 
and knowledge levels of 
pharmacists who provide services 
to drug misusers in the South 
West of England’
s  .Research Question 3
What are the views and experiences 
of pharmacists, who provide drug 
misuse services, and service users 
who use pharmacy based drug 
misuse services and how services can 
be improved and developed?_______
Objective Three 
‘Describe the views and 
experiences of pharmacists 
who provide drug misuse 
services, with a view as to 
identifying how services can 
be improved and 
developed.’
Objective Five
‘Describe the views and 
experiences of service users 
of community pharmacy drug 
misuse services, with a view 
to identifying how services 
could be improved and
developed.’
( ---------------------------------.-------------------------------'NResearch Question 4
What are the barriers and
opportunities to developing
community pharmacy services to
drug misusers?V  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ J
Objective Four 
‘Ascertain the barriers and 
opportunities to developing 
community pharmacy services 
to drug misusers’





3.1. OBJECTIVES AND SELECTION OF RELEVANT
M E T H O D S .............................................................................................  80
3.1.1. Objectives One and Two 80
3.1.1.1. Methodology .. .. .. .. .. .. 80
3.1.2. Objectives Three, Four and Five 83
3.1.2.1. Methodology .. .. .. .. .. .. 83
3.2. M E T H O D S ............................................................................................... 87
3.2.1. Postal Questionnaire of Community Pharmacists in the South
West of England 87
3.2.1.1. Questionnaire Development .. .. .. .. 87
3.2.1.2. Pre-Pilot and Pilot Studies .. .. .. .. 88
3.2.1.3. Main Survey .. .. .. .. .. .. 90
3.2.1.4. Management o f Questionnaire Data .. .. .. 92
3.2.1.5. Analysis o f the Attitude Scale .. .. .. .. 93
3.2.1.6. Analysis o f Knowledge and Training Data .. .. .. 95
3.2.2. Semi-Structured Interviews with Community Pharmacists 96
3.2.2.1. Development o f the Interview Schedule .. .. .. 96
3.2.2.2. Ethical Approval.. .. .. .. .. .. 97
3.2.2.3. Pilot Interview .. .. .. .. .. .. 97
3.2.2.4. Recruitment of Participants .. .. .. .. 98
3.2.2.5. Conduction o f the Interview .. .. .. .. 98
3.2.2.6. Data Analysis .. .. .. .. .. .. 99
3.2.3. Semi-Structured Interviews with Service Users 100
3.2.3.1. Development o f the Interview Schedule .. .. .. 100
3.2.3.2. Ethical Approval.. .. .. .. .. .. 102
3.2.3.3. Recruitment o f Participants .. .. .. .. 102
3.2.3.4. Conduction o f the Interview .. .. .. .. 103
3.2.3.5. Transcription and Analysis o f Data.. .. .. .. 103
3.3. SUMMARY OF OBJECTIVES AND METHODS 104
- 7 9 -
Chapter Three - Methods
3.1. OBJECTIVES AND SELECTION OF RELEVANT METHODS
The objectives of the study have been discussed in the previous chapter. This chapter 
will focus on each of the objectives, with a description of the methods used to meet 
each objective. The rational for selecting the methods used over other potential 
methodologies will first be briefly given.
3.1.1. Objectives One and Two
Objective One
‘Ascertain the level of community pharmacy involvement in the provision of services 
to drug misusers in the South West of England.’
Objective Two
‘Describe the range of attitudes and knowledge levels of pharmacists who provide 
services to drug misusers.’
3.1.1.L Methodology
Two quantitative methods were considered for use, the self-completion questionnaire 
and the structured interview. The term ‘quantitative’ refers to a property that exists in a 
range of magnitudes, such as numbers of pharmacies who provide drug misuse 
services, and can therefore be measured. Many attributes in the social sciences, 
including abilities and attitudes, can also be studied as quantitative properties.
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a) Structured Interview
Breakwell (1995) defines the structured interview as ‘a fixed set o f questions which 
the researcher asks in a fixed order.’ Respondents are asked to choose from a fixed 
range of options given by the researcher, and this type of interview yields 
information which is easily quantified, ensuring that questions asked of each 
respondent are comparable. However, as it is pre-structured, this type of research 
method does not allow for unanticipated answers. It is by definition, a verbal 
questionnaire, used to yield a higher response rate than a self-completion written 
questionnaire.
b) Self-completion questionnaire
The self-completion questionnaire describes itself. It is a questionnaire, written by 
the researcher that is completed by the respondent. Such a questionnaire is 
extremely versatile as a data gathering technique and can be used to gather 
demographic information, to gauge attitudes and knowledge, and to obtain 
numerical data on the area of interest.
Bryman (2001) discusses that the self-completion questionnaire and the structured 
interview are very similar methods of social research, the obvious difference is that 
there is no ‘interviewer’ to administer the self-completion questionnaire and therefore 
the research instrument must be easy to follow, and its questions unambiguous.
The table below looks at some considerations of data collection by postal questionnaire 
and structured interview.
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Postal Questionnaire Structured Interview
Cost • Inexpensive • Expensive in a large 
population
Ease of administration • Quick (via mail) • Time consuming
Ease of response • Can be done at 
respondents own 
leisure
• No interviewer to 
explain ambiguous 
questions
• Must be done at a 
mutually convenient 
time
• Interviewer can clarify 
any ambiguities.
Ease of data collection • Respondents may miss 
out questions leading to 
missing data
• Less chance of missing 
data
Type of question • Mostly ‘closed’ 
questions
• Opportunity for more 
‘open’ questions
Response Rate • May be lower due to 
respondent fatigue with 
long questionnaires.
• Generally better than 
postal questionnaires
Table 4: Considerations o f the postal questionnaire and structured interview as 
methods o f quantitative survey research
Using a postal questionnaire to obtain community pharmacy service provision data was 
considered to be the most appropriate way of getting information from a large 
population. (Moser and Kalton, 1986) The structured interview was considered to be 
too costly and time consuming for this part of the project. The inclusion of a set of 
attitudinal questions, measured with a five-point Likert scale was considered to be an 
appropriate manner to describe the range of attitudes of pharmacists who provide drug 
misuse services. (Oppenheim, 1992)
Previous studies that have sought to quantify levels of pharmacy service provision to 
drug misusers (Glanz, 1988, Sheridan, 1996 and Matheson, 1999) have used the postal 
questionnaire as a data collection tool. This method was also considered appropriate for
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the study reported here, primarily because of the size of the population under study (n= 
903 pharmacies in South West England) and cost limitations associated with the 
project. The use of this method will also allow tentative comparisons with past work to 
be made.
3.1.2. Objectives Three, Four and Five
Objective Three
‘Describe the views and experiences of pharmacists who provide drug misuse services, 
with a view as to identifying how services can be improved and developed.’
Objective Four
‘Describe the views and experiences of service users of community pharmacy drug 
misuse services, with a view to identifying how services can be improved and 
developed.’
Objective Five
‘Ascertain the barriers and opportunities to developing community pharmacy services 
to drug misusers.’
3.1.2.L Methodology
‘Qualitative’ research involves investigating participants' opinions, behaviours and 
experiences from the informants' points of view, as Miles and Huberman (1994) 
discuss; ‘Qualitative methods ...a  source o f well grounded, rich descriptions. ’
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The objectives above involve gaining an insight into individuals experience within each 
objective’s setting. As such, it was decided that the use of qualitative methods to 
establish the views and opinions of both service providers (the pharmacists) and service 
users (the drug misuser), was the most appropriate means of data collection.
This methodology is contrasted with quantitative research in that it does not rely on 
quantitative measurement. In the social sciences, qualitative research is a broad term 
that describes research that focuses on how individuals and groups view and understand 
the world and construct meaning out of their experiences. It is essentially narrative- 
oriented and uses analysis of individuals’ experiences to identify similarities and 
differences between them.
Two other methods of data collection were considered, these were postal questionnaires 
and telephone interviews. The former was considered unsuitable for qualitative data 
collection as a written questionnaire does not give the researcher the opportunity to 
prompt, probe or ask questions in order to clarify an answer. Asking open questions in 
the form of a self completion questionnaire can deter prospective respondents because 
of the amount of written material required. This in turn may lower the response rate. 
(Bryman, 2001) and limit the richness of data collected.
Telephone interviews were considered inappropriate for two reasons. Firstly, the 
telephone interview does not allow the researcher to engage in observation so that they 
are not in a position to respond to signs of puzzlement and unease on the part of the
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person being interviewed. Some of the questions may require the interviewee to 
recount difficult situations and this may be more difficult over the telephone as it is less 
easy to build rapport with an individual than in a face-to-face situation. Secondly, 
whilst pharmacist interviewees would have had access to a telephone, it could not be 
assumed that the service users would have the same access.
Face to face semi-structured interviews with both pharmacists and service users were 
considered the most appropriate way of obtaining data in order to fulfill the above 
objectives. The nature of the semi-structured interview allows the participant to provide 
a fuller, richer account than would be possible with structured interview or 
questionnaire and allows the researcher considerable flexibility in probing interesting 
areas which emerge.
Analysis of Interview Content
Consideration to two qualitative analytical methods was given. These were Grounded 
Theory and Interpretative Phenomenological Analysis (IPA).
Grounded theory was originally described by Glaser and Strauss (1967) and was 
developed to study basic social processes. The central theory behind the process of 
grounded theory is that the themes ‘evolve’ from the data and therefore, in order to 
conduct grounded theory, the researcher should have no assumptions about the answer 
to the research question.
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IP A is a new and still evolving method of qualitative analysis which Willig (2001) 
suggests is a specific psychological research method. The central theory of IP A is how 
people experience a particular event or situation and is associated with the work of 
Jonathan Smith (1995).
This method of qualitative data analysis was developed in Smith’s work in the field of 
health psychology and he argues that IPA is concerned with trying to understand lived 
experience and how participants themselves make sense of their world.
It has since been used in other social research projects, including pharmacy practice. 
Hughes and McCann (2003) used interpretative phenomenology to describe perceived 
interprofessional barriers between community pharmacists and general practitioners.
This method was felt to be most relevant to understanding the experiences of 
pharmacists who provide services to drug misusers, as the IPA approach recognises 
that the researchers’ own view of the world is necessary in order to make sense of the 
participants’ experiences through a process of interpretative activity. This was also an 
important consideration when deciding to use IPA, as the researcher is a pharmacist 
with her own experiences of providing drug misuse services. This was also considered 
appropriate for the analysis of the service user interviews, as the researcher has worked 
with a number of drug misusers who have, in the course of conversation, shared their 
experiences with her.
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3.2. METHODS
3.2.1. Postal Questionnaire of Community Pharmacists in the South West of 
England
3.2.1.1. Questionnaire Development
The questionnaire was based on that of Matheson et al (1999) with permission and 
adapted for use in England. A number of changes and additions were made to 
Matheson’s original questionnaire in response to changing practices and clinical 
governance guidelines. The section exploring pharmacists’ attitudes towards drug 
misusers and their treatment was expanded with questions generated from a review of 
the literature. A section at the end of the questionnaire asked respondents if they would 
like to participate further in the research. Those who expressed an interest were asked 
to give contacts details, allowing an ‘opt-in’ approach to further qualitative 
participation, (see Appendix One for a copy of the questionnaire)
Development of the ‘Knowledge’ section
The ‘Knowledge’ section was a novel addition to the questionnaire that aimed to 
explore the pharmacists’ knowledge around key areas of drug misuse.
Question 28 was developed following a review of training materials on drug misuse 
that are available to pharmacists. Question 29 was developed to test pharmacists’ 
understanding of the pharmacokinetics of methadone in relation to missed doses. 
Question 30 was developed in response to anecdotal reports of differing practices in
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supervising the consumption of buprenorphine with regard to the length of time that the 
client is required to stay in the pharmacy. Question 31 was designed to test the 
pharmacist’s awareness of the interaction between methadone and alcohol. This was in 
response to the link between the combination of methadone and alcohol and the risk of 
overdose. (Darke, 1996) Question 32 was designed to test the pharmacists 
understanding of the use of citric acid in the injection preparation process. Question 33 
was designed to test whether pharmacists could distinguish between opiate intoxication 
and opiate withdrawal.
3.2.1.2. Pre-pilot and Pilot Studies
The first version of the questionnaire was sent to ten pharmacists known to the 
researcher. These pharmacists were chosen as they have experience of working with 
drug misusers in the community pharmacy setting. The covering letter explained that 
the questionnaire was a pre-pilot version and the recipients were asked to comment on 
the layout of the questionnaire, the ease of understanding and language and the length 
of time taken to respond. In response to the pre-pilot changes were made to the layout, 
and a front page was added giving instructions on how to complete and return the 
questionnaire.
Following the changes, a new version of the questionnaire was sent out to fifty 
pharmacies in the Berkshire area. Berkshire was chosen as the pilot region because of 
the existence of a well established shared care agreement (Berkshire 4-way agreement, 
see Walker, 2001). The covering letter explained that the questionnaire was a pilot
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version and that their (the pharmacists) help was requested to develop the questionnaire 
for use in a larger study.
A list of pharmacies in Berkshire was obtained from the NHS website. These 
pharmacies were put onto an Excel spreadsheet and the random number generator 
function in Excel was used to pick fifty random pharmacies. The questionnaires were 
individually coded to allow responses to be tracked.
The pilot questionnaire was sent out in May 2003 and non-responders were followed 
up with another copy of the questionnaire after two weeks. Two weeks after the second 
mailing a further copy of the questionnaire was sent out to remaining non-responders.
The response rate of the pilot questionnaire was 32% (n=16). As this rate was lower 
than previous surveys of community pharmacy a telephone interview was conducted to 
explore why the remaining pharmacists had chosen not to respond.
The interview was conducted in order to establish why pharmacists had chosen not to 
respond and what would have made them more likely to respond. Of the 34 non­
responders, 76.5% (26) were contacted after three telephone calls. Five pharmacies 
(26%) claimed they had not received a questionnaire. Of those non-responders who had 
received a questionnaire, 50% (13) claimed that they did not have enough time in their 
working day to fill in the questionnaire. Two pharmacists (7.7%) felt that the 
questionnaire was too long.
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As a similar questionnaire had been conducted by Matheson (1999) with an adequate 
response rate, it was decided to proceed with the longer version with the intent of 
gaining maximum insight for the development of pharmacy based drug misuse 
services.
However, in order to ensure that maximum information on the level of service 
provision amongst community pharmacists was obtained, a shortened version of the 
questionnaire was developed, (see Appendix Two) This version would then be sent out 
to pharmacies who had not responded to an initial three mailings of the original (full 
version) of the questionnaire. By planning to maximise response in this way, accurate 
levels could be reported for the South West of England with due regard for the effect of 
non-response.
3.2.I.3. M ain Survey
Compilation of the Mailing List
The mailing list for the pharmacies in the South West of England was obtained from 
Carol Aston, National Content Co-ordinator for the nhs.uk programme. The number of 
pharmacies obtained in this way correlated with the number of pharmacies reported by 
the Department of Health (2001) at 903 pharmacies. Addresses of the pharmacies were 
categorised according the NHS Primary Care Trust (PCT) in which they were situated. 
As in the pilot survey all questionnaire were individually coded so that responses could 
be tracked. The codes were based on the PCT in which the pharmacy was based. For
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example, BNS 1 referred to the first pharmacy in the mailing list for Bath and North 
East Somerset PCT.
Timeline of the mail-out
In September 2003, the finalised questionnaire (Appendix 1) was mailed out to 903 
pharmacies in the South West of England. The questionnaire was sent, along with a 
FREEPOST return envelope, covering letter and entry to a prize draw in return for 
responding to the questionnaire. Respondents were able to choose from three potential 
prizes.
1. Hot Air Balloon Trip for one person
2. Marks and Spencer’s vouchers to the value of £100
3. A copy of Drug Interactions, by Stockley.
The addition of the prize draw was an incentive to pharmacists to complete the 
questionnaire. This method of increasing response rate has been used in previous 
studies involving community pharmacists. (Smith, 2002)
In November 2003, a reminder letter and copy of the questionnaire was mailed to all 
non-responders from the first mail-out. They were also sent a FREEPOST envelope for 
the reply and a further prize draw entry form.
In January 2004, a second reminder letter was sent out with a further copy of the 
questionnaire. Included were a FREEPOST envelope and a sachet of instant coffee. 
The letter asked the pharmacists to have a coffee break during which they could fill in
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the questionnaire. This method of improving response rate has been used previously in 
pharmacy practice research (Smith, 2002). It was felt to be pertinent to this study, as 
the results of the pilot study suggested that the questionnaire could be completed in 
fifteen minutes.
In March 2004 a shortened version of the original questionnaire (Appendix 2) was sent 
to those pharmacists from whom a response had not been received. The shortened 
questionnaire focussed on the quantitative data regarding service provision and did not 
include any free response questions or the section exploring attitude. The focus on 
service provision was justified by the need to obtain as many responses as possible in 
order to make meaningful observations on the level of service provision to drug 
misusers by pharmacies in the South West.
3.2.1.4. Management o f Questionnaire Data
An Excel spreadsheet was constructed for each PCT and the response was noted when 
a questionnaire was returned.
A database was set up by the author in a Statistical Package for the Social Sciences, 
SPSS for Windows (SPSS, version 11). The questionnaire was coded so that data could 
be input into the database and data entry was performed by the author. Once all the data 
had been input, the database was checked for errors by randomly selecting 35 (1 in 20 
sample) returned questionnaires. The database was also checked for ‘extreme outliers’,
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for example as a result of slips of the finger during data entry, e.g. ‘44’ instead of ‘4’. 
The data check identified very few errors indicating that data entry had been accurate.
3.2.1.5. Analysis o f the Attitude Scale
Assessment of Range of Responses and Plotting of Scores for Statistical Analysis 
Firstly, the frequency of responses to each statement was assessed to determine if there 
was a spread of opinion, as would be expected in a normal population. Then, a total 
score was calculated for each respondent by reversing negative statements (41, 42, 43, 
44,46, 47, 48, 50, 51, 53, 54, 58, 59, 66) then totalling the score for each statement (+2 
strongly agree to -2 for strongly disagree). Total scores were plotted for each 
respondent and the ‘normality’ of the distribution was assessed by calculating the skew 
of the resulting curve. The attitude scale was contained in the full version of the 
questionnaire; therefore attitude scores were only calculated for those respondents to 
the first three mailings of the questionnaire. Subsequent analysis of attitude refers, 
therefore, to the respondents of the full version.
Reliability of Attitude Scale
Reliability is the extent to which a measure (the attitude scale) produces the same 
measurement in the same individual at different point in time. It was not possible to re­
test the scale (test-retest reliability) in the same population because this may have 
resulted in survey fatigue in the population (Oppenheim, 1992). The measurement of 
attitude in this manner is a ‘single point in time’ measure; it is not possible to control 
interim factors that may influence attitude between re-tests. Therefore, the overall
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correlation between statements or internal consistency of the scale was assessed by 
determining the Cronbach’s alpha co-efficient. This was calculated in the following 
manner.
The scores for negatively worded statements in the attitude scale were reversed and the 
Cronbach’s alpha co-efficient was calculated using the method described in Pallant, 
2001 using SPSS version 11. The output was examined to ensure that the correct 
number of items had been included in the analysis, and the impact of removing items 
with low item-total correlation from the scale was considered.
Validity of Attitude Scale
Construct validity was assessed by considering whether the responses to individual 
statements were consistent with the theoretical framework (Oppenheim, 1992). For 
example, it was expected that those respondents who provided a supervised 
consumption service would disagree with the statement ‘I believe supervising 
consumption of CDs by drug misusers on the pharmacy premises is an inappropriate 
role for the community pharmacist’.
A factor analysis was conducted as an assessment of psychometric validity (Streiner 
and Norman, 1995). Factor analysis is an analytic statistical tool which may help to 
Ascertain what (if any) are the chief underlying dimensions of a set of responses, in this 
case, responses to the attitude statements (Oppenheim, 1992).
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SPSS (version 11) was used to conduct the factor analysis using the method described 
in Pallant, 2001. The data was firstly examined for suitability for a factor analysis by 
calculating Bartlett’s test of sphericity and the Kaiser-Meyer-Olkin (KMO) measure of 
sampling adequacy.
A principle component analysis was used to extract factors from the item population 
and using Kaiser’s criterion and the scree test the least number of factors that best 
described the underlying relationship among the variables was determined. These 
factors were then rotated orthogonally using the Varimax method available in SPSS 
version 11.
The resulting statements within each factor were interpreted and tested for internal 
reliability using Cronbach’s alpha co-efficient using the same method as described 
above.
3.2.1.6. Analysis o f Knowledge and Training Data
A ‘knowledge score’ was computed for each respondent to the full questionnaire. The 
marks awarded to each question are shown in the table below.




28 a) 5mg of methadone could be fatal to an opioid nai've adult 
b) Taking benzodiazepines with methadone will help with
False 1
withdrawal True 1
c) lOmg of methadone could kill a child
d) Opiate overdose may cause respiratory depression, coma and
True 1
death True 1
29 How long (days) on average does a persons tolerance to Three days
methadone decrease to the point where the original dose may 
cause toxicity?
1
30 When supervising consumption of Subutex (buprenorphine) Until tablet
how long does it take for the full dose to be absorbed from the is dissolved
mouth? 1
31 A drug user arrives at your pharmacy for his daily dose of Come back
methadone showing obvious signs of alcohol intoxication. What 
should you do?
when sober 1
32 People who misuse heroin may ask to buy citric acid. Why is To dissolve
this? street heroin 1
33 Please list three signs of opiate intoxication 1 sign 1
2 signs 2
3 signs 3
34 Please list three symptoms of opiate withdrawal 1 symptom 1
2 symptoms 2
3 symptoms 3
Table 5: Marks awarded to each correct answer in the *Knowledge9 section o f the 
questionnaire (max 15)
3.2.3. Semi-Structured Interviews with Community Pharmacists
3.2.2.I. Development o f  the Interview Schedule
The interview schedule (see Appendix Four) comprised six themes and topics for 
discussion. It was developed from the analysis of the free response questions (question 
numbers: 12, 13f&g, 15, 19d, 21, 22, 25 and 36) in study one. Questions one and two 
of the interview schedule were concerned with the role of the pharmacist and pharmacy 
staff in the care of drug misusers. Questions 3-9 were concerned with the provision of
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services to drug misusers whilst questions 10-12 were designed to obtain an 
understanding of the pharmacists’ wider knowledge of the field. Questions 13-20 
explored ‘problems and positives’ about providing services to drug misusers and 
questions 21-23 examined the pharmacists’ experience of the support that they received 
in order to provide these services. The final two questions examined whether 
pharmacists felt recognised for their role in drug misuse treatment and what they would 
like to see included in a model of care for pharmacy based drug misuse services.
3.2.2.2. Ethical Approval
Ethical approval was sought from the Central and South Bristol Research Ethics 
Committee in March 2004 and was granted in July 2004. (see Appendix Three)
3,2,23, Pilot Interview
The interview schedule was piloted on a pharmacist known to the researcher but 
unconnected with the project. The pilot ran smoothly and the interviewee stated that he 
had understood the questions being asked and felt able to give full answers. As a result 
of the pilot, the interview schedule was not changed and the pilot interview was 
included in the final analysis. It was not felt necessary to conduct further pilot 
interviews. The pilot interview lasted forty minutes so potential interviewees were 
asked to allow one hour for their interviews.
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3.2.2.4. Recruitment o f Participants
Interviewees were recruited from respondents to the postal questionnaire in study one 
who expressed an interest in participating in further research. Initially, letters were sent 
to those respondents who sent the questionnaire back from the first mail out, and then 
those respondents who responded to the second mail out were contacted. An initial 
letter explaining the research was posted to the potential interviewees. This also 
contained a ‘participant information sheet’ and a consent form. Potential interviewees 
were given the option to opt out of the research by faxing a form to the researcher.
Pharmacists who had responded with a willingness to be interviewed were contacted by 
telephone a week later and a date was agreed for the interview. Potential interviewees 
were assured that the contents of the interview would remain confidential and written 
consent was obtained before the interview commenced in order that it could be tape- 
recorded and subsequently transcribed.
3.2.2.5. Conduction o f the Interview
The interviews were conducted at locations that were suitable for the individual 
participants. The interviews occurred mainly at the participant’s place of work and the 
interviews lasted between half to one hour. At the end of the interview, the tape- 
recorder was switched off and the researcher was able to answer any questions about 
the research that the interviewee raised. After each interview, the researcher made notes 
about any thoughts that she had on the content of the interview. The tapes were 
professionally transcribed and the researcher checked each one by listening to the tapes
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and reading the transcription at the same time. Minor alterations were made where the 
transcriber had missed words or failed to hear the tape clearly. At this time all 
identifiable information contained in the transcription was either removed or 
anonymised.
3.2.2.6. Data Analysis
The transcriptions were analysed using IPA, as described in section 3.1.2.1. on page 77. 
Smith (1999) provides researchers with clear guidelines which allow for the 
identification and progressive integration of themes. Data analysis began by reading the 
transcripts in order to get a ‘feel’ for the data. The transcript was converted to rich text 
format which allowed it to be imported into the computer software package QSR 
NUD*IST VTVO (NVIVO) version 2.0 (QSR International). This package was chosen 
following the researchers attendance on a training course organised by the CAQDAS 
Networking Project at the University of Surrey. The package was easy to use and 
allowed the researcher to carry out the initial coding and subsequent theory building. 
Some categories had been identified from study one and these were used during the 
initial coding of the data. Subsequent categories were developed from the transcript 
itself (so called in-vivo codes). Each transcript was treated in a similar manner.
Theming
The initial analysis allowed categorisation of the contents of the transcript into distinct 
categories (for example: views..., problems..., positives..., practical aspects...). Each 
category was summarised using the software package so that a print-out which included
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the category, participant and quote could be produced. Each individual category was 
examined and emergent themes produced.
Clustering
This stage of IPA introduces structure to the analysis. Each initial category was 
examined along with the emergent themes and the association between them was 
considered. This was carried out using post it notes to represent the sub-themes. These 
were placed into clusters on a whiteboard, paying attention to the part of the transcript 
from which the theme emerged so that the ‘meaning’ of the theme was not lost during 
clustering. This exercise was carried out with the advice of a researcher in the 
Department who has extensive experience of qualitative data analysis, in order to 
examine the data in a context other than the computer software package.
3.2.3. Semi-structured Interviews with Service Users
3.2.3.1. Development o f the Interview Schedule
The interview schedule (Appendix Six) was developed as a result of the analysis of the 
pharmacists interviews. In this way the experiences of both parties were explored.
The interview schedule was divided into two parts.
1. Experience o f Pharmacy Services
Participants were asked about their experiences of community pharmacy services such 
as supervised methadone consumption and needle exchange. In view of the recognition 
that pharmacists often see drug misusing clients more often than other healthcare
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professionals, participants were asked if they ever used the pharmacist as a source of 
advice, either on minor illnesses or issues associated with their drug use. Participants 
were also asked why individuals sometimes missed picking up doses of methadone, 
and why they thought pharmacists sometimes had to withhold doses. These two 
questions were posed in the form of vignettes, so that the participant could answer 
without the need to relate their own experiences.
2. Development o f Pharmacy Services
This section of the interview schedule arose from the analysis of the interviews with the 
pharmacists. It was designed to explore the views of the service users as to how drug 
misuse services provided by community pharmacists could be improved. For example, 
service users were asked about information sharing between the pharmacist and 
prescriber or drugs worker. This was in response to the suggestion by some pharmacists 
that more information about the client would help them provide a better service to 
them. Other topics around the development of the pharmacy service included:
- The ‘law’ surrounding prescriptions
- Use of contracts
- Improving supervised consumption
Suggestions of training topics for pharmacists and support staff
- Views on prescribing of methadone by pharmacists.
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3.2.3.2. Ethical Approval
Ethical approval for the service user interview study was sought from the Nottingham 
Research Ethics Committee (2) as the next available REC available through the Central 
Allocation System at CoREC. (see Appendix Five)
3,23.3. Recruitment o f Participants
Five pharmacists, who took part in the pharmacist interview study described above, 
were approached and asked if they would allow the researcher to conduct interviews ■ 
with a self-selecting group of their drug-misusing clients. This was a purposive sample 
based on location of the pharmacy and the availability of a private area in which to 
conduct the interview.
An information sheet in a question/ answer format was sent to participating pharmacies 
with a request that they be handed out to their drug misusing clients. It is stressed that 
pharmacists were NOT asked to recruit interviewees themselves, as it is possible that 
some clients may have felt coerced into taking part if recruitment had been carried out 
by the pharmacist who provided the service. The leaflet made it clear that that 
participating interviewees would not be asked for their name, and this information 
would not be recorded on any written or electronic material.
At least two days after the leaflet handout, the researcher attended the pharmacy and 
recruited interested clients for interview. Potential interviewees were approached by the 
researcher as they attended for their prescription, or for needle exchange. Clients were
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identified to the researcher by the pharmacist. Potential interviewees were asked if they 
had had a chance to read the leaflet on the research, and if they had, were asked if they 
would like to be interviewed. Most interviews were conducted immediately, but some 
interviewees made appointments to come back later that day. Written consent was 
obtained by the participant filling in a consent form. Initials were used to preserve 
anonymity.
3,23.4. Conduction o f the Interview
The interview was conducted in a private room on the pharmacy premises. The 
interview was audio taped with the interviewee’s consent. The target number of 
interviewees per pharmacy was three (15 in total). Each interview lasted about 1/2 hour 
depending on the nature of the interviewee’s responses.
By means of a 'thank you1 for taking part in the interview, the interviewee was be 
offered a choice of gift voucher for redemption in a local retailer (e.g. Superdrug, 
Tesco, Boots or Asda). The value of the gift voucher was £10.00.
3.2.3.5. Transcription and Analysis o f Data
The interview data generated in this study was transcribed verbatim and analysed using 
Interpretative Phenomenological Analysis (IPA) in the same manner as the 
pharmacist’s interviews (see sections 3.2.2.5 and 3.2.2.6. on pages 92-93). Emergent 
themes arising from the interviews were generated and are presented in the ‘Results’ 
chapter, (section 4.3 on page 161)
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3.3. SUMMARY OF OBJECTIVES AND METHODS
The figure below summarises the five objectives of this thesis, and the methodologies 
employed to answer the objectives.






‘Ascertain the barriers and 
opportunities to developing 
community pharmacy services to 
drug misusers.’
Objective One
‘Ascertain the current level of 
community pharmacy involvement in 
the provision of services to drug 
misusers in the South West of England.’
Conduct semi-structured 
interviews with
pharmacists who provide 
drug misuse services.
- Explore their views and 
experiences of providing 
services and how they 
might be improved and 
developed.
Objective Two
‘Describe the range of attitudes and 
knowledge levels of pharmacists who 
provide services to drug misusers in the 
South West of England.’
Objective Five
‘Describe the views and experiences 
of service users of community 
pharmacy drug misuse services, and 
obtain their opinions of how services 
could be improved and developed.’
Objective Three
‘Describe the views and experiences of 
pharmacists who provide drug misuse 
services, with a view to identifying how 
services can be improved and 
developed.’
Conduct semi-structured 
interviews with users of 
community pharmacy drug 
misuse services.
- Explore their experiences 
of these services and their 
opinions on how the 
services might be improved 
and developed.
Undertake a postal 
questionnaire, to be sent to 
all community pharmacies 
in South West England.
- Include questions on 
service provision and 
knowledge, and a five-point 
Likert scale attitude 
measure.
Figure 2: Diagrammatic representation o f the objectives o f the thesis and the 
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4.1. COMMUNITY PHARMACY POSTAL SURVEY
4.1.1. Response Rate
Response rates are shown in Table 6 below; the response rate after three mailings 
was 60%. After the fourth mailing of the shortened version of the questionnaire, the 







1 -  September 2003 Full 362 (40%) -
2 -  November 2003 Full 458 (51%) 96(11%)
3 -  January 2004 Full 545 (60%) 87 (9%)
4 -  March 2004 Shortened 707 (78%) 162 (18%)
Table 6: Response and increase in response rate per mailing o f the postal 
questionnaire: ‘Community Pharmacy Services to Drug M isusers9
4.1.2. Demography of Pharmacies and Pharmacists
The demographic details reported below refer to the analysis of the first three 
mailings of the questionnaire. The forth mailing of the shortened version of the 
questionnaire did not include any demographic details.
An almost equal number of male (48%) and female pharmacists (50%, 2% missing) 
responded to the questionnaire (Table 7), and the mean age of respondents was 41.3 
(Standard Deviation (SD) 11.9). (Table 8)
Respondents had been on the Pharmaceutical register an average of 17.6 years (SD 
12.5 years) and had spent on average 6.5 years (SD 7.9 years) working in the 
pharmacy to which the questionnaire was sent. (Table 8) The majority of 
respondents (56.7%, n=313) reported working for a large multiple pharmacy chain.
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(Table 9) The majority of the pharmacies who responded described their location as 
‘Small Town’ or ‘Urban’ (71.2%, n=387). (Table 10)
The majority of pharmacists who responded to the questionnaire indicated that they 
had some decision making responsibilities with 45.5% (n=247) of respondents 
having sole responsibility, 37.6% (n=204) having decision making responsibilities 
in conjunction with someone else, and 15.8% (n=86) of respondents reported 
having no decision making responsibilities. (Table 11)
Most of respondents (65%, n=353) reported being ‘employees’ in the pharmacy in 
which they worked. Pharmacy owners accounted for 21% (n=114) of respondents, 











Male 101 (43.3) 66 (52.4) 94 (51.1) 261 (48.0)
Female 128 (54.9) 58 (46.0) 85 (46.2) 271 (50.0)
Missing values 4(1.8) 2(1.6) 5 (2.7) 11 (2.0)
* Avon, Gloucestershire and Wiltshire Strategic Health Authority 
** Dorset and Somerset Strategic Health Authority 
*** South West Peninsula Strategic Health Authority
Table 7: Gender o f Questionnaire Respondents
Mean Age (SD) Mean Years 
Registered (SD)
Mean Years at 
Present Pharmacy 
(SD)
AGW 40.3 (11.6) 16.8 (12.1) 6.5 (7.6)
DS 41.3 (11.7) 17.3 (12.5) 5.8 (6.3)
SWP 42.6 (12.4) 18.9 (13.0) 6.9 (7.9)
TOTAL 41.3 (11.9) 17.6(12.5) 6.5 (7.4)
Table 8: Age, Years Registered and Years at Present Pharmacy o f Questionnaire 
Respondents
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Single Outlet 41 (17.6) 25 (19.8) 36 (19.6) 102 (18.8)
Small Multiple 
(2-9 branches)
54 (23.2) 21 (16.7) 23 (12.5) 98 (18.0)
Large Multiple 127 (54.5) 74 (58.7) 112(60.9) 313 (57.6)
Health Centre 8 (3.4) 5 (4.0) 11 (6.0) 24 (4.4)
Missing values 1 (0.4) 1 (0.8) 2(1.1) 4(0.7)









Rural 12 (5.2) 11 (8.7) 7 (3.8) 30 (5.5)
Village 25 (10.7) 18 (14.3) 31 (16.8) 74 (13.6)
Small Town 65 (27.9) 59 (46.8) 88 (47.8) 212 (39.0)
Urban 99 (42.5) 30 (23.8) 46 (25.0) 175 (32.2)
City Centre 29 (12.4) 7(5.6) 9 (4.9) 45 (8.3)
Missing values 3 (1.3) 1 (0.8) 3 (1.6) 7(1-3)











103 (44.2) 62 (49.2) 82 (44.6) 247 (45.5)
Yes-
With Someone Else
92 (39.5) 45 (35.7) 67 (36.6) 204 (37.6)
No 37 (15.9) 17 (13.5) 32 (17.4) 86 (15.8)
Missing values 1 (0.4) 2(1.6) 3 (1.6) 6(1.1)









Owner 52 (22.3) 23 (18.3) 39 (21.2) 114(21)
Locum 21 (9.0) 15(11.9) 25 (13.6) 61 (11.2)
Employee 155 (66.5) 84 (66.7) 114(62.0) 353 (65)
Superintendent 4(1.7) 3 (2.4) 4(2.2) 11 (2.0)
Missing values 1 (0.4) 1 (0.8) 2(1.1) 4(0.7)
Table 12; Status o f Pharmacist iRespondents
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4.1.3. Part One -  Level of Involvement with Drug Misusers
4.13.1. Suspected Misuse o f ‘Over the Counter * (OTC) products
Those pharmacists who responded to the full version of the questionnaire were 
asked whether they believed ‘over the counter’ (OTC) products were being misused 
in their local area. 70.6% (n=382) believed that, yes, OTC products were being 
misused. 22.0% (n=119) did not think that OTC products were being misused in 
their locality whilst 6.5% (n=35) replied that they did not know. (5 respondents did 
not answer the question)
Of those respondents who believed that OTC products were being misused, 86.9% 
(n=332) mentioned opiate containing products such as Kaolin and Morphine and 
codeine linctus; 36.6% (n=140) mentioned sedative antihistamines found in 
products such as Nytol™ (diphenhydramine) and Night Nurse™ (promethazine) 
whilst 18.1% (n=69) mentioned laxatives such as senna and bisacodyl. Other OTC 
drugs were mentioned by 11.5% (n=44) including 18 respondents who listed citric 
acid.
Most respondents who believed that OTC product were being misused in their area 
had a sales policy relating to these products. (96.8%, n=370) Most commonly, lines 
that were believed to be being misused were not stocked or hidden from the 
customers view. (36.5%, n=135). Other ‘policies’ are shown in Table 13.
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POLICY No. of respondents (%)
Hide or do not stock certain products 135 (36.5)
Monitor sales to suspected misusers 78 (21.1)
Refer requests for certain products to the pharmacist 54 (14.6)
Counsel suspected misusers of OTC products 50 (13.5)
Refuse sale of products to suspected misusers 38 (10.2)
Staff use a ‘sales of medicines’ protocol 12(3.2)
Missing values = 3
Table 13: Reported ‘policies’ fo r  managing OTC products with misuse potential 
(n=370)
4,13.2. Sale o f needles and syringes to known or suspected intravenous drug 
users (IDUs)
Analysis of responses to both full and abridged versions of the questionnaire 
(n=707) showed that 19.1% (n=135) of respondents were prepared to sell needles 
and syringes to known or suspected IDUs and currently did so, with a further 31.4% 
(n=222) prepared to sell needles and syringes to known or suspected IDUs, but 
reported that they had not been asked to do so in the past week. This gave a total of 
50.5% (n=357) of respondents willing to sell needles and syringes to IDUs. (data 
missing from 10.0%, n=71 respondents)
The full version of the questionnaire explored why respondents sold needles and 
syringes to injecting drug users. The most common reason given for selling needles 
and syringes was ‘harm reduction’ (20.3%, n=110), followed by ‘inadequate local 
needle exchange facilities’ (4.8%, n=26).
42.3% (n=299) of respondents were not prepared to sell needles and syringes to 
known or suspected IDUs. (Data from full and abridged versions, n=707 responses)
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The most common reasons cited for this was that there was ‘needle exchange 
location nearby9 (15.9%, n=86) and ‘no returned sharps facilities' (7.8%, n=42). 
(Data from full version, n=545 responses)
4.1.3.3. Provision o f needle/syringe exchange services
One hundred and seven respondents (15.1%, data from full and abridged versions) 
said their pharmacy was part of a needle exchange scheme. In the week prior to 
responding to the questionnaire, they supplied needle exchange services to an 
estimated 2254 individuals. This gives an average of 21 clients per week (min 1, 
max 150, mode 20 clients), with four pharmacists reporting more than 100 clients 
per week.
Of the 107 respondents who reported running needle exchange schemes, 53.3% 
(n=57) said that they and their staff had received vaccination against Hepatitis B 
and 74 (69.1%) needle exchange pharmacies had had training on the scheme.
Respondents to the full version of the questionnaire who did not provide a needle 
exchange scheme (n=448) were asked, in a free response question why they did not. 
Of these, 413 gave reasons. The most common reason was that the respondent 
perceived that there was ‘no demand’ for the service (29.3%, n=130), whilst 80 
respondents said that they did not provide the service because it was ‘already 
available locally’ (18.0%). Fifty two respondents (12.6%) felt that their ‘premises 
were unsuitable. ’ Thirty respondents did not provide a needle exchange scheme 
because of a ‘previous bad experience ’ (6.7%), whilst 39 (9.4%) said that they ‘had 
not been asked’ .
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In a similar free response question, respondents not currently providing a needle 
exchange scheme were asked what would encourage them to do so and 337 gave 
answers. Most said that they would consider providing the service if an ‘increase in 
demand’ could be demonstrated. (32.0%, n=108) and 67 (19.9%) said they would 
be encouraged if there was ‘funding ’ available. Ninety-seven respondents (21.8%) 
replied that ‘nothing ’ would encourage them to provide such a scheme.
4.1.4. Part Two -  Methadone Dispensing and Practical Aspects
4.1.4.1. Provision o f Methadone Services
The results shown in Table 14 are from the analysis of both the full and abridged 
versions of the questionnaire. Of the 78.3% (n=707) of pharmacies who replied to 
the questionnaire, 69.2% (n=489) reported providing methadone services to a total 
of 3427 drug misusers with a mean number of 7.0 clients per pharmacy. Of the 489 
pharmacies who dispensed methadone, 70.1% (n=434) also reported supervising 
consumption.
Over 90% (92.1%, n=3155) of these clients were reported to have been receiving 
their methadone at the responding pharmacies for one month or more. In total, 
49.5% (n=1697) of these clients were receiving their dose of methadone by 
supervised consumption with a mean number of 4.9 supervised clients per 
pharmacy.
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AGW DS SWP TOTAL
Number of Pharmacies 383 219 301 903
Number of Respondents 305 162 240 707
% Response 79.6 73.9 79.7 78 3
% of respondents providing services 69.2 66.6 70.8 69.2
Number of methadone clients 1773 717 937 3427
Number of ‘regular clients’ 1608 649 898 3155
(%) (90.6) (90.5) (95.8) _ (92^1)










Mean number of clients per pharmacy 8.4 6.6 5.5 7.0
Mean number of clients on supervised 
consumption/ day 6.6 3.6 3.4 4.9
Table 14: Provision o f methadone services to drug misusers shown by StHA and 
the south west region as a whole
In the full version of the questionnaire, respondents were asked further questions 
about the supply of methadone to drug misusing clients. Of the 385 methadone 
dispensing respondents who replied to one of the first three questionnaire mailings, 
52.7% (n=203) reported that they had stopped dispensing methadone to one or more 
drug misusing clients. Of those pharmacists who had stopped dispensing to an 
individual, the most common reason for this was that the individual had been 
abusive or had engaged in shoplifting from the pharmacy. (64.5%, n=131). Thirty 
two pharmacies (15.7%) reported that they had stopped dispensing methadone to 
one or more clients because they had missed doses and 11 pharmacies (5.4%) had 
stopped because the client was ‘in breach of their contract’. Twenty nine 
pharmacies (14.3%) did not give reasons.
Similarly, in responses to the full questionnaire, 138 of the 385 methadone 
dispensing pharmacies (35.8%) reported having to withhold one or more doses of 
methadone to a client, with the most common reason being that the client presented 
to the pharmacy in an intoxicated state. (36.4%, n=50) Other reasons included 
‘missed previous doses’ (21.7%, n=30), ‘arrived late’ (15.9%, n=22) and ‘instructed
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by the prescriber’ (12.3%, n=17). Nineteen pharmacies (13.7%) did not give 
reasons.
One hundred and eighty-nine methadone dispensing pharmacies who responded to 
the full version reported supervising other drugs, with 182 supervising 
buprenorphine and 11 supervising the consumption of benzodiazepines.
4.I.4.2. Practical aspects o f providing services 
Standard Operating Procedures
Both the full and abridged versions of the questionnaire asked respondents who 
reported dispensing methadone (n=489) to indicate whether they had standard 
operating procedures in place in their pharmacies for dispensing Controlled Drugs 
and supervising their consumption. 42.9% (n=210, 21 missing responses) had an 
SOP for dispensing Controlled Drugs and 40.8% (n=200, 27 missing responses) 
reported having an SOP for supervising consumption.
Private Areas
Of those pharmacies who responded to the full version of the questionnaire, and 
who provided a methadone dispensing service (n=385), 46.5% (n=179) reported 
having a private area that could be used to supervise consumption of methadone 
andJ or other drugs. One hundred and thirty-eight pharmacies with a private area 
(77.1%) responded that they ‘always’ offered use of the private area to clients 
required to consume on the premises. Of the pharmacies who did not have a private 
area (n=197), 50 (25.4%) said that one or more client had commented that they 
would like more privacy than was available when they were consuming their
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methadone. Nine pharmacies (2.3%) did not provide information about the 
existence of private areas in the pharmacy.
Methadone Dispensing and Supervision of Consumption
Table 15 below lists some ‘desirable’ practices that may occur when providing 
methadone services and quantifies how many of the respondents to the full version 
of the questionnaire, who provide a methadone dispensing service, always, 
sometimes or never engage in these practices.
Laying down ground rules with new clients was common practice with 278 
pharmacies (72.2%) always doing this. These ground rules were usually backed up 
by the use of a written contract, always: 31.1%, n=120 and sometimes: 26.7%, 
n=103 and, 40.2% (n=155) of respondents reported never using a written contract. 
Most pharmacies always or sometimes asked for identification on the first occasion 
that the client presents a methadone prescription, (79.4%, n=306) but did not 
continue to ask for identification on subsequent collections (70.6%, n=272).
Most pharmacies always made up prescriptions in advance of the client attending 
the pharmacy with only 53 respondents (13.8%) reporting that they never did this. 
87.8% (n=338) of respondents reported that they ‘always’ treat drug misusers the 
same as other customers with 2.3% (n=9) reporting that they never did.
Of those pharmacies who responded to the full version of the questionnaire and who 
supervised consumption of methadone (n=319), 95% (n=303) reported providing
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water after the dose of methadone had been taken, with most always providing this 
in a disposable cup (63.3%, n=192).
Health Promotion
Those respondents to the full version of the questionnaire, who provided a 
methadone dispensing service, were asked to indicate how regularly they provided 
health promotion information (written or verbal) on drug misuse and HIV 
prevention. Those reporting ‘always’ providing written literature were, in general, 























































Provide plastic measures with prescriptions 



















If vou supervise consumption, do vou:















Table 15: Practical Aspects o f Methadone Dispensing (n=38S)
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Supply information leaflets concerning drug 16 112 252 5
misuse to new drug misusing clients (4.1) (29.1) (65.4) (1.3)
Supply information leaflets concerning 16 79 285 5
methadone to new clients who present with a 
prescription for methadone
(4.1) (20.5) (74.0) (1.3)
Supply information leaflets concerning HIV 8 55 315 7
prevention to new drug misusing clients (2.1) (14.3) (81.8) (1.8)
Offer face to face advice on the management 44 188 147 6
of drug misuse (11.4) (48.8) (79.4) (1.5)
Offer face to face advice concerning 53 217 109 6
methadone (13.8) (56.3) (28.3) (1.5)
Offer face to face advice on HTV prevention 22 108 248 7
(5.7) (28.0) (64.4) (1.8)
Table 16: Health Promotion Activities o f Methadone Dispensing Respondents to 
the Full Questionnaire (n=385)
4.1.5. Part Three - Knowledge and Training
4.1.5.1. Knowledge
Respondents scored an average of 8.4 (SD 2.8, Max 15, Min 0) on questions 28 to 
34. The range of the respondent’s scores was normally distributed, as shown in 
Figure 3. Of note was that 298 (56.3%) of respondents were 'Unsure ’ how many 
days (on average) an individual could miss their dose of methadone before their 
tolerance to that dose would decrease. (Question 29 -  Table 18). Just under half of 
the respondents to the full questionnaire knew that citric acid was used to dissolve 
street heroin (Question 32 - 42.5% (n=225). Interestingly, respondents were less 
able to list signs of opiate intoxication than opiate withdrawal, with 139 (26.3%) 
unable to list any signs of intoxication compared with 75 (14.2%) unable to list any 
signs of withdrawal. (Table 21)
Responses, in terms of percentages for each available answer are shown in Tables 
17-21.
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(a) 5 mg of methadone could be fatal to an 127 357 45
opioid naive adult M24- 0) ( 6 7 . 5 ) (8 .5)
(b) Taking benzodiazepines with methadone 291 200 38
will help with withdrawal ( 5 5 .0 ) (37.8) (7 .2)
(c) lOmg of methadone could kill a child 487 10 32
( 9 2 . ! ) ( 1. 9 ) (6 .0)
(d) Opiate overdose may cause respiratory 515 0 14
depression, coma and death . ( 9 7 .4 ) ( 0 . 0 ) (2 .6)













How long (days) on average does a 
person’s tolerance to methadone 
decrease to a point where the 













Missing values = 14 respondents
Table 18: Answers to ‘Knowledge and Training’ question 29
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>30s 30s-lmin 1-2 mins Until dissolved Unsure
(%) (%) (%) (%) (%)
When supervising 
consumption of Subutex 
(buprenorphine) how long does 
it take for the full dose to be 











Missing values =14  respondents



















A drug user arrives at your 
pharmacy for his daily dose of 
methadone showing obvious 
signs of alcohol intoxication. 











Missing values =17 respondents
Table 20: Answers to ‘Knowledge and Training* question 31
No correct signs 1 sign 2 signs 3 signs
(%) (%) (%) (%)
33. List three signs of opiate 139 166 160 64
intoxication (26.3) (31.4) (30.2) (12.1)
34. List three signs of opiate 75 100 185 169
withdrawal (14.2) (18.9) (35.0) (31.9)
Table 21: Response to *Knowledge and Training* questions 33-34
4.1.5.2. Training
Past Training
Overall, of the respondents to the full version of the questionnaire (n=545), 49.9% 
(n=272, 25 missing) had had training on drug misuse, and 23.4% (n=128, 29 
missing) had received training on the prevention of blood borne diseases.
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Format of past training
Most respondents who had had training on drug misuse most frequently mentioned 
the Centre for Pharmacy Postgraduate Education (CPPE) Distance Learning course 
as the source of their training. (58.8%, n=160) followed by Royal Pharmaceutical 
Society of Great Britain (RPSGB) local branch meetings. (30.8%, n=84) 15.1% 
(n=41) of respondents who had had past training on drug misuse reported that they 
had this as part of their undergraduate pharmacy degree course. The format of drug 
misuse training reported by the respondents to the full version of the questionnaire 
is shown in Table 22 below.
Yes (%) No (%) Missing (%)
Undergraduate Course 41 (15.1) 227 (83.4) 4(1.4)
Postgraduate Training 28 (10.2) 239 (87.8) 5(1.8)
CPPE Distance Learning 160 (58.8) 106 (38.9) 6 (2.2)
Local Branch Meeting 84 (30.8) 182 (67.0) 6 (2.2)
Other Training 61 (22.4) 205 (75.3) 6 (2.2)
Table 22: Format o f Drug Misuse Training (n=272)
Conversely, 48.4% (n=62) of respondents who had had training on the prevention of 
blood borne disease said that this had been taught as part of their undergraduate 
degree and only 19.5% (n=25) had undertaken training from the CPPE. The format 
of training on the prevention of blood bome disease is shown in Table 23 below.
Yes (%) No (%) Missing (%)
Undergraduate Course 62 (48.4) 66 (51.6) 0(0)
Postgraduate Training 19(14.8) 109 (85.2) 0(0)
CPPE Distance Learning 25 (19.5) 103 (80.5) 0(0)
Local Branch Meeting 17(13.2) 111 (86.8) 0(0)
Other Training 35 (27.3) 91 (71.1) 2(1.6)
Table 23: Format o/Blooa f borne Disease Training (n=128)
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Further training
The desire for further training was evident, with 80.4% (n=438, 30 missing) and 
76.3% (n=416, 36 missing) of respondents to the full version of the questionnaire 
stating that they would like further training on the topics of drug misuse and 
prevention of blood borne disease respectively. Most respondents felt that they 
would like this training in the form of distance learning packs, 60.5% (n=265, 4 
missing) and local workshops, 56.3% (n=247, 5 missing) for drug misuse training. 
Similarly, most of those desiring more training on the prevention of blood borne 
disease wanted it in the form of distance learning packages (64.1%, n=267, 19 
missing) and local workshops (46.1%, n=192,21 missing)
Suggestion of topics for future Drug Misuse training
Respondents were asked which topics they would find most useful in a future 
training session on drug misuse. Suggestions were made by 175 respondents with 
the majority suggesting that training on the practical issues surrounding providing 
services to drug misusers would be helpful (60.0%, n=105). Such issues included an 
understanding of how people ‘get into drugs’, how much they cost and how 
treatment programs work. Several respondents wanted to know ‘How to provide 
better services. ’ (14.3%, n=25)
4,1.5,3. Statistical Analysis o f Knowledge Scores and Demographic Information
Age and Gender
Neither the age group \p=0.933] nor gender \p=0.205] of the respondents had a 
significant difference on their scores in the ‘Knowledge’ section of the
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questionnaire. (Measured by one-way ANOVA and independent samples T-Test 
respectively.)
Years on the Pharmaceutical Register
The number of years that the respondent had been on the Pharmaceutical Register 
did not have a significant influence on their knowledge score. (p=0.995t one-way 
ANOVA)
4,1.5.4, Statistical Analysis o f Knowledge Scores and Service Provision 
Selling needles and syringes
The participants score on the knowledge section of the questionnaire did not 
significantly differ depending on the participants reported needle and syringe selling 
activity, ip =0.602, one-way ANOVA)
Providing a Needle Exchange scheme
The participant’s knowledge score significantly differed depending on whether they 
reported providing or not providing a needle exchange scheme. [Independent 
samples T-Test, /?=0.000]
Dispensing methadone to drug misusers
Participants did not differ in their knowledge score depending on whether they 
dispensed methadone to drug misusers or not. ip=0.319, one-way ANOVA)
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4.1.6. Part Four -  Opinions on Drug Misusers, their Treatment and the 
Pharmacists’ Role (Attitude Scale)
4.1.6.1. Range o f Attitude
As expected there was a range of attitude scores of the respondents to the full 
version of the questionnaire. The average score was 11.3 (max 47.0, min -38.0, SD
12.3. The attitude scores were normally distributed and therefore parametric 





0 Q 0 30 05 0 35 0 45 0
Total Attitude Score (respondents to full version)
Figure 4: Distribution o f responses to the attitude scale
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4.1.6.2. Reliability o f the Attitude Scale
Reliability of the attitude scale was measured using Cronbach’s alpha. The analysis 
resulted in an alpha score of 0.813, indicating that the scale had good internal 
consistency that is to say that the statements within the attitude scale correlate 
highly with one another.
4.1.6.3. Validity o f the Attitude Scale 
Construct Validity
The tests that follow demonstrate that the attitude statements had good construct 
validity.
1. Of those providing a supervised methadone consumption service, 90% disagreed 
with the statement, 7 believe that I  would never supervise the consumption o f doses 
o f Controlled Drugs by drug misusers on my pharmacy premises \
2. Of those providing a needle/ syringe exchange scheme, 68% agreed with the 
statement, 7 believe the community pharmacy is an appropriate place fo r a needle 
exchange scheme \
Psychometric Validity
Initial examination of the attitude scale using the Kaiser-Meyer-Olkin (KMO) index 
of sampling adequacy gave an index score of 0.853. Indexes over 0.6 are required 
for a robust factor analysis. (Pallant, 2002) Bartlett’s test of sphericity was 
significant with p<0.0001 indicating that the data is suitable for factor analysis.
The subsequent factor analysis indicated that there were nine factors with an eigen 
value over 1, whilst examination of the scree plot suggested that there were five
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factors before the change in shape of the curve. It was decided to retain five factors 
for the subsequent analysis.
The five factors were interpreted as:
1. Attitudes towards providing services to drug misusers.
2. Attitudes towards the supply of needles and syringes and the effect on the 
community.
3. Attitudes towards providing advice and support.
4. Attitudes towards the treatment of drug misuse.
5. Attitudes towards drug misusers.
















39 I believe that prescribing maintenance doses of a Controlled Drug to 
a drug misuser will improve their quality of life.
103 (19.3) 310(58.2) 78 (14.6) 27 (5.1) 9(1.7) 6(1.1)
40 I believe that providing drug misusers with maintenance dose of 
Controlled Drugs will stop them using street drugs.
35 (6.6) 147(27.6) 176 (33.0) 142 (26.6) 28 (5.3) 5 (0.9)
41 I believe drug misusers should only be prescribed Controlled Drugs 
if they are in reducing doses to help them ‘come off drugs.
98 (18.4) 158 (29.6) 82 (15.4) 158 (29.6) 31(5.8) 6(1.1)
42 I believe that providing maintenance doses of Controlled Drugs to 
drug misusers is a waste of NHS resources.
21 (3.9) 51 (9.6) 86(16.1) 247 (46.3) 123 (23.1) 5 (0.9)
43 I believe that Controlled Drugs should be dispensed to drug 
misusers through a central clinic rather than community pharmacies.
63 (11.8) 85 (15.9) 69 (12.9) 201 (37.7) 111 (20.8) 4 (0.8)
44 I believe that community pharmacists have a duty to provide 
services to drug misusers in order to protect the wider community 
from the consequences of drug misuse.
90 (16.9) 268 (50.3) 84(15.8) 66 (12.4) 20 (3.8) 5 (0.9)
45 I believe that providing maintenance doses of Controlled Drugs to 
drug misusers is part of a pharmacist’s professional duty.
89(16.7) 296 (55.5) 57 (10.7) 70(13.1) 16 (3.0) 5 (0.9)
46 I believe that my staff would rather not have to deal with drug 
misusers.
90(16.9) 182 (34.1) 79 (14.8) 156(29.3) 22(4.1) 4 (0.8)
47 I believe that drug misusers visiting my pharmacy endanger the 
safety of my staff.
31 (5.8) 82 (15.4) 123 (23.1) 245 (46.0) 48 (9.0) 4 (0.8)
48 I believe that drug misusers visiting my premises have a damaging 
effect on business.
46 (8.6) 107 (20.1) 138 (25.9) 206 (38.6) 32 (6.0) 4 (0.8)
49 I believe that drug misusers who visit my pharmacy are treated by us 
as ‘normal’ members of the public.
163 (30.6) 279 (52.3) 45 (8.4) 34 (6.4) 7 (7.3) 5 (0.9)
50 I believe it is a persons’ own fault if they become addicted to drugs. 30 (5.6) 106 (19.9) 150(28.1) 197 (37.0) 43 (8.1) 7(1.3)
Table 24: Response to Attitude Statements (Questions 39-50) (n=333)
















51 I believe that syringes/ needles should only be supplied as part 
of a needle exchange scheme.
132 (24.8) 236 (44.3) 56 (10.5) 91 (17.1) 13 (2.4) 5 (0.9)
52 I believe that drug addiction is an illness not a vice. 59(11.1) 229 (43.0) 131 (24.6) 95 (17.8) 15 (2.8) 4 (0.8)
53 I believe that all drug misusers should be encouraged to ‘come 
of drugs altogether.
159 (29.8) 288 (54.0) 51 (9.6) 23 (4.3) 6(1.1) 6(1.1)
54 I believe that selling syringes/ needles encourages illicit drug 
misuse.
33 (6.2) 116(21.8) 128 (24.0) 214 (40.2) 36 (6.8) 6(1.1)
55 I believe that drug misusers are taking some responsibility for 
their health if they ask to buy syringes/ needles.
43 (8.1) 360 (67.5) 78 (14.6) 38 (7.1) 9(1.7) 5(0.9)
56 I believe it is unethical to sell drug misusers’ needles or syringes 
without having a means of disposing of them.
121 (22.7) 277 (52.0) 73 (13.7) 49 (9.2) 6(1.1) 7(1.3)
57 I believe the community pharmacy is an appropriate place for a 
syringe/ needle exchange scheme.
75 (14.1) 237 (44.5) 110(20.6) 77 (14.4) 31 (5.8) 3 (0.6)
58 I believe that I would never supervise the consumption of doses 
of Controlled Drugs by drug misusers on my pharmacy 
premises.
12 (2.3) 16 (3.0) 40 (7.5) 199 (37.3) 263 (49.3) 3 (0.6)
59 I believe supervising consumption of Controlled Drugs by drug 
misusers on the pharmacy premises is an inappropriate role for 
the community pharmacist.
37 (6.9) 67 (12.6) 63 (11.8) 184 (34.5) 178 (33.4) 4 (0.8)
60 I believe that supervising the consumption of Controlled Drugs 
by drug misusers prevents the illicit selling of these drugs on the 
street.
168 (31.5) 231 (31.5) 51 (9.6) 55 (10.3) 25 (4.7) 3 (0.6)
61 I believe that a drug misuser should have a private area in the 
pharmacy when (s)he is being supervised consuming a dose of 
Controlled Drug.
149 (28.0) 290 (54.4) 58 (10.9) 24 (4.5) 7(1.3) 5 (0.9)
Table 25: Response to Altitude Statements (Questions 51-61)
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62 I believe that a drug misusers is embarrassed when they have 
to consume their dose of a Controlled Drug in front of a 
member of staff, or whilst other customers are looking on.
64 (12.0) 218(40.9) 136 (25.5) 103 (19.3) 7(1.3) 5 (0.9)
63 I believe that a written contract between the pharmacist and 
drug misusers would help to develop trust between the two 
individuals.
99(18.6) 263 (49.3) 105 (19.7) 51 (9.6) 9(1.7) 6(1.1)
64 I believe it is appropriate for pharmacists to provide advice 
(verbal or written) to drug misusers on the management of 
drug misuse.
67 (12.6) 329 (61.7) 91 (17.1) 33 (6.2) 5 (0.9) 8(1.5)
65 I believe that I have sufficient knowledge about drug misuse 
to be able to provide advice to drug misusers on the 
management of their drug use.
31 (3.9) 114(21.4) 175 (32.8) 177 (33.2) 39 (7.3) 7(1.3)
66 I believe that I would never provide advice (verbal or written) 
on safer injecting to intravenous drug misusers.
37 (6.9) 93 (17.4) 175 (32.8) 173 (32.5) 50 (9.4) 5 (0.9)
67 I believe that it is the responsibility of the pharmacist to 
provide information on Controlled Drugs used in the treatment 
of drug misuse to a drug misuser.
46 (8.6) 291 (54.6) 125 (23.5) 60(11.3) 5 (0.9) 6(1.1)
68 I believe it is ethical to sell syringes/ needles to drug misusers. 28 (5.3) 232 (43.5) 134(25.1) 96 (18.0) 37 (6.9) 6(1.1)
69 I believe that I am adequately supported by the local Primary 
Care Trust in providing services to drug misusers.
21 (309) 171 (32.1) 191 (35.8) 110(20.6) 32 (6.0) 8(1.5)
70 I believe that the reason services are provided for drug 
misusers is to improve the quality of life of that individual 
rather that the community as a whole.
21 (3.9) 171 (32.1) 191 (35.8) 110(20.6) 32 (6.0) 8(1.5)
Table 26: Response to Attitude Statements (Questions 62-70)
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4.1.6.4. Statistical Analysis o f Attitude Score and Demographic Information
Age and Gender
A two-way ANOVA was conducted to explore the impact of age and gender on 
attitude score. Respondents were divided up into three groups according to their age 
(Group 1: 21-34 years; Group 2: 35-47 years; Group 3: 48 years and above). There 
was no significant difference in attitude between age groups or gender. There was a 








Figure 5: Results o f two-way ANOVA showing the effect o f age group and gender 
on attitude score
To further investigate the effect of age on attitude score, a Pearson’s correlation co­
efficient was calculated. The analysis revealed a small, negative correlation between
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age and attitude (r= -0.12, p=0.034) indicating that attitude to drug misusers 
decreases with age.
Years on the Pharmaceutical Register
A one-way ANOVA was performed to explore the impact of the number of years on 
the Pharmaceutical Register on respondent’s attitude towards drug misusers. The 
number of years on the register was divided into three groups, 0-9 years, 10-24 
years and 25+ years. A significant difference in mean rank score was found between 
the three groups (p=0.024), with those respondents on the register for 0-9 years 
ranking higher (mean 12.57, SD 11.79) than those registered between 10-24 years 
(mean 10.02, SD 12.8) and those registered for more than 25 years (mean 10.86, SD 
12.3).
Similarly to the correlation between attitude and age, a small, negative correlation 
was found between attitude and the number of years that the respondent had been 
on the Pharmaceutical Register. (Pearson’s co-efficient t=-0.094,/?=0.039)
Location and Type of Pharmacy Business
A one-way ANOVA indicated that the location of the pharmacy (as previously 
defined) did not have a significant impact on the respondent’s attitude score 
[p=0.726]. Similarly, there was no significant difference in attitude score depending 
on the type of business that the respondent worked in [p=0.343] as previously 
defined.
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4,1.6.5. Statistical Analysis o f Attitude Scores and Service Provision
Selling Needles and Syringes to suspected drug misusers
A one-way ANOVA revealed that there was a significant difference in attitude 
score between those respondents who were prepared to sell needles and syringes to 
suspected drug misusers and currently did; those who were prepared to sell but 
reported no demand and those who were not prepared to sell [p=0.001] (Table 27).
Prepared to sell needles? N Mean SD
Attitude YES, currently do 103 14.49 11.49
Score YES, no demand 156 12.37 11.91
NO 232 9.30 12.57
Total 491
Table 27: Attitude score (mean and standard deviation) by willingness to sell 
needles and syringes
Providing a Needle Exchange Service
An independent sample T-test revealed a significant difference in attitude score 
between respondents who reported providing a needle exchange scheme and those
who did not. [p=0.000] (Table 28).
Provide Needle Exchange? N Mean SD
Attitude YES 88 15.65 13.26
Score NO 385 10.29 12.12
Total 473
Table 28: Attitude score (mean and standard deviation) by needle exchange 
provision
Dispensing methadone to drug misusers
A one-way ANOVA revealed that there was a significant difference in attitude 
score between those respondents who reported dispensing methadone to drug
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misusers, those who reported that they did not do so because there was no demand
/
and those who did not because they were not willing to [p=0.000] (Table 29).
Dispense Methadone? N Mean SD
Attitude YES 359 12.61 11.78
Score NO (no demand) 110 9.86 11.36
NO (not willing) 24 -3.16 16.06
Total 493
Table 29: Attitude score (mean and standard deviation by methadone dispensing 
activity
4.1.6.6. Statistical Analysis ofKnowledge Score and Attitude
There was a positive correlation between the participant’s attitude (measured by 
part four of the questionnaire) and their score on the knowledge section (part three). 
This indicates that participants with higher knowledge scores had a more positive 
attitude towards drug misusers. (Pearson’s rho r=0.167,/?=0.000)
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4.2. SEMI-STRUCTURED INTERVIEWS WITH COMMUNITY 
PHARMACISTS
4.2.1. Interpretative Phenomenological Analysis
Thirty-one interviews were conducted by the researcher between September 2004 
and January 2005.
Following the ‘Theming’ stage of the analysis, 108 themes emerged.
The ‘Clustering’ process resulted in 14 major themes with underlying sub-themes 
which helped to explain the meaning of the theme. Further clustering resulted in 
some sub-themes moving between major themes and major themes themselves 
being clustered. For example the themes of ‘Support’, ‘Teamwork’ and 
‘Communication’ were clustered together under the major theme of ‘Working with 
others’. These themes were renamed to reflect the nature of the theme. For example 
the major theme ‘Working with others’ was renamed ‘Experience of working with 
others’. This exercise resulted in 9 major themes.
4.2.2. Resulting Themes
Each major theme will be discussed and within each theme some of the constituent 
sub-themes will be shown in emboldened italics. Narrative extracts are included in 
order to illustrate the theme and allow explicit understanding of the meaning. 
Pseudonyms have been used to ensure participant anonymity. Numbers in brackets 
represent the paragraph number of the transcription in which the quote appears.
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4.2.2.L The pharmacists9 perception o f  their role
Participants described their role in the management of substance misuse in three 
ways. These were termed ‘traditional’, ‘social’ and ‘advice giving’.
a. Traditional Role
The *traditional role9 was described as dispensing and supply of drugs for the 
treatment of opiate addiction. Some felt that their only role was as a supplier of 
medication. Simon represented the views of these pharmacists when he said 7 think 
it (our role) is just to supply and make sure that they comply with the prescriber’s 
wishes o f daily consumption on the premises or take away ’ (5)
b. Social Role
This role was more difficult to define, but was centred on the observation that ‘We 
are the people that will see the client the most out o f anybody... ’ (Norman, 9). 
Participants talked about a *social role9, that, because they had regular contact with 
the client, they were able to build a relationship with them. George summed this up 
well when he said ‘We build up a close relationship with them, we are almost like a 
mother hen to them! ’ (9) he went on to describe how this relationship was perceived 
to benefit the client, 7 have known a lot o f them a long time and they will talk to 
me. I f  I  turn round and say “you don’t look very good today” they are more likely 
to talk to me than they would to a local GP. ’ (21) Other participants also recognised 
that clients may be more likely to ask advice of their pharmacist because they knew 
them better.
- 1 3 6 -
Chapter Four - Results
c. Advice Giving
Pharmacists talked about their advice-giving role, recognising that they may be the 
only healthcare professional that a drug misuser is in contact with. Harriet explained 
by saying ‘Essentially there is a point where you can intervene in the course o f a 
drug users ’ experience with drugs... you are seen as a place where you can start to 
get better, whether it is through needle exchange or by becoming scripted. ’ (7)
Many participants recognised that being accessible was a major part of their role. 
Paul said 7 think pharmacy is an ideal place [for needle exchange] because there is 
one on every street comer...’ (63) whilst Adam recognised that ‘they don’t need 
appointments, its easy access. ’ (50)
In conclusion, participants had varying views on their role and how much weighting 
the traditional versus social roles had. However, Norman summed this up well when 
he said 7 think we have a vital role, I  think a holistic role. It is not just a case o f 
preparing the methadone and Subutex every day. ’ (5)
4.2.2.2. The experience o f  working with others
This major theme consisted of teamwork, support, communication and pharmacy 
sta ff as sub-themes. These sub-themes represented the ‘core’ of what was being 
spoken about in the interviews and for this reason they will be discussed in turn.
a. Teamwork
The participants’ experience of working within a team (i.e. prescriber, key worker, 
pharmacist) was varied. Lottie echoed the experience of many pharmacists
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interviewed when she said ‘We are not seen as being an integral part o f their 
[clients] care. ’ (117) Indeed, Kath felt the problem of pharmacists’ integration was 
wider than in the treatment of drug misuse when she said 7 think it comes back to 
the health services generally, not just working with drug users. Pharmacists aren ’t 
seen as part o f the NHS team.' (125) and described how the failure to integrate 
pharmacists into the drug misuse team had had a negative impact on a client. ‘I f  
they had said, well let's try to get to the bottom o f what has happened because 
actually we have got problems, that might be the final straw that [stopped him 
getting] kicked off... but they didn 7 \  (93)
Some pharmacists had a different experience. Nigel said ‘We work really well as a 
team and it's quite good because at the moment the shared care team do see 
pharmacy as an important part’ (129). Those pharmacists who felt that they were 
part of the team talked about the benefits that this brought. Norman said ‘It is quite 
clinically rewarding to be considered part o f the team which were are in [location], 
you know, the pharmacist is quite a large part o f the drug and alcohol team... and I  
can 7 think o f another therapeutic area where I  have that much clinical influence. ’ 
(51) Some ‘integrated’ pharmacists also described how being included in the team 
could benefit the client. Grant said 7 spoke to the GP and recommended that she 
[the client] actually tried to get an appointment with the [psychiatry] specialist and 
that came about and she is on lithium now...I was able to make a difference by 
actually seeing her every day and having a positive impact on that’ (134)
Some pharmacists also talked about the barriers that prevented pharmacists 
becoming integrated into the team. Kath described how ‘they only want information
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feeding in and they never feed anything out and we have discussed this at the 
Shared Care Monitoring Group and it's “oh patient confidentiality” and “oh I  
don't know that we can say that'" (93). Other pharmacists spoke about the lack of 
two-way information sharing. Ellie summed this up when she said ‘More in the loop 
rather than there's your prescription, I'll see you in a couple o f days. Not there's 
your prescription I'll have a chat to the pharmacist to see how you are getting on 
and any problems you feed that back to them.' (237) Some participants suggested 
how team working and pharmacist integration could be improved, Sandra felt that 
‘by pharmacy becoming more involved with the NHS, you know electronic linking 
up to NHSnet, or whatever its called... to be able to send an email to a GP that says 
you have written this wrong, please send an electronically written script that is 
acceptable under law... I  think the whole system o f writing prescriptions and 
dispensing them needs to be re-thought.' (87) Harriet said that she ‘would like 
regular meetings with GPs and with practice staff in my opinion as it helps us work 
better as a team’ (126) she also suggested that a ‘model of care’ should have a 
description of ‘our [the pharmacists] role and how it interlinks with the other 
professionals. ' (178) and Paul described how he was part of the shared care team 
and was responsible for developing a contract ‘not so much to rein in the drug 
misusers but actually to make the services work together and support each other 
really’
b. Support
This sub-theme refers to the pharmacists’ experience of the support that they 
receive in order to provide services to drug misusers. Again, the experience varied 
between participants. Unfortunately, most participants felt that support in this area
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was lacking. Simon said ‘Well, I  don *t receive any support. The client turns up with 
their prescription and it is up to m e’ (139) and Paul felt the same, saying ‘as far as 
support generally at the moment there is very little in the way o f training or, well 
anything really. ’ (99) Nick described an incident whereby the pharmacy had 
complained to the local drug service that a client had been spitting at pharmacy 
staff. He said ‘we reported it to [the local drug service] who immediately got the girl 
in, stopped her methadone and told her it was us who reported her. Then had the 
audacity to phone us up and say watch your backs, she will be gunning for you. I  
don’t think that is support. '(115).
Other participants described ‘support’ in terms of financial reimbursement for 
providing supervised methadone whilst some said that there was initial support 
when the services were originally being set up although this was not maintained in 
all cases. Vicky explained; ‘initially as we set up the needle exchange there was 
support. Now I  think we are just left to manage it, which is fine, but it would be nice 
to have a review every so often to see how it is going and I  mean my experience 
might be totally different to the experience down the road, so these sort o f things 
make you reassess what you are doing. So, initially there was quite a lot o f input, 
that has gone. ’ (97)
A few participants indicated that they did feel supported although these comments 
were in the minority. Adam said ‘certainly the local drugs team are pretty good, 
um, it is the same as anything, until you have got a problem you never really know 
how good they are. ’ (98) George was more positive about his experience saying
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'Within the [local] group we tend to have [a network] we talk to each other and if  
there is a problem we can ring each other up. ’ (198-200)
Three participants who were involved with their respective local drug teams had 
similar views. An example of this view was demonstrated when Grant said 7 think 
an issue is that sometimes professionals don’t go out and look for the support and 
lookfor what’s available’ (148). David explained that it was possible to get support, 
but felt that you had to show your interest; 'You need to make contact so that you 
can put a name to a face and people know that you are interested and i f  you need 
support then they will come and give it to you. ’ (113-115).
One participant who works part time for the local DAT felt that individual 
pharmacists needed to build up individual relationships with the local drug service 
rather than all the support coming from her. She explained 7 circulated a laminated 
sheet to pharmacies with my phone number on with basic details about how 
treatment services work... I  want to sort o f empower them to build up their 
relationships with [local drug services] to sort out their own concerns. ’ (105)
Participants were asked about the support that they would like. The most common 
reply was centred on the need for more training in the areas of substance misuse. 
This said, there was a perception among some participants that there was little 
money available for this training. ‘There is money for training GPs, you know there 
is money for training everyone but it never filters down to pharmacists. ’ (Nigel, 
113). The importance of training was a recurring theme within the interviews and 
will be discussed later in this chapter.
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Another pharmacist felt that there should be more ‘formal’ lines of support for 
pharmacists involved in treating drug misusers and eluded as to where this support 
should come from. Bill explained ‘there is nothing formal and I  think having 
something formal would be useful. I  think the PCT sent out an audit that we were 
supposed to carry out which I  did, but that was years ago and there was no update 
on the audit etc. so that was a good beginning and that was about all there was. ’ 
(158)
c. Communication
The reported extent of communication between the pharmacist and the prescriber 
and/ or key workers varied greatly between participants. Many of the pharmacists 
interviewed felt that there was a lack of two-way communication between the 
pharmacist and prescriber. Nick said ‘They drop in prescriptions, we dispense 
them... ’ (119). Greg explained how this could cause confusion, ‘We have just had 
somebody who was on just a weekend pick-up and they have changed to a daily 
pick-up and we weren’t told about this. We suddenly got a script in the post and 
didn’t know what was going on.’ (161) He went on to explain how better 
communication with the pharmacist could help the outcome for the client, saying 
‘The patient’s demeanour, how they are looking, i f  they are looking ill, whether they 
are loosing weight, all kinds o f things like this... i t ’s silly things like this but I  think 
it would be useful information to be fe d  back. ’ (187). Similarly, Tim felt that he was 
only contacted when the drug and alcohol team had a concern about a client, 
‘rarely, usually when they are concerned about clients and they want to know about 
their behaviour.’ (197).
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Some participants gave examples of good communication between pharmacists and 
key workers. Adam described what happens at the start of a client’s treatment, 
' When you get new patients the key worker will come in and introduce the addict 
and give them their new script by hand, sort o f thing, and certainly that happens 
around here. ’ (102). Sandra explained how working with the DAT has ensured that 
her ‘needs’ are met, ‘...they call me up and we go through what I  want before and 
then their key worker sets that out. ’ (21). She later added, ‘Quite often one o f the 
key workers will bring over a correct prescription...’ (25). Maxwell felt that, ‘The 
more information we get, the better, but the key workers will ring us up i f  they have 
a problem with a patient or i f  they are going to change the patient’s medication, 
they will provide us with the prescriptions... and it works extremely well. ’ (114). 
Some participants felt that the feedback they gave about clients was given due 
thought. Norman said ‘from the general welfare point o f view, i f  you ring and say 
there are problems with this client then it is normally acted upon... ’ (13).
Participants had some suggestions as to how communication between pharmacists 
and prescribers/ key workers could be improved. Lottie simply suggested ‘having a 
point o f contact for that key worker... ’ (113). Similarly, Kath suggested, '... [the] 
key workers name on the prescription.’ (113) One participant talked of having 
regular conversations with key workers by way of a ‘check-up’, I  would like a 
system whereby they [key workers] took more interest in the individual client and 
there was like a three month check-up...with the pharmacist who is supplying the 
methadone. ’ (Nick, 123) Another respondent suggested some form of written 
feedback, '... maybe through like a questionnaire that we could post back to them,
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something like a feedback form it doesn't have to take long, a few words but it 
opens up a whole new window doesn *t it? * (Ellie, 209)
d. Pharmacy Staff
Participants talked about their experiences of working with their pharmacy support 
staff. The majority of participants felt that their staff were ‘happy’ to provide 
services to drug misusers. Lottie explained, 7 think they [pharmacy staff] see the 
benefits to the community as a whole because i f  they are helping to deal with 
people’s drug problems then they can have an impact on crime related to drugs and 
dirty needles on the street...’. (19) Another common comment was that pharmacy 
staff tended to follow the pharmacist’s lead. 7 think my staff are fine because I  am 
fine and I  think the staff will follow the pharmacist and I  think i f  the pharmacist is 
positive about it and treats the drug misusers with respect then the staff tend to 
follow suit. ’ (21)
Some participants conceded that some of their staff were not so enthusiastic about 
providing services to drug misusers. Most of Lottie’s staff were comfortable with 
their role, but ‘...others think that it is a complete waste o f time and is more o f a 
hassle than it is worth/ (15) She went on to explain why she though this was 
‘...they tend to focus on the bad things that have happened in the past and a small 
minority o f people have shop lifted and caused various other problems in the shop 
and they always tend to focus on those issues... they can't seem to see past that. ’ 
(27).
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Most participants felt that staff unease about drug misusers was because of concerns 
about their own personal safety, ‘...well i f  there is trouble in the shop the staff get a 
bit concerned about it...I mean i f  we get real problems then we will pull the plug on 
it [the prescription] and I  will talk to the drug team and they would stop it. But the 
safety o f the staff would come first in spite o f our goodwill. ’ (Malcolm, 25)
One participant registered concern about a member of staff who lived close by the 
pharmacy, saying, 7 must always remember that they live in the local area, so they 
live amongst them [the clients].../ also have to bear in mind that I  drive home at 
night but they are all walking past a particular member o f s ta ff s house and I  am 
concerned about that. ’ (Kath, 21)
In spite of some participants expressing staff concerns about providing drug misuse 
services, this comment from George represents a common theme in the interviews. 
7 think initially there was a certain amount o f resentment. I  think the more we do 
and the more they see results, they see people clean their act up, the more they are 
getting quite happy with it. ’ (29)
4.2.2.3. Legal and ethical considerations
The legislation surrounding Controlled Drugs was a major topic of the interviews. 
Participants were divided about how the Misuse of Drugs Act affected their work 
with drug misusing clients. Simon represented the views of some participants when 
he said ‘...the law is the law and I  will not dispense anything unless it is correct, in 
spite o f knowing that the thing is genuine. ’ (70)
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Other pharmacists were more pragmatic, Maxwell felt that, 'There has to be a 
certain amount offlexibility within that because pragmatically, i f  you are dealing 
with someone on a Friday night and there is no opportunity o f actually receiving 
that prescription until Monday morning and they need their methadone then one 
has to be flexible... however we have to be very careful not to break the law and not 
to abuse the situation that we find  ourselves in. ’ (87)
In one instance a participant received a letter from the Statutory Committee of the 
Royal Pharmaceutical Society after he had dispensed methadone from a faxed 
prescription. He explained 7 dispensed a fax prescription knowing fu ll well that it 
was going to come the next day. It wasn’t the client’s fault we had messed up...we 
should be able to, i f  we know that it has come from the prescriber, it is in his 
writing. (George, 235) He added later, 7 had to acknowledge that I  had received a 
letter and I  wouldn’t do it again. To me it was undermining our professional 
judgement. ’ (247).
A number of participants felt that incorrect prescriptions for Controlled Drugs had a 
negative impact on the client, ‘That’s probably the most nuisance because it is not 
the patient’s fault, it is not my fault... but I  can’t do anything about it and i f  I  have 
got to send somebody, who has already travelled 20 miles to my pharmacy because 
he likes to come here, back because the doctor’s written it wrong and they often 
don’t have easy transport, possibly because o f poverty issues involved with their 
habit, then it makes me feel bad that I  can ’t give them good service... ’ (Sandra, 83) 
and many felt that '... the doctors who should know how to write a prescription 
[are] not doing it correctly. ’ (Bill, 128)
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The ethical considerations discussed by participants were centred on client 
confidentiality. Confidentiality was seen, by some, as a barrier to information 
sharing about a client. Harriet explained ' When I  speak to a key worker, i f  I  
specifically ask some questions I  know they will only tell me some o f the 
information, they won’t necessarily tell me, some, will, but most o f them won’t tell 
me i f  there is something else in the offing for that client. You discover it later on and 
on odd occasions I  have been told -  that's because I  didn’t need to know it, so I  
have to assume that it is confidentiality. ’ (148)
Similarly, George felt he had a duty of confidentiality to his clients, saying ‘It 
depends what the information is; normally nothing and I  may counsel or talk to 
them. Most o f it is confidential, but i f  it is bad enough then, yes, I  might have an o ff 
the record conversation. ’ (25)
Simon raised a concern about the lack of confidential information sharing, saying, 7 
think i f  I  am going to be dealing with them on a daily basis, and my staff, then I  
think we should be given some information i f  they are HIV positive or anything. ’ 
(66)
Participants differed in the amount of confidential information that they wanted 
about the client. Some felt they needed very little, 'Not a lot, but I  don’t think we 
need a lot... ’ (Greg, 161) He went on to say ‘...what is happening and as much 
information as they can provide without jeopardising confidentiality. We don ’t want 
to be nosy but it’s just nice to be kept informed... ’ (173) others felt that they needed
- 147-
Chapter Four - Results
more information about the client in order that they could provide better support, 
Maxwell explained, 7 would like to know a little more about their background; 
where they have come from. Again, that is confidential information but i f  they have 
been on the scheme for some time and they have moved from another area I  would 
like to know that. I  would like to know their medical history; I  would like to know 
their social background as well, so that we can give greater support. ’ (75)
4.2.2.4, The importance o f training
Comments about the availability of training differed. For example, Tim said 
*Training? I  haven’t had any and wasn’t aware i f  there is any. ’ (133) whilst in 
another area the experience was different, ‘Everyone gets invited, [to training 
sessions] whether people go or not is up to them. ’ (George, 176)
The importance that participants linked to training sessions was evident, George 
commented on the chance to network, ‘...the chance to talk to people who are doing 
the same thing. ’ (196) He also commented on how his training had improved their 
service to clients, saying, we have even been taught, instead o f using heroin we 
use Nescafe, but how to actually draw the syringe up to the filter... you could 
actually tell them how to inject more safely... ’ (184) Greg, who had completed the 
Royal College of General Practitioners Certificate in the Management of Drug 
Misuse said that, 'It changed my opinions on drug treatment, like detox was the only 
goal and now maintenance is quite acceptable ...it was the evidence that was 
produced. The NTORS study and so on. ’ (118-120)
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Some participants felt that some of their colleagues would benefit from training in 
the area of drug misuse. Nigel commented, 7 think an awful lot o f pedantic 
pharmacists would learn a lot about not making life awkward for themselves. ' 
(121).
Participants spoke about the difficulty in attending training, for example, Kath said 
'pharmacists are really busy people; there is a limit to the number o f times you can 
call them out for an evening meeting... ’ (105)
The cost of training was also mentioned by a number of participants, ‘I f  you wanted 
30 pharmacists to turn up for a training day somewhere, the whole issue o f funding 
locum cover for an away day. ’ (Nigel, 117)
Despite the difficulties in attending training sessions that were mentioned, the 
majority of participants agreed that further training in the subject was important to 
them. They had a wide range of opinions as to what the training sessions should 
consist of; George suggested 'Anything and everything I  think! ’ (178) a summary of 
the training needs identified by the participants is shown below.
‘How they get into the problem’ ‘Use of pump dispensers’
‘How to inject safely’ ‘Cost of street drugs’
‘Street terminology’ ‘How much do people use?’
‘Why are people on maintenance?’ ‘Who is the prescriber?’
‘Needle exchange -  best practices’ ‘How to handle conflict’
‘Up to date procedures’ ‘What goes on at a drug clinic?
Figure 6: Summary o f Pharmacist Interviewees Training Suggestions
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4.2.2.5. The importance o f  job satisfaction
Participants were asked what the positive aspects were in providing services to drug 
misusers. Factors supporting a feeling of job satisfaction could broadly be divided 
into intrinsic and extrinsic.
a. Positive Change
Most participants commented on seeing a positive change in the clients and many 
felt that this experience encouraged them to carry on. For example, Harriet said I t ’s 
very encouraging when someone comes back and says I ’ve been clean for two 
years, or I  am walking around in town and someone taps me on the shoulder and 
says ‘do you remember me from five years ago?” (110) Ellie felt the same, saying 
‘you see them walking around and they are clean shaven and they are building 
relationships with people and they are in the park with their kids, it’s probably 
something they would not have done 5 or 10 years ago, that’s brilliant, really 
good!’ (193)
Other participants talked about seeing clients reduce their dose of methadone as a 
positive aspect of their role, ‘when the dose gets reduced, they see it as an 
improvement and then they [the staff] are happy. ’ (Simon, 127) Client ‘gratitude* 
was mentioned as a positive aspect of providing drug misuse services, 7 have had 
several addicts ...who on leaving have said that they really appreciated the fact that 
I  treated them like another patient as opposed to a drug addict. And that is quite 
rewarding when that happens. ’ (Sandra, 150)
b. Feeling Valued
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Another intrinsic aspect of job satisfaction was the feeling that the participants were 
valued for their role in the treatment of drug misuse. Participants had mixed views 
on whether or not they were valued. Bill said, ‘In my experience I  would like to 
think I  am valued by the users, I  would be disappointed i f  I  wasn’t and I  think I  am 
valued certainly by some o f the prescribers and the nurse I  was mentioning as well. 
She often phones for advice and I  have become valued by her. ’ (166) Sandra felt 
differently, saying; ‘Um, no. I  think it is probably getting better. I  think it is one o f 
those things we get patted on the back for when it is politically correct to pat us on 
the back for it, but when it comes to well i f  you value us this much are you going to 
pay us to do it at a reasonable level it is oh... ’ (151). David expanded on why he 
felt that pharmacists were not valued, ‘...because it is inherent to this profession. 
Pharmacists have been fulfilling a social role for free and they are expected to do 
that for ever because they are the first point o f contact with the community ...people 
expect you to deal with it and therefore that’s why they don’t value it. * (123)
c. Financial
The major extrinsic contributor to participants’ job satisfaction was the financial 
benefit of providing drug misuse services. Graham admitted, ‘Well it is financial, 
you know I  am afraid we are all in business and we are paid for doing the work. ’ 
(121) Getting paid an appropriate amount was also important, ‘there is an issue 
about how much you are paid and whether you can really afford to run the service. ’ 
(Harriet, 34)
Intrinsic aspects of the participants’ job satisfaction were centred on the feeling that 
they were helping, ‘Well, feeling that we are helping...as a national problem,
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community problem and because they are local people and we want to help local 
people as well. * (Malcolm, 117)
d. Anti-social behaviour
A factor that had a negative impact of the participants’ job satisfaction was when 
they experienced antisocial behaviour from the clients in their care, for example, 
‘...there are instances when I  have had people shoplift in my shop and I  have 
trusted them and have taken people back on occasions when they have promised 
they will never do it again and I  have had my trust thrown back in my face and you 
just think why do I  bother? ’ (Lottie, 97)
4.2.2.6. The experience o f providing services to drug misusers 
Participants talked of their experiences in providing drug misuse services such as 
selling injecting equipment and pharmacy based needle exchange. They also 
discussed their views and experiences of dispensing controlled drugs for the 
treatment of drug misuse and supervising consumption of controlled drugs.
a. Selling injecting equipment
Not all participants were happy to sell injecting equipment to heroin users. Those 
who did most commonly cited ‘harm reduction’ as the justification for doing so. 
‘Mainly to stop them sharing or using dirty needles, that is the main reason. ’ 
(Simon, 84) Other participants had reservations about selling injecting equipment, 
Bill explained, 7 have done in the past [sell injecting equipment].../ am not sure
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whether it is still frowned upon, which is something to do with it, but that in itself 
does not put me off, but it is the same sort o f thing in that I  know that none o f the 
good pharmacies in town sell needles, so i f  a pharmacy near you starts, in the same 
way as i f  a needle exchange starts in town you will be absolutely inundated, and 
that in itself is enough to put me off. ’ (76) Several participants spoke about the lack 
of control when selling needles and this was a reason for not wanting to sell them. 
‘I f  I  am providing needles I  want it to be in a controlled way, whereas the needle 
exchange service; i f  somebody came in I  didn ’t know and wanted needles we would 
be quite happy to provide a pack... so that would be my way o f supplying it. I  
wouldn’t want to get involved in selling. ’ (Vicky, 59) Several participants did not 
sell injecting equipment were worried about how used works were being disposed 
of. Tim explained, (We used to do that /sell injecting equipment], we stopped doing 
that, partly because we had a huge demand for it, mainly because we were finding 
used syringes thrown in the street around behind the shop. ’ (45). One participant 
referred to the RPSBG guidelines on the sale of injecting equipment, saying ‘...the 
pharmacist o f course refers to guidelines that say you shouldn ’t supply them unless 
you have facilities for disposal. ’ (Kath, 44)
b. Pharmacy Based Needle Exchange
Participants’ experiences of needle exchange were either positive or negative in 
nature. Most participants who provided the service felt that community pharmacy 
was an appropriate location for the service because of the ease of access for would 
be clients. Indeed, George went as far as saying 7 think in an estate like this it is the 
only place for it... ’ (56) Grant said that pharmacies were an appropriate place for 
needle exchange, ’...for the simple reason that the supply o f methadone and
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Subutex is done in the pharmacy. It is regarded by clients as a place where they can 
go, it is a great place for harm reduction. ’ (74) Norman represented the views of 
some participants with his concern about public perception of the scheme, saying, 
I t  is sometimes difficult to balance a mother asking you questions about her young 
child when somebody wants a pack o f needles. Not because it is not the right place 
to do it, it is the public perception o f whether or not it is the right place to do it. ’ 
(27).
Malcolm felt that needle exchange supplemented the advisory role of the 
pharmacist and that this encounter with a client could be used to offer advice and 
support, '...types o f treatment, up to date types o f treatment, what equipment can be 
supplied, types o f administration, you know... Hep C risk, that kind o f thing. * (181)
Negative comments about needle exchange were mainly around the number of 
needles returned to the pharmacy. Greg summed up the view of many participants 
when he said, 7 like the idea o f needle exchange; unfortunately it tends to get as a 
needles going out scheme and I  don't think enough are returned. . . ' (59) Lottie was 
more pragmatic, ‘...we have a duty both to the patient and the community to make 
sure that they do safely dispose o f any needles that we provide to them, um, but I  
think there also needs to be some degree o f flexibility within that service as at the 
end o f the day we are looking at a harm reduction service and it is important that 
they use clean needles and I  think that somebody who repeatedly doesn't bring back 
dirty needles then I  think I  would probably have an issue with that. ’ (51) Incorrect 
disposal of used syringes was seen by some as a source of conflict between the 
pharmacy and the general public. ‘We get a little bit o f alienation from some o f the
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customers, some o f the locals, because when they [needle exchange clients] don’t 
bring one back and when they find  needles in playgrounds. ’ (George, 56) Previous 
‘bad’ experiences with poorly run needle exchange schemes can put pharmacists off 
providing the service. Kath explained, ‘...I tried to persuade a pharmacist to 
become a needle exchange outlet recently and [they] had very bad experiences from  
a badly run needle exchange somewhere else in the country and it wasn’t 
exchange... it was badly run and no needles were coming back and staff had been 
threatened and so I  think that is a huge barrier. ’ (49)
Lack of funding to provide needle exchange was seen as a barrier by some 
participants to participating in the scheme. One participant did not know of any 
needle exchange pharmacies in his town. He said, ‘my main concern at the moment 
is funding... there isn’t any, and what little there is, is inadequate... they have asked 
fo r volunteers but there was no funding so we wouldn’t do it. ’ (Bill, 54-66) Bill 
also voiced a concern about potentially being the only needle exchange pharmacy in 
his location. He explained, ‘...ifyou have one pharmacy in the area that does it then 
you are absolutely inundated. I  think that i f  all pharmacies did it then everybody 
would have a little bit o f people coming in and it wouldn’t be a tidal wave... you 
have less o f an opportunity to sit down and have a chat with them... ’ (52)
Several participants who provided needle exchange voiced a concern abut paying 
for hepatitis B vaccination for staff involved in running the scheme. Harriet was 
quite clear with her view, saying, ‘I f  pharmacies are doing needle exchange, the 
PCT should stump up for the Hep B vaccination. That is my viewpoint. ’ (168). 
Some participants talked about the ‘risks’ associated with providing needle
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exchange. Most agreed that the risk of needle stick injury was theoretical, and could 
be minimised by following a set protocol for handling returns, however, in one 
pharmacy a purpose built facility had been built to handle needle exchange. ‘The 
girls don ’t want to do it, but they won’t be involved because it will be out the back 
in our new facility. ’ (Nick, 53)
c. Dispensine Controlled Drugs
Participants had varying views about the use of opiate substitutes to treat heroin 
dependence. Some had read the available evidence; '... from the studies that have 
been Most felt that it was an appropriate way to tackle the problem, Nigel said, 7 
don’t have a problem with it... Alcohol, I  mean, what’s the difference. People will 
still drink regularly; it’s the same thing. I t ’s just that alcohol is legal, drug abuse is 
illegal and i f  it keeps peoples lifestyle stable so they can look after their families, 
hold down a job or whatever then I  don’t have a problem with it. ’
‘Keeping people stable* was a common reason given by participants for the use of 
drugs such as methadone and buprenorphine. Some participants commented on the 
doses being used. 7 think the highest I  think we have had is 180ml a day for a girl 
who was about two stone wet through. But she has come back down and I  think is 
on about 50ml now. It does work, it takes time but it works. ’ (George, 134) Others 
were concerned about the low doses that they saw on prescriptions, ‘...it is 
frustrating that you see people on 30ml and OK, I  know i f  you present to a doctor 
for the first time they are not going to wham you on 60 or 70mls but... ’ (Ellie, 125)
Several participants commented about the numbers of clients who had successfully 
detoxed from methadone, ‘In all the years I  have seen quite a few  methadone
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addicts, not a single one has actually kicked the habit. ’ (Simon, 96) whilst 
Norman’s experience was different, ‘...we normally have one or two a year who 
come offprescriptions altogether and people say to me, well that's not many, but I  
think when we consider the lifetime experience and the lifetime it has take, a -  for  
people to start and ask for help and then b -  to break their own habits, you know 
two a year is pretty remarkable to be honest. ’ (71)
Participants commented on maintenance prescribing, for example, Bill said, 7 think 
that there are obviously some people who are going to be addicted for the rest o f 
their lives and I  think that giving them a maintenance dose, i f  that is going to stop 
them using street heroin or is going to stop them stealing to try to fund their 
addiction, then I  think it is the right thing to do. ’ (120) whilst David said 7 have 
gone through a phase where you see people day after day and you never see them 
going down. You just wonder what is happening really... ’ (77)
d. supervising consumption
Most of the participants who supervised the consumption of controlled drugs by 
clients felt that it was a good idea, for example, 7 think the majority o f it should be 
supervised so that we know the patient is getting the correct dose and that they 
actually consume the dose themselves. (Bill, 5) and 7 think it gives the treatment 
services confidence to work with the volumes that are necessary for some people. ’ 
(Kath, 137) However, Malcolm was concerned about the clients’ privacy and 
dignity, saying 7 feel uncomfortable fo r  them, you know, so I  don’t think it is the 
right place to do it. ' (105) and Grant admitted, ‘We don’t have the best facilities for  
doing supervised but we are actually not adapting the premises because we are
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moving into a surgery and we are going to have a counselling area for supervision. ’ 
(78)
Payment and training for supervised consumption were discussed by some 
participants. One had heard that some PCTs require their pharmacists to be 
accredited in order to be able to supervise consumption. He explained, ‘...to get 
accreditation you have got to do certain training courses but I  don’t know anything 
about it, but it sounds like it must be better than what is going on here. (Bill, 162). 
Tim voiced concern about the method of paying pharmacists for supervised 
consumption in his area, 7 haven’t seen a form for about a year or so and when you 
phone up they say, oh we posted [it] to you, you can’t have another. That’s it until 
the next quarter.’ (165)
Most participants who were involved in supervising Subutex had concerns about the 
process. ‘We have a policy o f three minutes, so yeah, they have to hang around but 
then again that is another issue isn’t it? What is supervision? There are a lot o f  
issues involving supervision o f Subutex. I  routinely check the patient’s mouth before 
they leave...there are ways around it. So there is no 100% way to supervise Subutex 
effectively. ’ (Grant, 87). Similarly, Ellie said, ‘It goes under the tongue and they sit 
or they stand and talk to me... I  never really know and there isn’t really any 
guidelines like methadone... ’ (157)
The use of ‘contracts’ with supervised clients was discussed by participants. Most 
participants were familiar with the use of contracts, but the perceived benefits of 
such a document were varied. For example, Ellie felt that contracts were ‘...a good
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icebreaker...it is nice on their first time to go through it, this is what I  expect from  
you and what you can expect from me. ' (33) Norman felt that contracts ‘make 
everybody realise that they should all be working to the same goal, which is in the 
client's best interests really and their overall health. ’ (17) Others felt that they were 
useful to reinforce the consequences of unacceptable behaviour, ‘They work to some 
degree and to give the addicts the knowledge that we are not going to take any old 
crap from them basically. ’ (Adam, 46) However, Tim felt that ‘the contracts were 
introduced more to appease the staff than anything, to keep the staff happy and say 
you know we have got it in writing. Once those staff had gone we didn’t feel the 
needfor a contract. ’ (33)
Some participants felt that the contract was no substitute for establishing a rapport 
with the client. Kath explained, 7 tend to think it is a bit o f paper that is going to 
get lost, basically. I  think it is much better when someone comes in, I  would say, oh, 
you haven't been to us before, can Iju st tell you a bit about us...Ifind to sort o f say 
that and make eye contact with people, I  find  that works much better than a 
contract. ’ (25)
4.2.2,7. The impact on clients and customers
Most participants were clear about the perceived benefits of services such as 
supervised consumption and needle exchange on the clients who used the services. 
They also made comments about the impact of these services on other customers of 
their pharmacy.
a. the clients
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The perceived benefit to the client was linked to the regularity with which the client 
visited the pharmacy (daily in many cases) Grant said, ‘...my experience is that they 
will always ask the pharmacist, always ask me anyway, but again I  think it depends 
on what their relationship is like with their pharmacist... ’ (15), similarly Lottie 
said, ‘I f  you build a good relationship with them, they can ask you for advice and 
information about things and perhaps it makes them feel more part o f the 
community then i f  they were just being dealt with elsewhere. ’ (81)
Most participants spoke about how they ‘are another patient... ’ (Sandra, 150), she 
went on to say how just treating them normally they really appreciate that and it 
makes me think that this is the right way forward for me. ’ (150) Almost all the 
participants spoke about how the clients were able to ask for advice about their 
health, for example, ‘We have certainly been approached by many o f the drug 
addicts fo r  skin infections ...people [have] presented with DVTs or that sort o f thing; 
infected injection sites where they have popped a vein and stuff like that, so they 
will do that quite often. ’ (13) and most participants felt that they were appreciated 
by the clients, ‘...to them it’s very valuable and we get those comments on a 
frequent basis that they appreciate the service and i f  it disappeared they would 
certainly miss it. ’ (Maxwell, 102)
However, some participants described the frustrations of working with this group of 
clients, for example, ‘We are really pleasant to our addicts I  must admit, they will 
tell you our Nick is the lad, he’s a good boy, Nick is alright, he will look after 
you...and then they will nick something! ’ (29)
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b. other pharmacy customers
Participants discussed how providing drug misuse services affected other pharmacy 
customers. Some did not think that the other customers knew what was going on, 
for example when a drug user came in for a needle exchange pack. We try to do it 
in a way so that it is not obvious what is going on. I  mean some people will know, 
but I  have never had any adverse comments. ’ (Malcolm, 109) Other participants 
dealt with customers concerns about needle exchange by explaining why they 
provided the service, ‘...whenever we have anybody that comes in complaining 
about, oh, you are giving needles to drug addicts free... we do try to discuss with 
that person that it is definitely best fo r society and it cuts down on health costs in 
the long term i f  these people have clean syringes. ’ (33)
Some participants felt that other customers were curious about drug misuse 
services, ‘...somepeople think they know, oh, it's a methadone user and they try to 
make their own comments about what they have read and just to show off a bit that 
they know what is going on. .. ' (David, 89) ‘...if they ask about it then obviously we 
don’t give any confidences away but we might say to them that these people have a 
problem in order to help them. * (Maxwell, 47)
Participants commented on the problem of intoxicated clients attending the 
pharmacy, Norman said, ‘He was obviously a bit out o f his tree and we had quite a 
large shop full o f people and one mum said to me, gosh, I  don’t think I  am going to 
bring my child in here again i f  you have got that sort ofperson here... '(31)
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4.2.2.8. Perceived facilitators and barriers to developing Pharmacy Services for 
Drug Misusers
This theme arose from the transcripts of the interviews. It refers to comments, views 
or experiences related by the interview participants that the researcher regarded as 
important facilitators or potential barriers to the development of pharmacy based 
drug misuse services.
a. Facilitators
Attendance on training courses allowed participants to network as well as 
understand more about drug culture. It was recognised that this type of training may 
benefit those pharmacists with a negative attitude towards drug misusers. One 
participant who had attended a training session run by the local drug service said, 7 
would recommend it to anybody, and it was quite good because [the organiser] 
actually said, “ Well it shouldn’t be you lot coming, it should be the pharmacies 
where they are abusive towards addicts... (Nigel, 21)
Recognising teamwork was seen by one participant as being an important facilitator 
in the development of pharmacy services, he explained, ‘...having some sort o f 
contract which recognises that everyone is equal and give some communication 
mechanism... recognising that everybody is in the team and it is a team work thing 
is certainly one key thing in terms o f a successful model. ’ (Paul, 117)
The new pharmacy contract was seen as a means of helping pharmacists integrate 
into the NHS team, as Kath explained, ‘ ...pharmacists aren’t fully seen as part o f 
the NHS team. Hopefully with the new pharmacy contract they will be. ’ (125)
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b. Barriers
Grant commented on the attitude of some of his colleagues, 7 do get frustrated with 
pharmacists sometimes, especially when I  go to local meetings and very respected 
pharmacists have such negative attitudes towards everything related to pharmacy... 
when I  talked to a few  key workers [at the local drug service] sometimes you get 
negative comments about the attitude o f some pharmacists. ’ (152) The attitude of 
pharmacy staff was also commented on, ‘nowadays more and more the girls and the 
ladies say to me why do we bother... they are very cynical about the whole thing 
because o f the behavioural problems. ’ (Nick, 29)
Some participants were concerned about the effect that providing drug misuse 
services might have on their business. Nick was very clear on his view, saying, 7 
honestly think that whatever we get paid we suffer as a result o f the public’s attitude 
to us, especially in a shop like this has got a lot o f them, the ‘druggie ones ’. You 
know, that is the druggies ’ chemist shop -  we won’t go in there. ’ (Nick, 77)
Lack of training and a wider understanding of the drug problem was seen as an 
issue by one participant, ‘...for a pharmacist who doesn’t actually want to know 
more about what’s going on behind the scene, behind the treatment... I  can 
understand that they might say, well i t’s useless, because they don’t see [anything] 
apart from handing something over to a drug addict every day, they don’t have a 
wider understanding o f the situation. ’ (David, 93)
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Some participants felt that some prescribers lacked understanding of the 
pharmacists’ role, ‘...from my training with GP’s, every meeting I  have done there 
have been some basic and what I  consider questions that you wouldn ’t dream o f 
asking what a pharmacist actually does. Until you actually tell them what you do 
they don’t really understand... they imagine you can dispense a controlled drug 
against a faxed prescription or word o f mouth. They don’t really understand the 
consequences o f that for the client or o f actually being seen to provide a good 
service for the client. ’ (Harriet, 170-174)
As has been described in a previous section (4.2.2.3) the sharing of confidential 
client information was regarded by some participants as an important issue. It was 
viewed as a potential barrier to two-way communication between the pharmacists 
and key worker/ prescriber.
4.2.2.9. Views on the content o f  a Pharmacy M odel o f  Care
At the end of the interview, participants were asked to reflect on what they thought
should form a Community Pharmacy Model of Care for Drug Misusers.
a. Guidelines
Most participants mentioned the need for guidelines on the dispensing and 
supervision of Controlled Drugs used to treat addiction, and the need for a gold 
standard, ‘Methadone and Subutex; there should be a protocol for supervision... 
there should be model standard operating procedures... ’ (Grant, 169), ‘...a service 
specification for supervised consumption... I  think that will be the ideal gold 
standard... ’ (Kath, 133)
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b. Teamwork
The majority of participants talked about the need for recognising teamwork, and 
including community pharmacists as part of the team. David explained, 7 would 
start with the clinic and the pharmacy’s interest in being part o f it, you know, have 
a meeting together to agree a form o f protocol so that everybody knows what they 
are doing, what their roles are and who to contact i f  there is a problem... there also 
needs to be a review like we do here every year where GPs, the clinic and the 
pharmacists meet together and share their experiences. ’ (131) Similarly Paul felt 
there needed to be ‘...some sort o f contract which recognises that every one is equal 
and give some communication mechanism...recognising that everybody is in the 
team... ’ (117) Several participants who had previously mentioned concerns about 
the two way exchange of confidential information between key workers/prescribers 
and pharmacists felt that this needed to be addressed; ‘confidentiality issues should 
be outline... ’ (Maxwell, 131)
c. Training
Several participants talked about standardising the training required to provide drug 
misuse services, for example, Bill said, 7 think it should contain some sort o f 
suggestion or formalisation for the training o f pharmacists so that pharmacists are 
not just trained on filling in the forms to claim the money for supervised 
consumption but how to handle difficult situations in aggressive patients etc. I  think 
that is really important i f  we want all pharmacists to take this on board... ’ (184)
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Other participants talked about the need for evidence based information, Elbe 
agreed, saying, ‘...definitely, it’s very important [evidence based information] I  
think, because you do get some pharmacists who won ’t touch it unless it has got a 
backing to it. ’ (253)
A summary of the interview participant’s suggestions for the Model of Care is 
shown below.
Guidelines
Supervised consumption -  methadone/ Subutex 
Needle exchange
Standard Operating Procedures -  Gold Standard 










Evidence behind treatment 
Best practices -  the guidelines 
Dealing with conflict
Figure 7: Pharmacist Interviewees Suggestions fo r  a Pharmacy Model o f  Care
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4.2.3. Summary of Themes and Sub-themes
Theme Pharmacists Perception 
of their Role
Experience of Working 
with Others




















Theme Experience of Providing 
Services
Impact on clients and 
customers
Perceived Facilitators 
and Barriers to 
developing services
Views on the Content 



















Table 30: Sum m ary o f Themes and Sub-themes o f  the Pharmacist Interviews
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4.3. SEMI-STRUCTURED INTERVIEWS WITH SERVICE USERS
4.3.1. Interpretative Phenomenological Analysis
Fourteen interviews were conducted with drug misusing service users of community 
pharmacies by the researcher between February and March 2006.
Following the Theming stage of the analysis, 209 themes emerged.
The Clustering process resulted in 13 major themes which were further reduced to 6 
final themes each with underlying ‘sub-themes’ which helped to explain the 
meaning of the theme.
4.3.2. Resulting Themes
Each major theme will be discussed, and within each theme some of the constituent 
sub-themes will be shown in emboldened italics. Narrative extracts are included 
where it is felt that the extracts represent the reports of the participants experience 
and to illustrate the theme to allow explicit understanding of the meaning. As with 
the pharmacists’ interviews, pseudonyms have been used to ensure participant 
anonymity. Numbers in brackets represent the paragraph number of the 
transcription in which the quote appears.
4.3.2.I. The effect o fpast experience on the attitude o f  service users 
The majority of the interview participants described past experiences of receiving 
drug misuse services from community pharmacy. So called extrinsic factors 
included being kept waiting for services, Sam described how this made her feel,
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‘ ...they kept serving people in front o f me. I  wasn ’t in a proper queue so I  stood in 
front o f the counter and she was serving people behind me and that annoyed me 
quite a bit because I  had been stood there for about 10 minutes. ’ (9). Other 
participants described how they were asked to come back for needle exchange 
because the pharmacist was at lunch, ‘[They won’t give you needles?], not unless 
the pharmacist is there. I t ’s got nothing to do with giving out methadone, it’s 
needles, the pharmacist has got to be there. I  don’t know why! ’ (Helen, 15-17)
Participants described how some pharmacies had stopped providing needle 
exchange services, ‘...they are really stuck up and they don ’t want to know because 
there are some pharmacies around that don’t do it because I  think junkies were 
stealing in the shop. ’ (Helen, 67). Others went on to describe how reducing the 
availability of needle exchange affected them. ‘I f  they haven’t got a needle 
exchange and you don’t belong to it or whatever, or not registered with it then 
basically you are screwed. You can’t do nothing. ’ (Adam, 89). Kate explained why 
a local needle exchange is vital, ‘...not being funny, i f  you’re sick and want a bit o f 
gear you just want to get those pins and get the gear in you to stop yourself from 
being ill, so you will go to the nearest place you know. ’ (37)
Pharmacy opening hours were discussed by some participants. Most commented 
favourably on opening hours, however, the issue of early closing on Saturday was 
brought up by more than one participant. Helen said, 7 find it unusual shutting at 
mid-day on Saturday, shutting for lunch, Ifind  it the dark ages! (91)
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Intrinsic factors are described as how an individual is made to feel by the 
experience of using a pharmacy for drug misuse services. These factors were almost 
always negative in nature. For example, Michelle described how she felt about 
getting methadone from her local pharmacy. ‘When I  first got a prescription to 
come in here I  was very embarrassed; I  was because although I  used it for  
prescriptions from the doctors for other stuff, I  was embarrassed because I  sort o f 
knew them then, only sort o f slightly knew them and I  thought they wouldjudge me. ’
(5)
Another participant described being frightened by local children’s comments, 
‘...there are lots o f kids that hang around outside and they call you dirty junkie and 
crack head, honestly they do...I was frightened to come down here some days...it is 
upsetting when you get called names. ’ (Kate, 169).
The attitude of pharmacy staff had an impact on how the participant felt. For 
example, Kate said, ‘The staff in here are very nice, after my experiences from other 
places ...they can be a bit, you know some people can be a bit like, ‘oh don ’t come 
near you, you’ve got AIDS’ or something. ’ (207)
43.2.2. Experience o f  current pharmacy services and perception o f  the 
pharmacists * role
Participants described their experiences of needle exchange, supervised methadone 
consumption and advice giving. These were associated with positive and negative 
experiences.
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a. Needle Exchange
Positive experiences were generally associated with the availability of needles and 
syringes; that is that the service was available locally. The problems associated with 
the lack of availability in certain areas have been described above. However, where 
needle exchange services were available, they were appreciated. 7 think it has been 
absolutely brilliant. I  have used needle exchange and there has never been a 
problem with collecting needles even i f  I  haven’t brought back a used one...' 
(Marcus, 5) One participant described how the pharmacy staff put the needles in a 
bag in order to conceal them, '...they try to put your needles and what they come in, 
in a bag for you.’ (John, 25)
Negative experiences of needle exchange services were associated with lack of 
availability of injecting equipment and paraphernalia. Adam described how he 
managed when he could not get hold of clean equipment. 7 keep it [cin bin] under 
my bed and my girlfriend’s got her own as well so i f  there was a problem and we 
couldn’t get any, I  know I  can go back into that bin and find some...and I  know I  
can use that one again maybe. I ’d  rather not, I ’d  rather use a new one altogether, 
but sometimes it and cause a problem and I  don’t think they understand. ’ (162) He 
also described the desperation felt by some individuals who cannot get clean 
injecting equipment. 7 knew this one guy...he used to walk around, it was the 
weekend and nothing was open, he used to walk around this warehouse where 
everybody used to have hits and he used to look for old syringes on the floor... ’ 
(Adam, 93) The availability of paraphernalia was perceived as a problem. 
'...certain chemists won’t sell citric acid which can be a blinking pain...people start 
using lemon juice, vinegar, I  mean that ain ’t good at all. ’ (John, 162)
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b. Supervised Methadone Consumption
Similarly to needle exchange, participants had positive and negative views and 
experiences of supervised consumption.
The ability to obtain methadone from a pharmacy local to them was important to 
several participants, 7 think they have improved it a lot by having all the 
pharmacists agreeing to supervise it over the counter rather than having to go to 
[the drug clinic] because it’s made life a lot easier for people, particularly i f  they 
have to come from far away... a lot ofpeople weren ’t able to keep on the methadone 
just because they couldn’t get hold o f it...so just being able to pick it up from the 
local chemist is great and a lot easier. ’ (Sam, 29)
The benefits of consuming their dose of methadone on the pharmacy premises were 
identified by a number of participants. These comments were centered on safety. 
For example, Emily pointed out that, ‘...if you didn’t take it supervised then 
perhaps sometimes you would take it all at once... ’ (5) Another participant pointed 
out that attending the pharmacy every day motivated people to get out, 7 think it’s 
to get them up and out instead o f wallowing at time... ’ (Michelle, 33).
Negative experiences of supervised methadone consumption were widely discussed 
by participants. Many found the procedure embarrassing with others describing 
being watched by other customers, ‘...my next door neighbour has seen me in here 
and I  found that really embarrassing, you know, partly because o f my age I  
suppose... ’ (Patrick, 7), similarly, Kate said, ‘...it is a bit embarrassing and I  have 
to stand in the middle o f the shop and people see me drinking it. They obviously get
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to know what it is and that is embarrassing because then people know that I  am a 
drug user. * (43)
In order to reduce the embarrassment of drinking their methadone on the premises, 
several participants discussed the use of a private area within the pharmacy. 
However, one individual did not realise that this was sometimes an option, ‘ ...but 
supervised, I  hated it, drinking it out there in front o f people. Apparently you can 
come in here [private room] but I  didn’t like it at all. ’ (Pamela, 9) Participant’s 
views on the availability and use of private areas are discussed below.
Several participants commented on the length of time that they had been on 
supervised consumption. Michael said, 7 have been doing it fo r three years now 
and it does piss me off. ’ (5)
Three participants described the temptation to ‘use’ when they came across other 
drug users in or around the pharmacy. Alex explained, ‘...it’s almost like a coming 
together place as well, unfortunately that is another downside o f coming to a 
chemist is you see other drug users and other drug users for a drug user is quite 
often the inspiration to go out, and “oh well I ’ll just have a bit today because I  have 
bumped into such and such " ’ (37)
c. Provision of Advice
Participants described how they used the pharmacist for advice about minor 
illnesses and skin care. Alex said, ‘ ...if it was concerning a sort ofpiece o f health,
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yes, I  would ask the pharmacists ’ advice. I  pick up, I  am an asthmatic, and get my 
insulin here, have done for longer than I  have been picking up methadone. ’ (68)
However, participants seemed less keen to ask advice on aspects of their drug use. 
For example, with regard to safer injecting, Adam felt that people would be more 
likely to ask someone who uses. ‘No, I  don’t think they would ask a pharmacist 
[about safer injecting] ...I think they would be embarrassed. You are probably more 
likely to ask someone who uses more than a pharmacist ...I think i t’s more o f a case 
o f you could call it class distinction. They think they can’t ask that person about 
that because what would they think o f me? ’ (63-73)
Others felt that the pharmacy was not suitably private to ask questions about their 
drug use. 7 don’t think people would [ask the pharmacist about drug use issues], 
because I  wouldn’t ask, especially standing in a shop saying excuse me, with people 
listening... ’ (Marcus, 73) It was also pointed out that there were other avenues of 
drug misuse advice open to individuals, ‘You can go to centres and places like 
that... and ask questions there. ’ (Helen, 115)
One participant commented on a leaflet that had been given to him by his 
pharmacist, [and the leaflet, did it tell you how to inject safely?] 7 assume it did, I  
didn't read it! ’ (Marcus, 33)
4.3.2.3. Attributes o f  pharmacy s ta ff
Participants described both positive and negative attributes of pharmacy staff. Most 
of the comments were positive in nature and seemed to impact well on the
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participant, however, where negative comments were made it was clear that these 
also had an impact on the participant.
a. Positive attributes
Several participants talked about being treated like any other customer. 7 have 
come in here for needle exchanges and, you know, have been on drugs at that time 
and they just talk to you like, you know, you ’re a human being. Have a laugh and a 
joke with them sometimes.’ (John, 45) Similarly Natalie said, ‘...they treat you as 
normal people, you know, talk to you about normal things. ’ (41)
Participants also talked about the rapport, respect and trust that are built up with 
pharmacy staff over a period of time. This was always appreciated, ‘...since I  have 
got to know them all properly and have been coming in here for a year and it’s been 
fine, I ’ve been fine. I ’ve got to know them; they don ’t judge you, or I  don’t feel they 
do anyway and they are really nice people. ’ (Michelle, 17) Patrick remarked that 
they attitude of the pharmacy staff made him look forward to going to the 
pharmacy, ‘Most o f the staff are fine, you know I  quite look forward to coming up 
here actually because they react with us, they are good people... ’ (43)
Two participants remarked on the pharmacists’ knowledge of drugs, ‘...they know 
what they are giving. They are also probably very well clued up on the kind o f  
pharmaceutical stuff that can be abused. So they probably see that it doesn ’t get 
into the wrong hands, which is good. ’ (Alex, 126)
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Participants also spoke about the empathy shown by the pharmacists and their staff. 
Michael said, ‘Like when I  just come in then, the lady down the counter said “Oh 
Michael where was you on Friday? ” because I  pick up on Friday, she said “I  was 
worried about you. ” So they are lovely ladies and I  said “Oh thank you, that’s nice 
that is!” They are always polite. I  think you couldn 't get a better chemist than this. ' 
that is!” (35)
b. Negative attributes
Many of the negative attributes of pharmacy staff were the opposite of the positives 
described above.
Unfortunately, some participants described how they felt that the pharmacist and 
pharmacy staff judged them. Michelle described how ‘...the first day I  walked in I  
was totally really embarrassed, put my head down, stood there andjust fe lt like they 
were judging me.' (5) Michael explained how he felt labelled, he said, 7 mean they 
think, oh well look at that junkie and you have got a label on you straight away.’ (5) 
Kate explained how she felt that there was a stigma attached to needle exchange, 
...like when they do the needle exchange bit, you know, I  have had them like give me 
the needles as i f  they don 't want to touch me, things like that. ' (9)
Some participants described the. lack of conversation and rapport in some 
pharmacies. 7 remember the last chemist ...do you know what I  mean, it's like give 
you your methadone and that's it, out the door.' (Michael, 35)
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Two participants described how staff reacted when other customers made adverse 
comments about them, '...often you get comments like “Do you get sherry with 
that?” or things like that you know, it’s not good [Do they defend what is going 
on?] No they don’t say anything, no. (Patrick, 23-39)
43.2.4, Consequences o f  being in drug treatment
All the interview participants commented about the wider issues around being in 
drug treatment. The discussion and therefore the sub-themes were divided into three 
main areas; Treatment Services, Consequences o f  being in drug treatment and  
Compliance.
a. Treatment Services
Alex described how the ‘harm reduction agenda’ had increased the availability of 
methadone, ‘ ...attitudes have changed over the years and realistically now there 
seems to be an attitude o f harm reduction so they are giving out methadone scripts 
quite freely to people who are using heroin in order to stop them causing 
themselves self-harm. ’ (10)
However despite this, in some areas participants commented on the excessive 
waiting times for treatment, ‘...if a person wants to go to [local treatment service] 
now and say “listen I  am a heroin addict and I  need help now” not in 14 months 
time like the waiting time is. I  mean I  have known people who go out to get arrested 
on purpose, to do an arrest and referral... 7 days and they don’t do no more. ’ (John, 
201)
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Several participants commented on the stabilising nature of being on a methadone 
prescription. Alex commented that ‘the methadone programme itself probably is 
one o f the most stabilizing things that there is... ’ (10) Similarly, Patrick said that 7 
haven’t been in prison for 13 years but the only time I  ever get into trouble is when 
I  haven ’t got a script. ’ (204)
b. The consequences of being in drug treatment
Participants discussed the difficulty in going away because of the need to attend the 
pharmacy on a daily basis, ‘...if I  wanted to go out at the weekend I  couldn’t go 
because i f  someone said ‘do you want to come away for the weekend’ I  can’t go on 
Saturday because I  have to pick up my methadone... ’ (Adam, 81)
Similarly, Michael commented on how getting to the chemist every day was 
‘ruling’ his life. 7 don’t know about other people, but I  have got other things going 
on in my life and I  have to come from  [location] every day to get my methadone. I  
didn ’t pick up Friday because I  couldn ’t be bothered to come over here. ’ (9)
Several participants commented on the ‘fear of being ill’ and saw getting a 
methadone prescription as a way of preventing this. One participant explained how 
his friend committed suicide because he could not handle the heroin withdrawal. 
‘...there are so many people on the street that get ill and they get suicidal, you know 
I  have known people hang themselves. My best mate hung himself ‘cos he was 
staying at his mothers and he was ill and he just didn’t know what to do... at the 
end o f the day these people can’t take being ill and it is not fair when things like 
methadone and that which could sort people out... ’ (Patrick, 240-251)
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c. Compliance
Participants alluded that the nature of the methadone treatment program was based 
on compliance or adherence driven. There was significant discussion about the 
impact of missing doses. Marcus explained, 7 have missed doses o f methadone 
before, and it’s been having to keep appointments, not being able to get back in 
time, thinking, ‘Oh I  should be able to get back in time ’ and not being able to make 
i t . . / (83)
Other participants suggested that some people missed doses because they had been 
using heroin. ‘ ...sometimes i f  people are using, I  suppose. I f  they have used they 
think oh well you know I  don ’t need to come and get it... ’ (Kate, 91)
Several participants could not understand why people would miss their doses of 
methadone. 7 actually can’t realistically understand it... when you can pick up 
from 9.30 in the morning right through to 6.30 at night, that’s a bit wishy washy, 
you know i f  they miss it’s their own fault. ’ (Alex, 130)
Participants were asked whether the pharmacist should tell the prescriber if a client 
was missing doses, most agreed that they should divulge this, if a client was 
regularly missing doses. Helen pointed put that people risked overdose if they 
missed their methadone pick up. 'Well, you keep your programme together. I f  you 
miss then you could obviously be using elsewhere and you [the pharmacist] could 
put someone at risk by giving them an overdose... ’ (155)
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Some participants had had experience of pharmacists withholding doses of 
methadone from clients. The main reason cited was if a client attended the 
pharmacy under the influence of alcohol or other drugs. Sam explained, 7 used to 
drink quite heavily but I  don't drink at all now. They [the pharmacist] are not 
supposed to give it out i f  they think you are going to overdose i f  you have 
methadone as well That would be quite a problem... ’ (85)
It was acknowledged that the pharmacist may face a difficult situation should they 
decide to withhold a dose of methadone, '...people are likely to get very irate, 
especially i f  they are drunk, but I  suppose they have to explain it to their faces and 
tell them bluntly i f  they think they are going to overdose and kill themselves... ’ 
(Sam, 89)
Several of the pharmacist interview participants talked about the existence of a 
contract between the client and the pharmacist. Service user interviewees were 
asked about their experiences of these contracts.
Participants discussed the nature of the contracts and most agreed that it was a way 
of defining acceptable behaviour on the part of the client, '...just to be on good 
behaviour, when you are coming into the premises don’t try and thieve nothing, you 
know you are coming in here for a reason, fo r your medication... ’ (John, 165) 
Marcus suggested that the contract could state that 'prescription drugs will be 
withheld i f  you come in under the influence, or i f  the chemist thinks you are too fa r  
under the influence, then he has got the right to withhold it and any violence, 
whether it be verbal or physical then the chemist has got the right to refuse. ’ (181)
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Some of the participants thought that to have a contract regarding behaviour was 
assuming that the pharmacist was going to have problems. ‘I t ’s sort o f assuming 
that they are going to be a problem before anything actually happens... ’ (Sam, 
115) Other asked why they should be treated differently from other customers, 
‘...as far as I  am concerned they are just getting a prescription and they are there 
to give us our medicine, the same as anybody else who’s prescribed medicine so 
why should we be treated [differently]... (Kate, 127)
4.3.2.5. The importance o f privacy and confidentiality
a. Privacy
Participants discussed the importance of private areas that are available in some 
pharmacies in order for clients to take their methadone dose in private. Marcus said, 
7 just come in daily and stand there and drink it, but yeah, it could be a room or 
something like here to drink it in. It would be a lot better because I  do feel 
embarrassed sometimes when I  have to stand there and drink it and especially when 
you know people. I  walk past sometimes and see people I  know... ’ (9) One 
participant thought that a private area would be a good idea, but acknowledged that 
it was impractical in some pharmacies, ‘...if they haven’t got the space then 
obviously you have to make do with what you have got... ’ (Patrick, 7)
John felt that pharmacies that provide supervised methadone consumption should 
have their premises modified in order to provide a private area, 7 feel that it should 
be done to quite a lot o f pharmacies if, you know, they are doing methadone and 
suchlike...’ (XT)
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b. Sharing Information
Participants were asked what information about themselves and their treatment they 
would be happy for the pharmacist to know. Interviewees were split into two main 
views. Some felt that information about them was confidential between the client 
and their doctor, 7 think at the end o f the day it should be a confidential thing 
between you and the doctor. A pharmacist is just somebody who is dishing out what 
we got. I t ’s like i f  anybody goes in with an illness, do they ask anything about them? 
So what’s the difference really...? (Adam, 134) Helen did not see why pharmacists 
would need more than basic information about the client, 7 don’t know, I  think they 
know enough really; the name and address, date o f birth. I  can’t see why they 
would need more information... ’ (143)
Other participants did not seem worried by pharmacists knowing and sharing 
confidential information with the prescriber and key worker. John said, 7 can’t see 
no harm, I  can’t see no harm in the pharmacist knowing a bit more about this 
person who they are serving... ’ (123)
Sam made a good point whilst talking about information sharing between the 
pharmacist and doctor, saying, '... this is highly contentious. It is how much 
information people want to give I  think... out o f choice and whether they answer 
questions, i f  there were questions involved in it or not... ’ (123) she went on to 
clarify this point by saying, ‘ Whether you get your methadone or not shouldn ’t 
depend on whether you answer the questions... ’ (127)
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43.2.6. Views on a proposed extension to the pharm acists9 role
Interview participants were asked for their views on the idea of pharmacists being 
able to prescribe methadone following a change to the laws around prescribing. 
Participants also discussed their suggestions for training topics that pharmacists 
who provide drug misuse services should undertake.
a. Pharmacist Prescribers
Participants had a variety of views with some supporting the notion and other 
suggesting that prescribing should be left to doctors.
John thought that pharmacists prescribing methadone would make treatment more 
accessible. He said Well, that sounds unbelievable really... that’s just what’s 
needed Rachel, you know, because i f  a person wants to go to [local drug service] 
now and say ‘listen I  am a heroin addict and I  need help now’, not in 14 months 
time like the waiting time is. ’ (197-201)
Other participants thought that pharmacists prescribing methadone was a good idea, 
but that it should be for people on maintenance prescriptions, ‘...if you were on 
methadone regularly and had been on it a while then I  think that is quite a good 
idea really to save me going there [to the drug clinic]. You know they could drug 
test you and as long as you were drug free and that continues doing methadone 
from here [the pharmacy] could save you going [to the drug clinic] ’ (Kate, 149) 
Similarly Sam agreed with the idea, providing the pharmacists had had the correct 
training. ‘As long as they had the training to know about it I  think it would be
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excellent because again it would mean a lot more than just a few  people being able 
to deal with prescriptions... ’ (157)
Those who were not in favour of pharmacist prescribing felt that it may be abused 
by some heroin addicts, '...people would abuse it wouldn't they...I don’t think it 
would be a good idea because I  could say, fo r whatever reason, maybe I  wanna get 
loads o f prescribed drugs and sell it... ’ (Marcus, 233-241)
There was a perception that the pharmacist would be ‘easier’ than a doctor when it 
came to getting a methadone prescription, '...with a doctor i t’s a lot harder, as I  
would say, to get blood out o f a stone from any o f them, but doing it the way you 
have just mentioned I  think there would be a lot more people taking the mickey... ’ 
(Michelle, 136)
b. Training Tonics
Most of the participants suggestions for pharmacist training could broadly be 
described as having a harm reduction theme.
Several participants suggested that pharmacists should know more about the 
injection process and the use of paraphernalia. Adam said, '...as I  have said, some 
pharmacists don’t sell needles and how important that can be...certain chemists 
won’t sell citric acid which can be a blinking pain... people start using lemon juice, 
vinegar, I  mean that ain ’t good at all. ’ (162)
- 1 8 5 -
Chapter Four - Results
Two participants felt it was important that the pharmacist was able to recognise 
when clients were intoxicated. Marcus suggested, ‘...training so that they can tell 
which drugs people are under the influence of, like I  can tell, because I  have done it 
all, whether someone’s on an upper or a downer. ’ (201) He went on to describe 
how it was possible to tell the difference, ‘By pupils, i f  they are on crack their 
pupils are massive, i f  they are on heroin their pupils will be pins, i f  they are drunk 
or stoned they are watery and red... ’ (205)
Helen gave reasons why it was important to know what drugs an individual could 
have used, ‘Recognising the right signs to not give people their methadone because 
they could be high on something else that methadone could be useful. Because i f  
someone is high on crack, methadone would be very handy to bring that person 
down, you know they might be really jittery and acting really oddly, you know, so it 
would be helpful to recognise things like that. Holding it back from someone in that 
state could be fatal really for their sanity. ’ (171)
John felt that pharmacists should have a deeper understanding of why a person is on 
a methadone prescription. He said, ‘They should have a bit more understanding 
about what methadone is and a bit more understanding about why a person has 
gone down that path... ’ (173) He explained that his pharmacist ‘...doesn’t really 
understand about why a person is getting methadone, why it’s fo r heroin misuse, 
yeah, but it goes far deeper and I  think i f  they was to know a little bit more about 
that, why this person is getting methadone... ’ (177)
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One participant suggested that pharmacists should know more about street drugs. 7 
mean I  think it would be good to have that extra knowing about hard drugs on the 
street and such... ’ (Michelle, 106)
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5.1. STRUCTURE OF THE DISCUSSION
The discussion will be divided into two main parts. Firstly, the results of the project 
will be discussed in the context of the objectives that were described in section 2.11. on 
page 71. Following this there will be a discussion of the methods used for each 
objective.
5.2. CONSIDERATION OF THE OBJECTIVES OF THE THESIS
5.2.1. Ascertain the current level of community pharmacy involvement in service 
provision to drug misusers
5.2.L1. Selling Injecting Equipment to Injecting Drug Users (IDUs)
Analysis of the postal questionnaire has allowed the number of pharmacies in the South 
West who are prepared to make injecting equipment available by way of sales to IDUs 
to be ascertained. 19.1% (n=135) of respondents had sold injecting equipment in the 
week before the questionnaire was completed, with a further 31.4% (n=222) of 
respondents replying that they were willing to sell, but had not had any requests in the 
week before the questionnaire was completed. This gave a total of 359 ‘willing sellers’ 
(50.5% of respondents) However, over two-fifths (42.3%, n=299) of respondents did 
not make sterile injecting equipment available to IDUs through the sales of such 
products.
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The relationship between lack of willingness to sell and lack of request to buy could 
not be deduced from the results of the postal questionnaire, however a comment made 
by a pharmacist who was subsequently interviewed for the second part of this research 
(see section 4.2.2.6. on page 145) suggests that some pharmacists may be unwilling to 
sell injecting equipment for fear that they may become inundated with drug misusers 
requesting sales, especially if other local pharmacies choose not to provide a needle 
exchange service or do not sell injecting equipment. Therefore increasing the number 
of pharmacy based needle exchanges in an individual location will help prevent 
pharmacies from being inundated.
The last estimate of the number of pharmacies in England willing to sell injecting 
equipment to IDUs was made by Sheridan in 1995. As methodological differences exist 
between Sheridan’s work and the work presented in this thesis (for further discussion 
of this see section 5.3.1.5 on page 241) direct comparison between the studies should 
be done with caution. However, if the situation in the South West in 1995 is reflected in 
the findings of Sheridan this would suggest that the number of ‘willing sellers’ of 
injecting equipment has fallen with Sheridan reporting that 75.9% (n=1489) of her 
sample of pharmacies in England and Wales were either currently selling or willing to 
sell injecting equipment. Furthermore, the number of pharmacies unwilling to sell 
injecting equipment appears to have risen since the 1995 survey. (24.1% in 1995 and 
42.3% in 2003)
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These findings raise concern about the overall availability of sterile needles and 
syringes to IDUs. Those pharmacies that were not prepared to sell or exchange needles 
and syringes commonly stated their reasons as ‘needle exchange location nearby’ 
(15.9%, n=86) and 'no returned sharps facilities' (7.8%, n=42). The former suggests 
the assumption that only one outlet per area is deemed adequate to meet need, a belief 
not supported by the findings of a recent survey of needle exchanges conducted by the 
NT A, (NTA, 2006) or in the work of Parsons et al (2002). The latter is likely to be in 
response to the RPSGB’s statement in their Code of Ethics (December 1997 onwards) 
that says ‘Only in exceptional circumstances should pharmacists provide clean 
injecting equipment i f  the pharmacy has no arrangement for taking back contaminated 
equ ipm entThe question as to why pharmacies refuse to sell needles and syringes 
rather than provide disposal facilities requires more detailed study. It may be the cost of 
providing disposal facilities falling onto the pharmacy owner is a deterrent. It could 
also be a lack of willingness to handle disposal bins of used equipment or a desire to 
discourage IDUs from entering the pharmacy. One avenue for exploration could be the 
provision of free sharps bins and disposal facilities to pharmacies, coupled with 
training on the safe handling of sharps bins, to establish whether this promotes an 
increase in the number of pharmacists willing to sell equipment. The RPSGB’s ethical 
code statement is apparently well meaning advice to protect public health, but it pays 
no attention to the findings of Parsons et al showing that there is only one new set of 
injecting equipment for every two (or in Scotland every four) injections administered. 
Thus removal of used injecting equipment from circulation is unlikely to be achievable
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as long as the need for injecting equipment is unmet by the supply levels of new sterile 
needles and syringes.
5.2.I.2. Needle Exchange
The results of the postal questionnaire indicate that 15.1% (n=107) community 
pharmacies in the South West of England provide a needle exchange service and 
tentative comparison with the results of Sheridan’s 1995 survey suggest that the extent 
of pharmacy based needle exchange in the South West has fallen. (17.9% - Sheridan 
(1996) versus 15.1% - current study).
The current level of pharmacy based needle exchange in the South West of England is 
higher than recent figures from Scotland where Matheson (2006) reported that 13.9% 
of Scottish pharmacies were providing the service. However, the trend in Scotland is 
that increasing numbers of pharmacies are providing needle exchange, (8.6% in 1995; 
9.7% in 2000 and 13.9% in 2006) whilst in England the numbers appear to be 
declining.
Concerns regarding the availability of needle exchange for injecting drug users in 
England have recently been raised following an audit of needle exchange provision 
conducted by the NTA (2006). Whilst the report admits that data collection for the 
audit was challenging, it concluded that there was significant variability in the 
commissioning and provision of schemes by local drug action teams. The report 
suggests that rural areas were more poorly served than urban areas; however living in
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an urban area did not always guarantee access or availability to harm reduction 
services.
The findings of the NTA audit provides weight to the apparent reduction in pharmacy 
based needle exchange in the South West of England that has been described in this 
thesis, and strongly suggests that it should be a priority to identify whether pharmacy 
based needle exchange numbers have remained static across the rest of England and in 
Wales.
Twenty-nine per cent of respondents to the full version of the questionnaire who did 
not provide needle exchange said it was because there was ‘no demand’ in their area. 
This is despite the increasing numbers of injecting drug users, the increasing 
prevalence of HCV, concerns previously expressed about HCV incidence in newer 
injectors and the sharing of equipment (Judd, 2005). Demonstrating this increasing 
need for sterile injecting equipment may make some pharmacists more likely to provide 
the service, as 24.3% of respondents who did not provide needle exchange said that 
they may consider doing so if an increase in demand could be demonstrated.
Sixty-seven respondents (19.9%) to the postal questionnaire who were not providing a 
needle exchange scheme said they would consider doing so if ‘funding’ was available. 
In England, the amount of funding for needle exchange schemes varies according to the 
commissioning body. However in Wales, a national contract and payment scheme for 
needle exchange has been negotiated (Community Pharmacy Wales, 2006) which
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standardises the level of payment available to Welsh pharmacy contractors who 
provide a needle exchange scheme. Close attention should therefore be paid to the 
extent of pharmacy based needle exchange in Wales to ascertain if the national 
payment scheme increases the availability of injecting equipment through pharmacies.
5.2.13. Methadone Dispensing
Analysis of the postal questionnaire has ascertained that 69.2% (n=489) of pharmacies 
in the South West of England dispense methadone for the treatment of dependence.
Cautious comparison with previous studies conducted in England and Wales would 
suggest that the number of pharmacies dispensing methadone to drug misusers appears 
to have increased with the mean number of clients per pharmacy also increasing. This 
is to be expected, as the number of drug misusers receiving treatment has increased. 
The data also suggests that the apparent increase in the percentage of pharmacies that 
dispense methadone between 1995 and 2003 (19.1%) is mirrored by a smaller rise in 
the mean number of methadone clients per pharmacy (1.1 clients between 1995 and
2003). Thus the workload between these dispensing pharmacies is now suggested to be 
better spread than it was in 1995.
1988 1995 2003
Glanz Sheridan Current studv
Dispense methadone (%) 23.0 50.1 69.2
Mean methadone clients per pharmacy 3.5 5.9 7.0
Table 32: Comparison o f  methadone dispensing activity
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5.2.I.4. Supervised Consumption o f Methadone
Analysis of the postal questionnaire shows that 70.1% (n=434) of pharmacies in the 
South West of England who dispense methadone provide a supervised consumption 
service.
Previous studies in England and Wales did not collect data on this aspect of service 
provision; however such data does exist for Scotland, where Matheson (2002) reported 
the number of community pharmacies providing supervised consumption to be 56.7%.
More Scottish drug misusers were receiving their daily methadone dose under the 
supervision of a pharmacist (65.1%) compared with 49.5% in South West England, 
showing that a greater level of service activity is undertaken by fewer pharmacies in 
Scotland with an increase in workload of those pharmacies who participate.
The National Treatment Agency (NTA) advocate primary care services in the treatment 
of drug misuse and mentions pharmacy based services including supervised methadone 
consumption. It is not a surprise, therefore, that the majority of prescriptions for 
methadone in this study arose from primary care. Supervised consumption of 
methadone is also recommended in the Department of Health publication ‘Drug Misuse 
and Dependence: Guidelines on Clinical Management (1999) for the first three months 
of treatment and the results of this survey show that just under half the prescriptions for 
methadone were supervised. There are regional variations across the South West of 
England, In Avon, Gloucestershire and Wiltshire StHA, 60.2% of methadone clients
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received their methadone by supervised consumption compared with 38.9% in Dorset 
and Somerset StHA, and 37.2% in South West Peninsula StHA. More information 
about the drug misusers and where they are in the treatment programme before 
comment on the relative rates of supervised consumption is made. Despite this, Dorset 
and Somerset, and the South West Peninsula StHAs contain more rural areas than 
Avon, Gloucestershire and Wiltshire StHA. Drug misusers living in more rural areas 
may have difficulty in getting to a pharmacy for a daily dose of methadone. It is also 
possible that more drug misusers in these rural areas are on maintenance treatment and 
may therefore be able to pick up their prescriptions less frequently. High levels of 
supervised consumption in individual locations may be in response to local policy or a 
local response to reports of methadone entering the illicit market.
Problems associated with dispensing methadone to drug misusers 
Two hundred and three (52.7%) respondents to the full version of the questionnaire 
reported having to stop dispensing methadone to one or more individuals. This was 
mainly due to unacceptable behaviour on the part of the drug misusers.
The decision to stop dispensing to an individual was often difficult to make, as until 
2004, refusing to dispense an NHS prescription was at odds with the NHS terms for the 
provision of pharmaceutical services, which required that ‘All valid prescriptions for 
drugs that are presented must be supplied with reasonable promptness. ’ However, with 
the introduction of the new contractual arrangements in advance of the ‘New Pharmacy 
Contract for England and Wales’ (PSNC, 2004) a change in the wording of the contract
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does not now require a contractor to dispense ‘all valid prescriptions’ thus giving 
pharmacists the ability to stop dispensing to an individual.
The refusal to dispense medication to a drug misuser is not therefore illegal, but 
becomes an ethical consideration, since refusal to dispense substitute medication may 
provoke the individual concerned and precipitate an altercation. The individual may 
start to use or increase their use of illicit drugs with associated increase in harm to that 
person
It is suspected, but cannot be concluded from the questionnaire data that the level of 
support for pharmacists who provide drug misuse services is variable. This is important 
because it is likely that such support would be welcomed by pharmacists who have to 
decide whether or not to carry on dispensing for an individual. Pharmacists should be 
encouraged to consider the ethical implications of refusing to dispense substitute 
medication to an individual as well as the legal consequences of doing so.
Similarly, it is likely (but cannot be concluded by the data from the questionnaire) that 
support and training will be important if a pharmacist has to make the decision to 
withhold a dose of methadone from a client. For example, pharmacists who dispense 
methadone should be aware of the risks associated with alcohol and methadone 
combined, as this is a major precipitant of opiate overdose (Dark, 1996), and one which 
could be reduced if clients intoxicated with alcohol were asked to return for their 
methadone when sober.
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5.2.1.5. Practical Aspects o f Providing Services
Use of private areas
Since this questionnaire was carried out, it has become a requirement of the New 
Pharmacy Contract in England and Wales, that all pharmacies who supervise the 
consumption of controlled drugs for the treatment of addiction should have a private 
area in which to carry this out. At the time of the survey, 46.5% of methadone 
dispensing respondents had a private area, but not all chose to offer this to clients who 
were required to consume their dose on the premises.
The availability of private areas in which to consume their methadone was discussed by 
service user interviewees. Many felt embarrassed at having to drink their daily dose in 
view of other pharmacy customers. It was suggested by one participant that pharmacies 
that provided a supervised consumption service should have their premises modified to 
include a private area.
Therefore the requirement of the contract is likely to be welcomed by clients required 
to consume on the premises as pharmacists who responded to the postal questionnaire 
reported that one quarter of their clients (25.4%, n=50) who did not have access to a 
private area had expressed a wish for more privacy.
Use of contracts
Most respondents indicated that they lay down some ‘ground rules’ with new 
methadone clients, but not all did this with a written contract. This suggests that the
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usefulness of contracts is debatable as 40.2% said they ‘never’ used one. However, 
67.9% of respondents ‘Strongly agreed’ or ‘Agreed’ to the statement; 7 believe that a 
written contract between the pharmacist and drug misusers would help to develop trust 
between the two individuals. ’ This suggests that not all pharmacists who think that 
contracts would help develop trust actually use them in practice. The reasons why are 
unclear, but it is possible that some respondents do not have access to a suitable 
contract.
S.2.1.6. Health Promotion and Advice
Respondents were more likely to give face to face (verbal) advice to drug misusers than 
provide leaflets. Two-thirds of the respondents (65.4%, n=252) ‘never’ gave out 
leaflets about drug misuse but would ‘always’ or ‘sometimes’ give verbal advice 
(60.2%, n=232). Similarly, nearly three-quarters of respondents (74.0%, n=285) ‘never’ 
supplied information leaflets about methadone to new clients but would ‘always’ or 
‘sometimes’ give face to face advice about methadone (70.1%, n=270). These results 
suggest that respondents do regularly communicate with their drug misusing clients; 
however, by not providing leaflets, they may be missing an opportunity to provide 
health promotion advice to a wider audience of drug misusers. In interviews with drug 
misusers conducted by Sheridan (1996), respondents felt that pharmacies should 
provide information leaflets. It is unclear as to whether these leaflets would actually be 
read however, as interviews with service users for the current study suggested that 
whilst leaflets are provided (for example, in needle exchange packs); they are 
sometimes not read.
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It is possible that some clients may not feel able to ask for advice, but would pick up a 
leaflet. The service user interviews conducted for this study revealed that whilst clients 
regarded the pharmacist as a source of advice for general health concerns, they were 
less likely to seek verbal advice about aspects of their drug use, especially on the topic 
of safer injecting. Service user interview participants described feeling uncomfortable 
about the thought of asking advice on safer injecting from a pharmacist. Bearing this in 
mind, it is likely that leaflets would be a useful source of anonymous advice for these 
clients.
The availability of advice from respondents’ pharmacies about the prevention of HTV 
and other blood borne disease is concerning. The majority of respondents (81.8%, 
n=315) reported ‘never’ providing leaflets about HIV prevention to new drug misusing 
clients and 64.4% (n=248) ‘never’ offered face to face advice on the prevention of 
HTV. As the community pharmacy is an accessible place for health related advice, it is 
vital that pharmacists seize the opportunity to provide this advice. It is not possible to 
explain why written information on HIV prevention was not provided by the vast 
majority of respondents. However, since only 24.0% (n=127) respondents to the full 
version of the questionnaire reported receiving training on the prevention of blood 
borne disease, it is likely that the majority of respondents felt unable to provide verbal 
advice. It is encouraging however that 78.6% (n=416) said that they would like further 
training on the prevention HIV transmission.
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The results of this study are of limited value in assessing the provision of information 
about reducing the transmission of other blood borne disease, since the questionnaire 
asked only about HIV. A study of IDUs conducted by the Health Protection Agency 
(HPA) in 2003 revealed that the incidence of HTV is low (approximately 1%) whilst the 
incidence of antibodies to the hepatitis C virus (HCV) in IDUs is around 40%.
These figures suggest that pharmacist training should focus on the prevention of all 
blood borne disease and not just HTV. If the consequences of injecting drugs were 
focused around the increasing prevalence of HCV, more pharmacists may be motivated 
to provide needle exchange schemes.
The current lack of relevant training on blood borne disease in the light of the findings 
of the HP A is likely to be associated with a lack of advice provision on the subject. 
This, coupled with an apparent reduction in the numbers of pharmacies providing 
needle exchange schemes in the last decade (15.1% versus 18.9% in 1995) and a 
reduction in the number of pharmacies willing to sell needles and syringes to suspected 
drug misusers (31.6% versus 41.3% in 1995) suggests that the prevention of the 
transmission of blood bome disease should once again become a priority for policy 
makers to help reduce the incidence of HCV in IDUs.
In addition to a UK wide strategy to increase the number of pharmacy based needle 
exchanges, the ease of availability of advice on the transmission of HCV should be 
regarded as an important consideration.
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However, it is of concern that the recent Department of Health pharmaceutical public 
health strategy (Department of Health, 2005) excludes the provision of services to and 
care of drug dependent people, suggesting that the extension of needle exchange and 
other services has been overlooked as a necessity. Similarly the new community 
pharmacy contract defines needle exchange as an ‘enhanced’ service, not core activity.
5.2.1.5. Summary o f Objective One
The results of the postal questionnaire suggest that whilst the number of pharmacies 
dispensing methadone in the South West of England appears to have increased since 
Sheridan’s 1995 survey, the extent of needle exchange provision and needle/ syringe 
selling activity appears to have decreased.
It is possible that these two results are linked, with pharmacies choosing to stop needle 
exchange services in favour of dispensing methadone, however, this hypothesis 
requires further research and cannot be confirmed from the results of the postal 
questionnaire.
In view of the recent NTA audit on needle exchange provision in England, it should be 
a priority to ascertain how increases in pharmacy based schemes can be achieved.
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5.2.2. Describe the range of knowledge and attitude of pharmacists who provide 
services to drug misusers
5.2.2.1. Knowledge o f Respondents on Aspects ofD rug M isuse 
The aim of part three of the questionnaire was to gauge respondent’s knowledge on the 
subject of drug misuse. The results give an indication of the areas that could be 
addressed in training sessions for pharmacists who provide drug misuse services.
Respondents scored an average of 8.4 marks (max 15) on questions 28 to 34. These 
results cannot be compared with other studies as this is the first survey which has 
attempted to quantify pharmacist’s knowledge in this area. However, one can look at 
the spread of answers to each question and identify areas of potential training 
requirements. One area is around methadone pharmacokinetics and dosing as over half 
of the respondents to the full version of the questionnaire (56.3%, n=298) did not know 
when a person’s tolerance to methadone would be reduced to a point where the original 
dose may cause toxicity.
A degree of knowledge of the pharmacokinetics of methadone is important if 
pharmacists are presented with a client who has not picked up their dose of methadone 
for a number of days. After a break of three days without methadone or other opiates, 
consuming the original dose of methadone may cause the patient to overdose as their 
tolerance to opiates will have fallen (Darke, 1996), thus, a pharmacist who dispenses 
the original dose after a break of more than three days may put the patient at risk.
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Similarly, pharmacists should be aware of the risks of overdose when methadone is 
given to a patient who is intoxicated with alcohol. Although relatively few pharmacists 
(16.1%, n=85) said that they would give methadone, the implications of this to the 
patient is concerning as methadone and alcohol together are responsible for a number 
of deaths. (Darke, 1996)
Recognising the signs of opiate intoxication is an important clinical governance issue if 
a pharmacist is presented with a patient for whom dispensing a dose of methadone may 
result in harm to the patient, and it is therefore concerning that 26.3% (n=139) of the 
respondents to the full version of the questionnaire were unable to list any signs of 
opiate intoxication. Failure to recognise the symptoms of intoxication and subsequently 
dispensing methadone to an individual may result in an accidental overdose, therefore, 
recognising symptoms of opiate intoxication should also form part of a pharmacists’ 
training on drug misuse.
Another potential area for training is around the supervision of sublingual 
buprenorphine. Respondents appeared to be confused about how long it takes for the 
full dose to be absorbed from the buccal cavity with 90.8% (n=480) respondents 
replying between ‘30 seconds ’ and 'until dissolved’ .
This highlights the need for clear guidance on supervising the consumption of 
buprenorphine, however useful guidance will need to include an indication of the 
length of time that a patient is supervised. The Royal College of GP’s suggests that this
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should be until the tablets are dissolved which may be five minutes or more (Ford,
2004), however at the time of writing, the UK manufacturers of sublingual 
buprenorphine were unable to provide any information on the time taken for the dose to 
be absorbed from the buccal cavity. It is possible that waiting for the tablet to be 
dissolved completely is unnecessary and if this were to be the case then the length of 
time that the patient has to remain in the pharmacy could be reduced.
Further guidance and training on the supervision of buprenorphine is required as there 
is likely to be a variety of practices occurring, which may not all the appropriate or 
necessary.
Relationship of knowledge to service provision
Respondents who provided a needle exchange scheme had a significantly higher 
knowledge score than those who did not provide the service. This may be because the 
majority of needle exchange pharmacists (71.7%, n=66) reported having received 
training in order to provide the service.
The knowledge score was calculated from questions about several aspects of drug 
misuse and treatment and not just needle exchange. This suggests perhaps that these 
pharmacists have undertaken other training in order to extend their knowledge of the 
subject or simply that these pharmacists have a greater contact with drug misusers 
which has subsequently raised their knowledge in the area.
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Past training received and future training requirements
The number of respondents who reported having received training on drug misuse and 
the prevention of blood borne disease was lower than numbers reported by Matheson 
(2002) in Scotland, Table 34 summarises these differences.
Matheson (2002) Current study
Received training
... on drug misuse 66.8% 51.7%
... on blood bome disease 35.2% 24.0%
Desire training
... on drug misuse 70.5% 82.8%
... on blood bome disease 79.4% 78.6%
Table 33: Differences in levels o fpast and fu ture training on drug misuse and blood 
borne disease between Scotland and the South West o f  England
One possible reason for the higher numbers of pharmacists who have received training 
in Scotland compared to the South West of England may be related to the average 
number of methadone clients that pharmacies in Scotland have. (13.2 compared to 7.0 
in the South West of England) This may make Scottish pharmacists more likely to 
undertake such training as providing services to drug misusers may be seen as a 
substantial part of their professional duties, however in parts of Scotland; pharmacists 
have to undertake training in order to be paid for providing drug misuse services (J. 
Scott, personal communication).
More pharmacists from the south west of England desired further drug misuse training 
than their Scottish counterparts and this may simply reflect the fact that less south west 
pharmacists have had any training on drug misuse (51.7% in SW England versus
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66.8% in Scotland). Similar numbers of Scottish and south west pharmacists desired 
further training on blood borne disease (79.4% in Scotland and 78.6% in SW England).
Sixty per cent (n=105) of respondents who made suggestions about the content of 
future training sessions (n=175) mentioned the need for information on the 'practical 
issues’ surrounding drug misuse. These issues and others such as ‘how to provide a 
better service ’ could be dealt with by way of local workshops which were a suitable 
training vehicle for 57.0% (n=247) respondents. Local workshops give the opportunity 
for interaction and networking between pharmacists and other healthcare professionals. 
Workshops give a wider scope for the type of training that can be given, but time and 
availability may prevent some from attending.
Training needs were further explored in qualitative interviews with pharmacists who 
provide drug misuse services. The ‘practical issues ’ were around best practice and 
taking an evidence based approach to service provision as well as a desire to have 
training on how to handle ‘difficult situations’ that may be encountered.
Service users were also asked about the training that pharmacists should have. In 
general they felt that pharmacists should be more aware of the impact that using illicit 
drugs and being in treatment for drug dependence has on the individual. A fuller 
discussion on the training requirements for pharmacists from the perspective of the 
pharmacist and the service user may be found in section 5.2.4.I. on page 215.
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5.2.2.2. Respondent’s Attitude to Drug Misusers 
Response to individual attitude statements
The responses to each individual attitude statement (i.e. the proportion of respondents 
who answered in each stage of the Likert scale) warrant some discussion.
The majority of respondents (83.8%) ‘Strongly Agreed’ or ‘Agreed’ that all drug 
misusers should be encouraged to ‘come off drugs altogether (Question 53). Whilst 
this may be the ‘ideal’, in the strongest evidence for methadone treatment is when it is 
used in maintenance programs. (Ward, 1999) The response to this question could 
indicate that the respondents do not fully appreciate the evidence for maintenance 
rather than abstinence programs or it could be that they are simply answering the 
question ‘in an ideal world’. Understanding the response to this question is made 
clearer when looking at the response to question 52. Respondents were split over 
whether they perceived drug addiction as an illness or a vice. Those who tend to regard 
addiction • as an illness may be more accepting of methadone maintenance as a 
treatment for opioid dependence and interestingly, respondents were also, split over 
whether methadone should be used for abstinence programs only (Question 41), 
suggesting that there is a lack of understanding of the evidence that supports the use of 
methadone for long term maintenance. A further suggestion for a lack of understanding 
of the evidence around methadone maintenance is provided by comments made by 
some of the pharmacists interviewed for part two of this research. One commented that 
he had never seen any one ‘kick the habit’ (section 4.2.2.6 on page 149).
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Most respondents (74.7%) ‘Strongly Agreed* or ‘Agreed’ that it was unethical to sell 
drug misusers’ needles and syringes without having a means of disposing of them 
(question 56). The response to this statement is likely to be in response to the RPSGB 
Code of Ethics which states that ‘Only in exceptional circumstances should 
pharmacists supply clean injecting equipment for drug misusers if  the pharmacy has no 
arrangements for taking back contaminated equipment. ’ (RPSGB, 2006)
This response is one possible reason why the number of pharmacists willing to sell 
clean injecting equipment to drug misusers has fallen in recent years and it suggests 
that more pharmacists may be willing to sell needles and syringes to drug misusers if 
they were provided with a method for safely disposing of returned sharps.
Most respondents (82.4%) believed that the drug misusers should have access to a 
private area in the pharmacy whilst being supervised consuming their daily dose of 
methadone or buprenorphine. This is encouraging, as the new pharmacy contract for 
England and Wales has a requirement for such an area for any pharmacies who 
supervised the consumption of controlled drugs by drug misusers. (See appendix 7 for 
the Enhanced Service Specification for supervised administration)
Relationship of attitude to demographic information
A two-way ANOVA revealed that male pharmacists in the 21-34 year age group had a 
significantly higher attitude score than female pharmacists in the same age group.
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Conversely, female pharmacists in the 48+ age group had a significantly higher score 
than males in the same age group, (see figure 5, on page 131)
Overall, the analysis of age and gender effects on attitude suggests that male 
pharmacist’s attitude to drug misusers’ decreases with age, with the reverse being the 
case for female pharmacists.
There was a small correlation between the respondent’s age and their score on the 
attitude scale (Pearson’s, r= -0.094,/f=0.039). This suggests that older pharmacists may 
have a more negative attitude towards drug misusers. This hypothesis is given some 
strength by the correlation between the number of years that the respondent had been 
on the Pharmaceutical Register and their attitude score (Pearsons’s r=-0.094,/?=0.039).
These findings suggest that older pharmacists and those who have been registered for a 
longer period of time have a more negative attitude towards drug misusers. Oppenheim 
(1992) suggests that most attitudes lie dormant, and are expressed in speech or 
behaviour only when the object of the attitude is perceived. Attitudes are influenced by 
experience; therefore it is possible that older pharmacists have had more ‘negative’ 
experiences of drug-misusers which have adversely affected their attitudes towards 
them than those who have been registered for a shorter length of time. The act of filling 
in an attitude questionnaire may therefore have bought any negative experiences to the 
surface and influenced the individuals’ responses to the questionnaire.
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Relationship of attitude to practice
There was a significant difference in attitude between those respondents who sell or are 
prepared to sell needles and syringes to drug misusers and those who are not. Similarly 
there is a significant difference in attitude between those respondents who provide 
needle exchange and those who do not, and between those respondents who dispense 
methadone and those who do not. These results are similar to those by Matheson 
(1999) in a survey of Scottish pharmacists who demonstrated a link between attitude 
and various aspects of service provision. Matheson concluded that since negative 
attitudes may inhibit service provision, addressing negative attitudes should be a 
priority. However, the link between attitude and service provision may be more 
complex than it first appears, since it is not possible to tell from the results of the study 
presented here or that of Matheson (1999) whether respondents have a more positive 
attitude score because they provide drug misuse services or if they provide such 
services because of a more positive attitude towards drug misusers in general. In order 
to test these hypotheses, a longitudinal study would be required to test the attitude of an 
individual before they have experience of delivering drug misuse services and then 
again after they have been providing these services for a suitable length of time.
If the first hypothesis is proven then it would suggest that encouraging pharmacists to 
provide drug misuse services through training will enhance their attitude. However, if 
the second hypothesis is shown to be correct then it would indicate that an individual 
pharmacists’ attitude towards drug misusers may not be dependent whether they 
provide drug misuse services. In this case, modifying attitude by way of increasing the
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level of training may not yield an increase in the number of pharmacists who provide 
services. Indeed, whilst suggesting that further training may address negative attitudes, 
Matheson (1999) points out that those pharmacists desiring further training already had 
more positive attitudes than those who did not desire further training.
Relationship of attitude to knowledge
A positive correlation between the respondent’s knowledge score and their attitude 
towards drug misusers was found (Pearson’s rho r=0.162,/?=0.000).
This is an important finding as it is the first occasion that a link has been demonstrated 
between the knowledge that pharmacists possess on aspects of drug misuse and the 
treatment of opioid dependence and their attitudes towards drug misusers and their 
treatment.
This new finding provides further weight to Matheson’s suggestion that training on 
drug misuse can help influence attitude. It is now possible to conclude that the more 
knowledgeable an individual is in the area of drug misuse, the more positive their 
attitude is likely to be.
5,2,23, Summary o f  Objective Two
The range of scores of knowledge on the subject of drug misuse and attitudes towards 
drug misusers were normally distributed across the respondents to the postal 
questionnaire.
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Knowledge on aspects of drug misuse appeared to be influenced by whether or not 
participants provided certain drug misuse services, for example those who provided a 
needle exchange scheme had a significantly higher knowledge score than those who did 
not.
The range of pharmacists’ attitudes towards drug misusers and their treatment appears 
to be influenced by the age and length of registration of the respondent, whether or not 
they provide drug misuse services and the score on the ‘Knowledge’ section of the 
questionnaire. The link between attitude and knowledge had been previously suggested 
by Matheson (1999) and the analysis of the results of the postal questionnaire presented 
in this thesis adds further weight to this suggestion.
5.2.3. Describe the views and experiences of pharmacists who provide drug misuse 
services
5.2.3.I. Clarification o f the Community Pharmacist’s Role
Before the views and experiences of pharmacists who provide drug misuse services are 
discussed, it is pertinent to describe the participants’ views of their role.
The role that the pharmacist plays in the treatment of people who misuse drugs was 
seen as an extension to their traditional role of dispensing and supply of medication. 
This was described by one interview participant as a ‘holistic role’. For drug misusers 
in treatment, their pharmacist is likely to see them more often than the prescriber or 
drugs worker. Many participants in this study recognised the importance of this and felt
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that they could positively impact on the client if they identified that ‘you don 't look 
very good today \ Because of their regular contact with clients on opiate substitution 
schemes, pharmacists are in an excellent position to be able to provide feedback to the 
client’s prescriber or key worker, although the participant’s experience of 
communication with the treatment services was very varied and in many cases 
participants felt that there was a lack of communication.
5.2.3.2. Experience o f Communication and Confidentiality Issues 
Where there was communication with the treatment services, the reported extent of 
information sharing varied. Some participants recognised that they had discussions 
with the client that they felt should not be relayed back to the prescriber/ drugs worker. 
Equally, it was recognised by other participants that certain information about the client 
was withheld from them because of ‘client confidentiality'. Indeed there was a 
perception that confidentiality is a barrier to two-way information sharing. There 
appears to be a ‘grey area’ surrounding information sharing between pharmacist and 
prescriber/ drug worker and vice versa. It is possible that this is because the pharmacist 
may not be regarded as an integral part of the clients care, compounded by the fact that 
most community pharmacists work in isolation from other the other healthcare 
professionals involved. In a qualitative study, Hughes (2003) investigates the perceived 
interprofessional barriers between community pharmacists and general practitioners 
(GP’s). These barriers were centred on the ‘shopkeeper’ image of the community 
pharmacist, and accounted for the GP’s concerns about the involvement of the 
community pharmacist in extended services. This image of the community pharmacist
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may hinder the sharing of confidential information between GP/ key worker and 
pharmacist if the pharmacist is regarded as a shopkeeper rather than a fellow healthcare 
professional.
As the importance of the pharmacist in the delivery of care to drug misusers has been 
highlighted in the current clinical guidelines for drug dependence (Department of 
Health, 1999) it follows that the pharmacist should be privy to confidential client 
information in order that their quality of care is sustained and improved.
The Department of Health’s document entitled ‘Confidentiality -  NHS Code of 
Practice’ (2003) gives explicit guidance on how confidential information about patients 
should be handled. The document poses a number of questions that are designed to 
ensure that the requirements of law, ethics and policy are adequately addressed when 
making decisions about the use or disclosure of confidential patient information. The 
document asks; ‘Is the disclosure needed to support the provision o f healthcare or to 
assure the quality o f that care? ’ and the explanation that justifies such disclosure is as 
follows: ‘Patients understand that some information about them must be shared in 
order to provide them with care and treatment, and clinical audit, conducted locally 
within organisations is also essential i f  the quality o f care is to be sustained and 
improved. Efforts must be made to provide information, check understanding, reconcile 
concerns and honour objections. Where this is done there is no need to seek explicit 
patient consent each time information is shared. ’
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Interpreting this guidance suggests pharmacists, who are involved in the treatment of 
opioid dependence through the dispensing and supervised consumption of methadone 
and other drugs should be privy to confidential information about the client. Failure to 
share information such as previous history of, and current illicit drug and alcohol 
misuse may indirectly lead to harm if an intoxicated patient is given methadone. If the 
pharmacist was already aware that an individual client is likely still to be using illicit 
drugs and alcohol the risk of overdose from a prescribed dose of methadone may be 
reduced.
The Department of Health guidance on confidentiality also states that information may 
be shared in order to improve the quality of care given to the patient. There was a 
perception amongst the pharmacist interviewees that concerns over confidentiality 
made two-way information sharing difficult. In order to improve services to drug 
misusers, the pharmacist must be confident that information about a client that is 
pertinent to their care is not withheld, in this respect, the guidance on confidentiality 
should give prescribers and drugs workers the confidence and framework to share 
information with the pharmacist.
In order to facilitate communication and information sharing between professionals 
involved in a drug misusers care, there must be clear communication pathway to ensure 
that each member of the treatment team is aware of information that is pertinent to the 
clients care. One way of defining this communication pathway is by the use of 
contracts. One participant viewed the contract as a way of defining individual roles
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within the team. An example of such a contract is the ‘Berkshire 4-way agreement 
(4WA)’ (Walker, 2001). In this paper, Walker acknowledges that ‘communication is 
built on trust and confidence and this has to develop over time for each professional 
involved. ’, but recognises that the 4WA *allows new pharmacists and GPs to join the 
scheme and be supported, gaining experience and expertise while still ensuring a safe 
system and high quality o f care for the patient. ’
Variations of the 4WA exist outside Berkshire (G. Parsons, personal communication) 
but there is no ‘standard’ agreement that defines the individual healthcare 
professional’s role. A role clarification should therefore form part of a model of care to 
ensure that there is clarity amongst healthcare professionals about what each others role 
is.
S.2.3.3. Participants experiences o f support received to provide services 
Unfortunately, most interview participants’ felt that they did not receive enough 
support whilst providing drug misuse services. The participants’ description of support 
varied, with some talking about the need for clear communication pathways so that 
they knew who to contact if a problem arose. Other participants talked about the need 
to be properly remunerated for the services that they provide. Training was also 
identified as a means of providing support to pharmacists and is discussed further in 
section 5.2.4.1.
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Support -  contact with other Healthcare professionals
Community pharmacists often work in isolation to other healthcare professionals, and 
clearly, there must be a recognised support network for those pharmacists engaged in 
providing substance misuse services. Unfortunately, there is anecdotal evidence that 
some drug services are unwilling to share contact telephone numbers with pharmacists. 
(M. Bennett, personal communication). The provision of contact names and numbers of 
the local drugs service could be facilitated by writing the drug workers contact details 
on the prescription.
Interviews with three participants uncovered an interesting point of view from those 
who are actively engaged with the drug treatment services. These participants all felt 
that there was support available if it was sought out, and pharmacists (in general) 
should actively seek out the support that they need in order to provide drug misuse 
services rather than passively wait for it. They were critical of other pharmacists who 
complained that there was no support.
These participants were also similar in that they had gone out to seek support because 
they were ‘interested’ in the subject of drug misuse.
This finding is important as it provides depth to Matheson’s hypothesis that positive 
attitudes influence service provision to drug misusers. The finding here suggests that 
there is a link between interest and therefore willingness to provide drug misuse 
services and a proactive approach to seeking support. This ‘interest’ in service
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provision may have been a motivation for them to find the support that they needed. It 
is unlikely, however, that all pharmacists who provide drug misuse services have the 
same motivation to seek support. For these pharmacists, then, it is important that clear 
support pathways are defined.
The introduction of compulsory Continuing Professional Development (CPD) by the 
RPSGB may influence pharmacists who provide drug misuse services to actively seek 
support through the mechanism of the CPD cycle by identifying areas of practice which 
require development and defining the support needed to develop.
Remuneration
Most pharmacists are paid for providing drug misuse services by way of a piecemeal 
system. That is, they are paid per supervision or per needle exchange transaction. This 
method of payment rewards volume of work rather than quality of the service provided 
and as such there is currently little incentive to improve these services.
Drug misuse services such as needle exchange and supervised consumption are classed 
as ‘enhanced services’. In order to provide an enhanced service, the pharmacy must 
meet a service specification that is defined by the Department of Health. The service 
specifications are included in appendices seven and eight.
Defining drug misuse services as enhanced services is a cause for concern. Pharmacists 
are not obliged to provide enhanced services under the terms of the new contract and it 
is therefore possible that some may opt out of providing such services if they cannot
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easily meet the service specification. Earlier work in this thesis has shown that the 
numbers of pharmacies providing needle exchange services appears to have fallen since 
the last survey in 1995 was carried out. It is possible that more may drop out of needle 
exchange in favour of other enhanced services such as Medicines Use Review.
A recent paper by Bradley et al (2006) examined the extent of enhanced service 
commissioning by Primary Care Trusts (PCTS) in England. Whilst needle exchange 
and supervised consumption schemes were commissioned by 85% and 88% of PCT’s 
respectively, only 15.7% of pharmacies provided a needle exchange scheme and 31.1% 
provided a supervised consumption service.
The authors concluded that the high level of commissioning of substance misuse 
services map national priorities for public health, however the paper does not comment 
on the extent of the cover needed to meet need and allow workload to be shared. In the 
case of needle exchange, the results presented in this thesis along with work by Parsons 
(2002) and the NTA (2006) suggest that the extent of needle exchange provision does 
not currently meet the need of the injecting drug users. PCT’s should be encouraged to 
explore reasons why pharmacies appear reluctant to provide needle exchange.
5.23,4, Summary o f  Objective Three
The views and experiences of pharmacists who provide drug misuse services were 
varied. Those participants who perceived that they were supported in providing such
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services tended to have a more positive view of their role and saw it as an extension to 
the traditional role of the pharmacist.
The reported extent of communication between the pharmacist and other healthcare 
professionals varied. Issues surrounding confidentiality were often seen as a barrier to 
two-way information sharing.
5.2.4. Ascertain the barriers and opportunities to developing community 
pharmacy services to drug misusers
The barriers and opportunities to developing drug misuse services are discussed in the 
following section. Consideration has been paid to the analysis of the questionnaire data 
and of the interviews conducted with pharmacists and service users. Due attention has 
been paid to the structure of community pharmacy services, such as the development 
and implementation of the New Pharmacy Contract for England and Wales.
5.2.4.1. Training
The need to adequately train pharmacists involved in the care of drug misusers has 
been discussed in section 5.2.3.3 on page 211 and Matheson (1999) has made the link 
between level of pharmacist training and attitude towards drug misusers, suggesting 
that those pharmacists who had undertaken training on drug misuse had significantly 
higher attitude scores than those who had not, adding that those who desired further
- 2 2 2 -
Chapter Five - Discussion
training in the area had significantly higher attitude scores than those who did not want 
further training.
Analysis of the pharmacists’ interviews suggests that the perception of the availability 
of training differed amongst the participants and that training with other healthcare 
professionals allows the individual to network as well as improve the standard of care 
to the client. Pharmacists are now able to work towards part two of the Certificate in 
the Management of Drug Misuse which is organised by the Royal College of General 
Practitioners, and one interview participant who had completed the certificate felt that 
it had updated his knowledge on the evidence surrounding the treatment of opiate 
addiction.
Distance learning from the Centre for Pharmacy Postgraduate Education (CPPE) is 
available to all pharmacists in the United Kingdom. The publication ‘Opiate treatment 
-  Supporting pharmacists for improved patient care’ provides a useful background to 
the area as well as some excellent resources, such as a description of the Berkshire 
4WA. Whilst this is a useful document, interview participants expressed the desire for 
other, less ‘pharmaceutical’ information, such as how people get ‘into’ drugs, what do 
they cost and how much do people use. They also highlighted the need for guidance 
and support on how to handle conflict. The later requirement would be best dealt with 
during a face to face training event. The former suggestion indicates that pharmacists 
might benefit from understanding drug misuse from the eyes of the misuser. In this way 
they may gain an insight into the world of the drug misuser, helping them to understand
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certain behaviours and allow them to give advice on other aspects of the drug misuse 
problem such as injecting technique.
Face to face training with other healthcare professionals may help to build relationship 
and trust amongst individuals and gives the opportunity to clarify each others role. It 
has been suggested that multidisciplinary training involving the whole clinical team 
enhances the successful implementation of clinical guidelines (Grimshaw, 1993). This 
finding is pertinent to the development of drug misuse services and suggests that the 
successful implementation of new pharmacy based drug misuse services will be 
enhanced by ensuring that the whole clinical team is committed and trained to deliver 
the service in a consistent manner.
Barriers to the delivery of training were discussed by some participants. Principally 
these barriers were time and cost. Training events for community pharmacists tend to 
take place outside of working hours. This removes the need to find locum cover in 
order to be able to attend. However it would be difficult to address all the training 
needs in one evening session, thus attention must be paid to funding pharmacists in 
order that the appropriate level of training can be provided.
In the light of the findings of Grimshaw (ibid) it is likely, therefore, that inadequate 
training of pharmacists and pharmacy support staff may be a barrier to providing 
existing drug misuse services and developing new services, whilst adequate training 
involving the multidisciplinary team is likely to increase the pharmacists knowledge
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and understanding of the subject and may facilitate the enhancement of current drug 
misuse services provided by community pharmacists.
Content of training
Both pharmacist and service user interviewees commented on the topics that should be 
included in drug misuse training for pharmacists. It is interesting to examine the 
difference between suggestions of the two groups.
The pharmacist interviewees were mainly concerned with processes and evidence, 
suggesting that training should include a clarification of their role within the team; a 
review of the evidence behind treatment and best practices associated with providing 
needle exchange and supervised methadone consumption; and practical experience of 
dealing with conflict.
Service user suggestions of pharmacists’ training needs were more practical in nature 
and could all be linked to a ‘harm reduction’ theme. Suggestions included an 
understanding of how people use drugs, and the use of paraphernalia in the preparation 
of injections and how to recognise infections associated with intravenous drug use. One 
participant suggested that pharmacists should be able to recognise when an individual 
is under the influence of alcohol or drugs and which drugs they may have used. Service 
users also suggested that pharmacists should have more ‘streetwise’ knowledge about 
drugs, for example the different ‘slang’ terms used and how much street drug cost.
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What becomes evident from the service user suggestions is that if put in place, these 
topics would increase the pharmacists’ awareness of some of the issues and problems 
faced by people who abuse drugs, thereby increasing the overall understanding of the 
nature of drug use. In this way, pharmacists may find it easier to build rapport with 
their clients.
5.2.4.2. Providing Support and Recognising Teamwork
The pharmacist interviews revealed differing experiences of teamwork and support. 
Those who felt that had avenues of support available to them, were, in general more 
positive about providing drug misuse services than those who commented about the 
lack of support. Indeed, a lack of support following an incidence of violence against his 
pharmacy staff caused one previously positive pharmacist to question why he was 
providing drug misuse services at all.
Community pharmacists tend to work in isolation from other healthcare professionals 
and it is therefore vital that adequate support mechanisms are available to them. A 
support mechanism that worked well for one participant was the existence of a ‘local 
network’ of community pharmacists and GP’s who provide drug misuse services. The 
network meet on a formal basis at training sessions but also contact one another on an 
informal basis to discuss problems as they arise.
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Once again, training was viewed by the interview participants as the most important 
area of support. As discussed above, training events allow individuals to network with 
other professionals and help to successfully implement new initiatives.
The recognition of the pharmacist as part of the substance misuse team was seen as an 
important facilitator to enhancing services. Suggestions of a mechanism by which this 
could occur included a ‘role clarification’ exercise for all members of the drug misuse 
team. One method of role clarification is the use of a contract between the prescriber, 
drugs worker, service user and pharmacist. The Berkshire 4-Way agreement (Walker, 
ibid) is one such contract that defines the individuals’ roles and responsibilities. The 
use of this contract or variants to it was mentioned by some of the pharmacists 
interviewed.
It was felt by one interviewee that the New Pharmacy Contract in England and Wales 
would facilitate the pharmacist’s involvement as part of the drug misuse team. The new 
contract has been in place since April 2005 and thus after the pharmacist interviews 
took place, so it is not possible to surmise whether this is the case. However, provision 
of needle exchange and the supervised consumption services have been deemed as 
‘Enhanced Services’ under the terms of the new contract. As such, primary care 
organisations can opt to commission such services on the basis of local need and 
individual pharmacy contractors can choose whether or not provide them.
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At the time that the pharmacist interviews took place, there was some discussion about 
the nature of the service specifications for drug misuse services and how they would be 
developed. More recently, it has become clear that service specifications for Enhanced 
Services have been developed using experience from locally negotiated services rather 
than from an assessment of the quality of such services with the views of service users 
and providers taken into account. For example, the service specification for supervised 
administration of prescribed medicines (included in Appendix Seven) suggests 
individual CPPE training packages such as ‘Opiate treatment: Supporting pharmacists 
for improved patient care open learning’ however, this differs from the suggestions 
made by service user interview participants who felt that a more practical approach was 
required.
5.2.4.3. Pharmacist Attitude
A negative attitude towards drug misusers and their treatment is likely to be a barrier to 
enhancing services. As discussed in section 5.22.2. on page 202, Matheson (1999) 
concluded that addressing these negative attitudes could encourage more pharmacists to 
provide services and enhance the process of service delivery.
Similarly, some pharmacists interviewed for this study suggested that a number of their 
colleagues had poor attitudes that prevented them from engaging in providing high 
quality services to drug misusers. Whilst the development of an individual’s attitude to 
a topic is multi-factorial, it is likely that a wider understanding of substance misuse 
from the misuser’s point of view may inform an individual’s attitude in a positive way.
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The positive correlation between knowledge and attitude performed in section 4.1.2.6. 
adds weight to this suggestion.
5.2.4,4. Sharing Information
Difficulties in sharing confidential client information were seen as a barrier to 
providing drug misuse services. The pharmacist interviewees described occasions when 
‘client confidentiality’ was use as a reason for not divulging information that the 
pharmacist had deemed important to be aware of. Some pharmacists felt that they were 
‘kept out of the loop’ when decisions about an individual’s treatment had been made. 
Exactly what information should be shared between prescriber, drugs worker and 
pharmacist is the matter of some debate. However this needs to be addressed in order 
for pharmacy services to be developed.
The service user interviewees also had varying opinions on what confidential 
information they would be happy for the pharmacist to know. Some did not mind what 
information was shared, whilst others questioned the need for pharmacists to know any 
more about them than other non-drug misusing pharmacy customers.
As discussed in section 5.2.3.2. on page 215, the Department of Health document on 
confidential information sharing provides the framework for sharing confidential client 
information. However, in order to remain sensitive to the views of service users, one 
method of defining what information should be shared could be the development of a
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set of questions that allows the individual service user to determine the level of 
information that is shared between the prescriber and pharmacist.
5.2.4.5. Summary o f Objective Four
Providing support and recognising teamwork were identified as important facilitators in 
developing community pharmacy services to drug misusers whilst a poor pharmacist 
attitude and lack of two way information sharing between the pharmacist and other 
healthcare professionals involved in the drug misusers’ care were identified as potential 
barriers to developing such services.
Providing relevant and adequate training in a multi-disciplinary setting was identified 
as the most important facilitator as it was recognised that a lack of training was a 
barrier to enhancing services.
5.2.5. Describe the views and experiences of service users of community pharmacy 
drug misuse services, and obtain their opinions of how services could be improved 
and developed
The views and experiences of service users in this study are similar to those service 
users interviewed in previous studies. (Sheridan and Barber, 1996, Matheson, 1998 and 
Neale, 1999)
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In this study, services provided by community pharmacists include remunerated 
services such as needle exchange and supervised consumption and the ‘ad hoc’ service 
of advice provision.
5.2,5.1. Service Users views o f Pharmacy Needle Exchange
In general, those interviewees who had used pharmacy based needle exchange were 
positive about the service. They recognised the need for such services to be available 
locally and felt that the pharmacy opening hours made clean injecting equipment more 
available than it would be from a specialist drug service.
Features of the service were discussed by some interviewees. Encouragingly, no one 
had experienced a limit on the number of syringes that they were permitted to take 
away if they did not bring back used ones. Whilst pharmacists encouraged returns, 
users did not appear to be penalised for failing to return syringes. This was a feature of 
at least one needle exchange of which the author has experience. However, with only 
one set of injecting equipment being available for every two injections administered 
(Parsons, 2002) it is perhaps understandable that some drug users may wish to keep 
used equipment in ‘reserve’ rather that run out completely.
Unfortunately, some interviewees had experienced their local pharmacy based needle 
exchanges closing down. Most felt that this was because the pharmacists did not want 
drug users to come into their pharmacies. Others described having to travel 
considerable distances to find a needle exchange.
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Unsurprisingly, negative experiences of pharmacy needle exchange services were 
mainly due to lack of availability, both of needles and syringes but also of associated 
paraphernalia such as citric or ascorbic acid.
The use of acids to dissolve heroin is now regarded as a harm reduction strategy 
(Ponton, 2004) and following a recent change in the law permitting the provision or 
sale of citric acid and other injecting paraphernalia to injecting drug users it has been 
recommended that citric or ascorbic acid be incorporated into needle exchange packs in 
order to prevent the use of less suitable acids such as lemon juice and vinegar.
However, a recent survey of needle exchanges conducted by the NTA (NTA, 2006) 
revealed a disparity between pharmacy based schemes and those run by specialist drug 
services with only 44.4% of pharmacy schemes providing citric acid compared with 
80.5% of ‘specialist’ schemes.
The report found that pharmacy schemes accounted for 80% of needle exchange 
services in England, but it is limited in its assessment of the quality of pharmacy based 
schemes due to the poor response rate from pharmacy needle exchange scheme co­
ordinators (48%). This suggests that the NTA should focus on obtaining data directly 
from the providers of pharmacy needle exchange schemes in order to more accurately 
assess the quality of the schemes in respect of the provision of injecting paraphernalia 
as pharmacy based schemes represent the majority of needle exchanges, however it is 
recognised that this would be a major undertaking with over 10,000 community 
pharmacies in England.
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The organisation of individual needle exchanges was commented upon by 
interviewees. Most were concerned with privacy surrounding the transactions. This is 
an importance consideration as some participants described the embarrassment of 
having to dispose of their sharps bin in front of other customers. Unfortunately, other 
interviewees had been asked to come back to the pharmacy at an alternative time as the 
pharmacist was at lunch. Both these points suggest that pharmacy based needle 
exchanges should consider the privacy of the client as well as ensuring that adequate 
numbers of staff are able to carry out needle exchange transaction in the absence of the 
pharmacist.
5.2.5.2. Service Users9 Views o f Supervised Consumption
Similarly to needle exchange, the local availability of the service was important to most 
of the interviewees, with those in more rural areas describing having to travel some 
distance to their drug clinic in order to receive their daily dose of methadone before 
their local pharmacies started to participate in the scheme.
Whilst locality was seen as a benefit to some, other felt that this was a disadvantage as 
they were more likely to come into contact with people e.g. neighbours, who they may 
not want to know that they are on a methadone prescription. This was especially the 
case in pharmacies were there was little privacy for the client to consume their dose of 
methadone. Others explained that coming into contact with certain other drug users 
were more likely to make them use. This was because they associated that individual 
with periods of time in their life when they used.
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The service user interviewees pointed out some of the benefits of supervised 
consumption. The participants of this study gave similar reasons to those interviewed 
by Neale (1999) in that supervised consumption prevented the abuse of the substitute 
prescribing system.
However, in contrast to Neale’s findings, supervised consumption was seen by most as 
a negative condition of substitute prescribing principally because of the lack of privacy 
in the pharmacy.
Neale suggests that there may be scope for increasing the level of supervision, but that 
this should not be a blanket condition applied indiscriminately. However, in some 
areas, interviewees in this study described that everyone who received methadone from 
their pharmacy was supervised irrespective of how long they had been on a 
prescription. This finding suggests that guidelines for supervision of consumption 
published by the Department of Health and the ACMD may have been overlooked by 
some local drug agencies. The rational for supervised consumption should be 
considered by individual agencies to ensure that it is appropriate and not applied in a 
‘blanket’ fashion.
Individual interviewees commented on the length of time that they had been supervised 
and the effect that this had on their lives. Effectively, being supervised meant that they 
were ‘tied’ to the pharmacy and the local area with trips away difficult to organise.
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Problems associated with supervised consumption were described by some clients. 
They recognised that pharmacists were sometimes put in a difficult position when a 
client presented intoxicated. Most understood the need for the pharmacist to withhold 
methadone doses under these circumstances but recognised that this may be difficult to 
do if a client became aggressive.
5.2.5.3. Service Users9 views o f Advice from  Pharmacists
The results clearly indicate that the interviewees were more likely to ask advice about 
general health matters than about aspects of their drug misuse. Previous studies have 
suggested that drug misusing clients of community pharmacies would like to see 
leaflets on aspects of drug misuse on display in pharmacies and regarded the 
pharmacist as a potential source of advice. (Sheridan, 1996)
The postal questionnaire conducted in part one of the research reported here suggests 
few pharmacists provided leaflets on drug misuse and methadone to drug misusing 
clients, and that the majority of respondents to the postal questionnaire never gave out 
leaflets concerning HTV prevention to new drug misusing clients. Therefore it is 
possible that the lack of availability of advice leaflets of drug misuse coupled with the 
service users’ reticence to ask advice on aspects of their drug misuse means that whilst 
the pharmacy is regarded as a source of advice, in practice it is neither being provided 
nor sought.
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5.2.5.4. Service Users9 Views o f Pharmacy Service Development
The interviewees discussed their views on the extension of prescribing rights to include 
pharmacists. This makes it possible for opioid substitute medication to be made 
available through prescribers other than doctors.
Whilst several participants had reservations, most recognised that allowing pharmacists 
to prescribe would make drug treatment more widely available. In some areas where 
reported waiting times were in excess of 14 months this was seen as a significant 
development.
Some participants felt that getting methadone prescribed by a pharmacist would be ‘too 
easy’ and open to abuse. The potential organisation of opioid substitution prescribing 
service conducted by pharmacist was not discussed with the interviewees. This is 
because the author was not aware of any such schemes at the time of interview.
It is suspected that the reservations of the interviewees were based on the assumption 
that an individual would be able to get opioid substitution medication in a manner 
similar to other pharmacy ‘P’ medicines, from a local community pharmacy. The 
interviewees felt that pharmacists would not have access to urine testing that could help 
to ensure compliance with the programme. The participants recognised that their drugs 
workers and doctors worked together, often in the same clinic, to ensure that 
prescribing was appropriate and safe. In comparison they recognised that pharmacists 
were often based away from the surgery or clinic and would not have access to the
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same level of support. It is suspected that, for this reason, interviewees felt that 
pharmacists could have a role to play in prescribing in maintenance treatment to those 
who were established on an opioid substitute rather than initiating new clients on to a 
substitute prescription.
Maintenance prescribing by pharmacists has the potential to benefit access to treatment 
services whereby clients are initiated on medication at a drug clinic or general practice 
and then transferred to a pharmacist once maintenance prescribing had been 
established. This model would require a clear treatment plan that defines when and for 
how long prescribing is the responsibility of the pharmacist.
In order to ensure that a new model of prescribing is safe, clear communication 
pathways between pharmacist prescriber and GP or drug clinic must be defined and 
established. The service users should be part of the consultation about what information 
is shared between members of the drug treatment team.
The service users who participated in the interviews conducted in this research had 
clear views on the level of confidential information that is shared between the 
pharmacist and doctor or drugs worker. Most felt that that the pharmacist did not need 
to know anymore about them than any other patient. This was because they saw the 
pharmacist as a supplier of their medication rather than being more explicitly involved 
in their care, for example, by prescribing substitute medication.
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Pharmacists who act as prescribers are likely to need more information about an 
individual client than those who dispense. This level of confidential information 
sharing should be discussed with the client before alternative prescribing arrangements 
are made.
5.2.5.5. Summary o f  Objective Five
Service user interview participants were generally positive about the type of services 
that they received from community pharmacies. The convenience of a pharmacy local 
to home was important to most service users, especially where they had had previous 
experience of travelling some distance to obtain injecting equipment or to get then- 
daily dose of methadone. Some participants described asking the pharmacist for advice 
about minor illnesses and recognised that the pharmacist was an source of advice on 
such matters. They were less likely to ask advice on aspects of their drug misuse, for 
example safer injecting. Most said that they would feel embarrassed to do so, whilst 
other recognised that they had alternative sources of advice in this area.
The suggestion of pharmacist prescribing of substitute medication received a mixed 
response. Some participants recognised that this model of prescribing would increase 
the availability of substitute medication. Others participants were less positive, 
questioning the level of training that the pharmacist possessed. However, most felt that 
there was a role for pharmacist prescribing in maintenance situations.
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5.3. METHODOLOGICAL CONSIDERATIONS
This study was conducted in three parts and used two methods of data collection in 
order to fulfil the objectives of the study which were summarised in section 2.11. on 
page 71.
Each part of the study will be discussed in turn in order that the appropriateness of each 
method can be assessed and reviewed. In this section methodological comparisons with 
other studies will also be made.
5.3.1. Community Pharmacy Postal Survey
5.3.1.1. Appropriateness o f the M ethod
The questionnaire allowed current levels of service provision to drug misusers from 
community pharmacies in the South West of England to be ascertained and to gauge 
the attitudes of these pharmacies to drug misusers and their role in providing services 
allowing objectives one and two to be fulfilled.
This method of obtaining data on service provision and attitude was considered to be 
the most practical and cost-effective way of getting information from a large 
population.
Bryman (2001) states that the self-completion questionnaire and the structured 
interview are very similar methods of social research, however it can be argued that
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this depends on the content of the questionnaire. For example, it would have been 
difficult to obtain numbers of methadone prescriptions in a structured interview without 
interrupting the interview as it is likely that the participant will have to examine the 
methadone prescriptions in order to provide the data required.
A structured interview has more ‘context’ which can influence the responder, for 
example interviewer personality, style and manner of questioning. This is especially 
important when obtaining data on attitudes which may be influenced by the rapport (or 
lack of) built between the interviewer and interviewee during the course of 
administering the questionnaire. In comparison, a postal questionnaire that can be 
answered at the respondent’s leisure removes the ‘personal influence’ of the 
interviewer.
In this case, the advantages of a self-completion postal questionnaire, that is; relative in 
expense when compared to other methods, ease of administration for a single person 
research project and convenience for the respondents, were considered to outweigh the 
potential disadvantages of this method which could include potential confusion on the 
part of the respondent and the lack of opportunity of the researcher to prompt or help 
the respondent with an answer. The questionnaire used in this survey concentrated on 
obtaining quantitative information, whilst some qualitative ‘free response’ questions 
were asked, these were used mainly to inform the next stage of the research.
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5.3,1.2. Data Collection
Use of pilot questionnaire
A pilot was used in order to test the layout and ease of understanding of the developed 
questionnaire as well as to predict the level of response that may be expected in the 
survey population. The pilot questionnaire were filled in as was anticipated by the 
researcher, however the response rate (32%) after three mailings was lower than was 
predicted from previous postal surveys of community pharmacies (Sheridan (1996) -  
74.8% and Matheson (1999 and 2002) -  79.1% and 83.4% respectively).
As the questionnaire was developed using Matheson (1999) as a template, it was 
surprising that the resulting questionnaire performed poorly in the pilot with regard to 
response rate. With hindsight, the use of Berkshire as the pilot area was potentially 
biased. The 4-way agreement (Walker, 2001) was developed in Berkshire and for this 
reason Berkshire was chosen as the pilot area. However, the existence of the 4-way 
agreement in Berkshire does not reflect the ‘typical’ situation in the South West of 
England where the use of a 4-way agreement is varied.
The poor response rate from the pilot survey may have reflected a degree of ‘drug user 
survey fatigue’ amongst these pharmacies as a result of the 4-way agreement 
development and subsequent validation. It may have been more appropriate to pilot the 
questionnaire on the population to be surveyed (i.e. the South West of England) to 
more accurately assess the response rate that could be expected.
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Following telephone interviews with pilot non-responders where it was revealed that 
50% (n=13) felt that they did not have enough time in their working day to fill in the 
questionnaire, it was decided to develop a much shorter version of the questionnaire in 
order to maximise the data obtained on level of service activity at the expense of 
obtaining data on knowledge and attitude.
Length of the questionnaire
Response rates suggest that the length of the questionnaire have had an influence on 
response. Referring to Table Six on page 102, it can be seen that the last mailing of the 
full version of the questionnaire resulted in an increase in response rate of 9%. The 
subsequent mailing of the shortened version of the questionnaire resulted in an increase 
in response of 18% indicating that pharmacists were more likely to fill in a shorter 
version of the questionnaire. This finding is an important learning for future research 
that involves administering questionnaires in order to maximise response.
Judging the length of a questionnaire to maximise both response and richness of data 
collection is challenging, and whilst the shortened version lacked information on the 
demographic details of the respondent, it allowed information on service provision to 
be obtained from pharmacies that had not replied to the full version. This is shown by 
the response from a further 18% (n=162) of pharmacies.
The benefit of increasing response rate by using two versions of the questionnaire 
presented a challenge when analysing the data. It was important to be clear which
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sections of the analysis referred to the responses obtained from both versions (78%, 
n=707) and those from the original length version (60%, n=545) when interpreting the 
results of the questionnaire.
Non-responders
A response to the questionnaire was not received from 21.7% (n=196) pharmacies. In 
Dorset and Somerset StHA non-responders accounted for 26.0% (n=57) of pharmacies. 
Whilst in Avon, Gloucestershire and Wiltshire, and South West Peninsula StHAs non 
response rates were similar, 20.3% (n=78) and 20.2% (n=61) respectively. Non­
responders were not followed up, so it was not possible to discuss the characteristics of 
non-responders to this questionnaire.
As no data were obtained on those pharmacists who chose not to respond to the 
questionnaire it is not possible to assume that they would have responded in a similar 
manner to those who did respond. Sheridan and Strang (1998) examined the 
significance of late or non-response to their 1995 survey on drug misuse services 
provided by community pharmacists. They found that late or non-responders were 
significantly different from those who did respond in terms of the extent of their service 
involvement.
Non-response bias should therefore be considered when interpreting the results of this 
questionnaire since pharmacists who are highly motivated and involved in providing 
services may be more likely to respond that those who are have a negative attitude to
-243-
Chapter Five - Discussion
r
drug misusers (Matheson, 1999). Therefore the 196 pharmacists from whom data was 
not gathered may have more negative attitude and be less involved in service provision.
Examination of the data provided by the 2003 Pharmacy Workforce Census revealed 
that Dorset and Somerset StHA is home to a higher proportion of locums than the 
national average, (36% compared with 28% nationally). Locum pharmacists may not 
feel able or willing to fill out a questionnaire that relates to a specific pharmacy and this 
may reflect the slightly lower response from pharmacies in Dorset and Somerset (Table 
Six, page 102).
In order to ‘correct’ the results for non-response, a telephone interview could have been 
carried out on the remaining 196 non-responders. This was deemed too costly and time- 
consuming to perform at the time. Therefore acknowledgement is given to the 
problems in generalising these results to the whole population of community 
pharmacists in the South West of England. The objective of providing information on 
service provision have been met by ensuring that a good response rate (77.8%) was 
achieved as it is acknowledged that the higher the response rate, the lower the potential 
bias due to non-response (Sheridan, 1998).
Demography of Respondents
Respondents were similar in terms of demographic information to those who responded 
to Matheson’s 2000 survey of Scottish pharmacists (Matheson, 2002) and allows for 
comparison to be made between the two groups.
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A comparison of demographic information was not possible with the work of Sheridan 
(1996) as they did not report the demographic information of their respondents. We 
cannot, therefore, assume that the two groups of respondents are similar.
5.5.7.5. The ‘Knowledge’ section
This section was designed to test pharmacists’ knowledge on aspects of drug misuse 
and treatment of opiate dependence. The testing of pharmacists’ knowledge in this 
manner has not been attempted by authors of previously conducted surveys of 
community pharmacists and as such no comparisons between surveys can be made.
The ‘correct’ answers were determined by the author using her own professional 
knowledge of drug misuse and treatment of dependence and from reference to texts. 
However, the confidence in the findings of this part of the survey is limited by the lack 
of external validation of the answers. The findings would have been more robust had 
the answers to the questions posed had been validated using answers from an expert 
panel. Using a panel in this way would help to gain consensus should differing 
opinions arise on the ‘correct’ answer.
For example in the analysis of the answers to question 30, (when supervising 
consumption of Subutex (buprenorphine) how long does it take for the full dose to be 
absorbed from the mouth?) it is apparent that there is a spread of opinion as to the 
correct answer (see Table 19 on page 115). The ‘correct’ answer may be considered to 
be unclear, as the manufacturers of Subutex were unable to provide the author with
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buccal absorption data. In the absence of such data, the views of an ‘expert panel’ 
could have provided a consensus which could then have been compared with the 
responses of the pharmacists who answered the questionnaire.
5.3.1 A . The Attitude Scale
Reliability and Validity of the Attitude Scale
The attitude scale used in the questionnaire was similar to that used by Matheson 
(1999) who demonstrated the scale to be reliable; that is that it would yield the same 
results if it were to be repeated in the same population and valid; that is that it 
measured what it is supposed to be measuring.
The reliability of the attitude scale reported here was tested by computing Cronbach’s 
alpha coefficient for the scale. At 0.813 the coefficient compared well with that of 
Matheson (1999) at 0.92 and was above the 0.80 quoted by Bryman (2001) as the 
figure typically employed as a rule of thumb to denote an acceptable level of internal 
reliability.
The validity of the scale was assessed in two ways. Firstly, the construct validity of the 
questionnaire was assessed by looking at how responses to two attitude statements 
(questions 57 and 58) compared with respondents responses to questions about the drug 
misuse services that they provided. Examination of these responses revealed good 
construct validity as 90% of those pharmacists who provided a supervised methadone 
consumption service disagreed with question 57, 7 believe that I  would never supervise
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the consumption o f Controlled Drugs by drug misusers on my pharmacy premises. ’ 
Similarly, 68% of pharmacists who provided a needle exchange scheme agreed with 
question 58, 7 believe the community pharmacy is an appropriate place for a needle 
exchange scheme. ’
Secondly, the psychometric validity of the attitude scale was determined using factor 
analysis. The process of factor analysis takes a large set of variables (in this case the 
attitude statements) and looks for groups among the inter-correlations of the set.
Determining the number of factors that best describes the underlying relationship 
among the attitude statements is done by looking at two results of the analysis. Firstly, 
Kaiser’s criterion suggests that only factors with an eigenvalue of 1.0 or over are 
retained. In the factor analysis presented here, nine factors with an eigenvalue over 1.0 
were found to exist. This was felt to be too many to describe with clarity. Kaiser’s 
criterion has been criticised however, as resulting in the retention of too many factors 
in some situations (Bryman, 2001). It was felt that this factor analysis was one such 
occasion. Secondly, one can examine Catell’s scree plot. Catell recommends plotting 
each of the eigenvalues of the factors and finding the point at which the shape of the 
curve changes direction and becomes horizontal. The factors that occur before the 
change in direction are then retained for subsequesnt interpretation. Examination of the 
scree plot for the attitude scale in this study revealed the existence of five factors that 
occurred before the change in direction of the plot. Thus five factors were retained for
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the subsequent analysis and were interpreted as described in section 4.1.6.3. on page 
121.
The factor analysis confirmed that the scale was measuring different attitudes (i) 
towards drug misusers themselves, (ii) the effect on the community, (iii) the services 
provided and (iv) advice and support but all on a similar theme, that of drug misuse.
Normality of the attitude scale
A graph of number of respondents versus attitude score revealed a normal distribution 
(Figure Four, page 119). Because of this parametric statistics were used to relate 
attitude to demographic details, service provision and knowledge.
5.3.I.5. Comparison with Other Studies
Tentative comparisons with other surveys of community pharmacists have been made 
in section 5.2.1. above. However there are methodological differences between the 
previous studies and the work reported in this thesis and these are now further 
discussed.
Both Sheridan (1996) and Glanz (1989) conducted a 1 in 4 survey of community 
pharmacies in England and Wales whilst the study reported here used the population of 
community pharmacies in the South West of England.
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As earlier surveys used a sample comprising only 25% of the population, there has to 
be an element of caution in assuming that their findings can therefore be regarded as 
national statistics. Additionally, their data was not reported by region, so it is unknown 
whether the South West was similar to or different from the rest of the sample. The 
South West is made up of large urban, small urban, suburban, small town and rural 
areas with a diverse urban population. English national drug policy and funding 
systems apply, as do national pharmaceutical practice guidance, so there is no evidence 
to suggest that the South West would be significantly different from a national average 
although it is making an assumption to say that it would not. The author of the 1995 
survey of community pharmacies was approached for regional data but this was not 
made available.
Therefore, in the absence of more certain historic data for England, tentative 
comparisons have been made between this study and those of Sheridan and Glanz.
Surveys of Scottish pharmacies conducted by Matheson et al (1999, 2002) surveyed all 
Scottish pharmacies rather than a 25% sample. This allows more confidence in their 
findings and a more robust comparison can be made with the results of the current 
study due to the similar methodologies employed.
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5.3.2. Semi-Structured Interviews with Community Pharmacists
53,2.1. Appropriateness o f the Method
The aim of this part of the study was to understand pharmacists’ experiences of 
providing services to drug misusers. In addition the participant’s views on the role of 
pharmacists in the treatment of drug misuse, and their views on potential barriers and 
opportunities to the development of services were elicited in order to further explore 
the data obtained in the quantitative data obtained from the questionnaire.
This study was qualitative in nature and used Interpretative Phenomenological Analysis 
(IPA) to help interpret the differing experiences of the interview participants. A 
discussion of this analytical method and the differences between IPA and Grounded 
Theory can be found in section 3.1.2.1. on page 79.
The semi-structured interview was chosen as the data collection tool because it has the 
benefit of allowing personal views and experiences to be described in an environment 
where they will not be challenged by others and allows detailed descriptive data to be 
gathered which were needed in order to perform the analysis.
The interview schedule was developed from analysis of responses to the free-response 
questions in the postal questionnaire. In this way, the results of the postal questionnaire 
have informed the next stage of the research and ensured that the pieces of work are not 
mutually exclusive. A pilot interview allowed the schedule to be tested, and evaluate 
the interviewee’s comprehension of the questions.
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Thirty-one interviews were conducted with pharmacists. However, after fifteen of the 
transcripts had been analysed, it was felt that no new themes were emerging from the 
data and following consultation with a researcher with considerable experience of IPA 
it was decided not to analyse the remaining 16 transcripts as the view was taken that 
data saturation had been reached.
It was subsequently recognised that careful planning and analysis of the interviews as 
they occurred could have prevented interviews that were not required for the analysis 
from being conducted. It is intended that in future research projects of this nature, 
further interviews will only be arranged once initial interviews have been analysed and 
a need for more qualitative data has been established.
In order to use the data obtained from the remaining 16 transcripts that were not 
included in the IPA analysis, further work could involve a deviant case analysis of 
these transcripts.
53,2.2, Recruitment and Selection o f Participants
Participants were recruited on the basis of their indication of willingness to participate 
in further research following their responses to the postal questionnaire. The reason for 
individuals’ decision to participate (or not to participate) is unknown. It is possible to 
examine whether the attitude score of the interview participants varied from the rest of 
the respondents to the postal questionnaire. A one-sided T-Test revealed a significant
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difference between the two groups \p=0.000]. Table 35 summarises the differences in 
mean attitude score.





Interview Participants 15.4 11.9
Table 35: Difference in mean attitude scores between Interview Participants and all 
questionnaire respondents
It can be concluded from this comparison that those respondents with a more positive 
attitude score were more likely to agree to be interviewed. Potential bias is therefore 
introduced because the candidates for the interviews were self-selecting. Whilst this 
bias is noted, it was not deemed to be a limitation of the study since by the nature of the 
method and in order to demonstrate good practice research and to obtain ethical 
approval for the study; participants must be able to demonstrate willingness to 
participate, and capacity to give written consent to the interview being recorded. If they 
were not truly willing then it could be argued that they were coerced into taking part 
which is clearly at odds with a sound ethical study.
It is also possible that those respondents to the postal questionnaire were positively 
selected as candidates for interview because letters inviting individuals to be 
interviewed were sent out in the order that responses to the postal questionnaire were 
received, so that those who responded to the initial mail-out were invited to be 
interviewed first. In order to prevent this potential bias in future work, letters inviting
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potential interviewees to participate could be sent out at the conclusion of the 
questionnaire so that respondents to earlier mailing are not positively selected for.
Previous research (Sheridan, 1998) has shown that the level of service provision to 
drug misusers varied according to the wave of mailing to which the individual 
responded, with those providing services tending to respond earlier than those who did 
not. Applying these findings to the study reported here, it could be argued that the 
recruitment methods employed have positively selected for those pharmacists who do 
provide services to drug misusers and interviewing pharmacists with a more positive 
attitude than the whole population (of pharmacists in the south west of England) may 
have resulted in an unrepresentative view of the services provided to drug misusers and 
how they could be developed. However, the purpose of this study was not to provide a 
representative qualitative assessment of the views of pharmacists who provide drug 
misuse services, but rather to examine how these services could be developed. Because 
of this, interviewing pharmacists with a negative attitude to drug misuse service 
provision, whilst difficult in terms of recruitment may also have resulted in a lack of 
new thinking in the area because of a poorer attitude to existing services.
Whilst recognised, it was not felt to be a limitation of the study since the objectives of 
the research are centred on those who provide services rather than those who do not.
There were many more pharmacists willing to participate further than were needed for 
the interviews. Therefore, a purposive sample was selected from the initial set of
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volunteers. This selection was carried out on the basis of the location of the participants 
so that pharmacists from various geographical locations across the South West of 
England were chosen to be interviewed. As this was a purposive sample, potential bias 
is again introduced because the researcher selected the final list of interviewees.
5.3.2.3. Reliability o f  the Findings
The semi-structured interview, as with other self-report methods of research relies on 
the respondent being able to give accurate and complete answers to the questions 
posed. This may depend on how the questions are structured, and how the respondent 
interprets the meaning of the question. In order to facilitate the gathering of data in this 
study the interview consisted of a series of questions in the form of a topic guide.
This allowed the researcher to vary the sequence of questioning and gave some latitude 
to ask further questions in response in order to explore topics that arose in more depth. 
Where incomplete answers were felt to have been given by the respondent, the 
researcher had a number of prompting questions in order to illicit the maximum amount 
of data from an individual question.
The interview was carried out at the participant’s place of work, most often during a 
lunch break. It was not always possible to arrange this, and therefore it is 
acknowledged that the interviewee may have been distracted from the interview in 
order to perform tasks associated with their role, for example, checking prescriptions or 
counselling patients. During the interview the researcher assessed how much the
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interviewee had been distracted by other tasks, however, it was felt that none of the 
interviews were significantly affected by interruption.
The interpretation and reliability of the findings assume that the participant answered 
the questions by drawing on experiences that they have had as a result of providing 
services to drug misusers. Thus, a recent ‘bad experience’ with a drug misuser may 
affect the overall ‘tone’ of the interview and the subsequent views and opinions of the 
participant. No assessment was made of the reliability of the individual interviews. One 
way of assessing this would have been to send the interviewee a transcript of the 
interview and ask them to comment on the tone and answers given. This may have 
uncovered interviews which were negatively biased because of a recent negative 
experience. However, asking an interviewee to comment on the tone of an interview 
may lead them to retract part or the entire interview on the basis that they do not like 
how they sound adding further bias to the analysis. (Silverman, 2000)
5.3.3. Semi-Structured Interviews with Service Users
Services users of healthcare in the United Kingdom are viewed as stakeholders in the 
comment on and development of new clinical guidelines by the National Institute of 
Health and Clinical Excellence (NICE) and the organisation has committed itself to 
involving the patients, carers and the public in the development of new guidelines. The 
views of users of a service are important when considering how services can be 
improved in order to ensure that improvements are relevant and acceptable to the 
patients who may benefit from them.
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In the context of this research, therefore, it was felt vital to ascertain the views of the 
service users on the care they currently receive and to gain their insight into how 
pharmacy service to opioid dependent individuals could be improved and extended.
5.3.3.1. Appropriateness of the Method
The semi-structured interview was again considered to be the most appropriate way to 
collect data in order to understand the views and experiences of drug misusing service 
users of community pharmacies. Consideration of alternative methods of data 
collection and analysis are discussed in section 3.1.2.1 on page 83.
The interview schedule was developed following the analysis of the pharmacist 
interviews. This allowed service user interview participants to comment on the 
pharmacists’ suggestions for development of community pharmacy drug misuse 
services. A link between the first two stages of the research is therefore maintained
5.3.3.2. Recruitment o f Participants
Service users were recruited from four pharmacies who had responded to the postal 
questionnaire and whose pharmacists had been interviewed for stage two of the 
research. Obtaining agreement from the pharmacists to conduct interviews with their 
service users was facilitated because the pharmacists had previous knowledge of the 
research and the researcher. The pharmacies were selected based on their differing 
geographical location in the south west of England (Bristol (inner city), Bournemouth 
(council estate), Swindon (suburban) and Torquay (tourist destination).
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Considerable thought was applied to how the service user interviewees were to be 
recruited. It was acknowledged that service users may have felt obliged to take part if 
the pharmacists themselves had carried out the recruitment. For this reason, 
pharmacists were asked to hand out information leaflets about the study the day before 
the researcher attended the pharmacy to conduct the interviews. Recruitment and 
consent to be interviewed was then carried out by the researcher on the day scheduled 
for the interviews to take place. In practice, some service users actively indicated to the 
pharmacist that they were willing to be interviewed. In these cases ‘appointments’ for 
the following day were made. Five of the 15 interviewees were recruited in this way. It 
was reiterated to these interviewees that the content of the interview would not be 
discussed with the pharmacist and would not influence future prescriptions from the 
pharmacy.
Following learnings made from the pharmacist interviews, fewer interviews (15) were 
conducted with service users than took place with the pharmacists. This resulted in all 
of the transcriptions being included in the analysis. It was noted however, that few 
‘new’ themes emerged from the service users after 14 interviews had been analysed.
This demonstrates that it is difficult to ascertain how many interviews to conduct in 
advance, in order to ensure that no new themes emerge from subsequent interviews. 
This could be overcome by analysing the content of the transcriptions as the interviews 
are conducted and only then arranging more interviews if new themes were still
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emerging from the data. In practice this was difficult to achieve within the design of 
this study.
5,3.33. Reliability o f the Findings
The reliability of the findings drawn from the service user interviews rely on the 
interviewee being able to give full and honest answers to the questions posed, in a 
manner similar to the interviews conducted with the pharmacists. Similarly, recent bad 
experiences of a pharmacy may have resulted in an overtly negative interview.
An additional factor associated with the service user interviews is the location that the 
interview took place. In all cases the interviews were carried out within the pharmacy 
from which they obtained methadone or injecting equipment. As the participants were 
asked to evaluate services that they received from the pharmacy, they may have felt 
obliged to give positive responses, because of concern that a negative response may 
affect their relationship with the pharmacist and staff. Concerns of this nature were 
addressed by ensuring that the interviewee was aware of the confidential nature of the 
study and by using a room in which pharmacy staff could not overhear the interview.
Previous studies with drug misusing clients (Amsel, 1976) have suggested that this 
group of people give reliable and truthful answers to questions asked of them in a 
research context if there is no perceived adverse consequence or gain. There was no 
evidence that the group of service users interviewed from this study were any different.
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In practice, many of the participants described ‘negative’ experiences of the pharmacy, 
but encouragingly most went on to describe how these ‘negatives’ had been overcome.
5.3.4. Final Methodological Comment
The methods employed to fulfil the objectives of the study produced data that 
confidently allowed the current level of service provision in the South West of England 
to be ascertained, and an assessment of the knowledge and attitudes of pharmacists who 
provide these services to be made.
The use of both quantitative and qualitative methodologies enabled the researcher to 
examine and explain the findings of the objectives in a more rounded manner than 
would have been possible with the use of solely quantitative data.
The use of the postal questionnaire to collect data on service provision allowed some 
comparisons to be made with previous surveys; however methodological differences 
have been acknowledged and therefore comparisons have been made in terms of trends 
in data rather than absolutes.
The use of semi-structured interviews with pharmacists and service users resulted in a 
rich data set which allowed the researcher to describe the views and experiences of 






6.1. COMMUNITY PHARMACY INVOLVEMENT IN THE CARE
OF DRUG MISUSERS ................................................................ 261
6.1.1. Dispensing Controlled Drugs for the Treatment of Dependence 261
6.1.2. Supply of Clean Injecting Equipment .. 262
6.1.3. Pharmacists’ Knowledge and Attitude on aspects of Drug Misuse 263
6.2. DEVELOPING COMMUNITY PHARMACY SERVICES TO DRUG
M IS U S E R S ...................................................................  264
6.2.1. Information Sharing 264
6.2.2. Support to Provide Services 265
6.23. Training and Attitude .. 266
6.3. METHODOLOGICAL LEARNINGS 268
6.3.1. Quantitative Postal Questionnaire 268
6.3.2. Qualitative Semi-Structured Interviews 269
6.4. THE PLACE OF THE RESEARCH .......................................  270
6.4.1. Updated Model of Care 270
6.4.2. Guide for Commissioners and Providers of Pharmacy
Services .. 274
6.4.3. Implications for Pharmacy Practice 275
-260-
Chapter Six - Conclusions
6.1. COMMUNITY PHARMACY INVOLVEMENT IN THE CARE OF DRUG 
MISUSERS
This research has updated and added to the literature on the level of community 
pharmacy involvement in the care of drug misusers in the following ways.
6.1.1. Dispensing Controlled Drugs for the Treatment of Dependence
The level of community pharmacy service provision to drug misusers in the South 
West of England has been quantified with a reasonable level of confidence. Data was 
obtained from 707/903 pharmacies in the South West, a response rate of 78%.
The postal survey of community pharmacies in the South West of England has 
suggested that more pharmacies are now dispensing controlled drugs for the treatment 
of dependence than were doing so in the whole of England following the last survey 
which was carried out in 1995, although caution with these comparisons is needed for 
reasons discussed in section 5.3.1.5.
The number of pharmacies that provide a supervised consumption service and the level 
of supervised consumption of methadone have been quantified in the South West for 
the first time with rates of supervised consumption showing regional variation, with 
lower levels in Dorset and Somerset possibly due to the more rural nature of these 
counties.
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Comparison of the data with that from surveys of Scottish pharmacies suggests that 
while more pharmacies in the south west provide a supervised consumption service, 
more Scottish drug misusers are receiving their methadone by supervised consumption 
showing that a greater level of service activity is undertaken by fewer pharmacies in 
Scotland.
6.1.2. Supply of Clean Injecting Equipment
The results of the postal questionnaire have allowed quantification of the extent of 
needle and syringe selling activity and provision of needle exchange services by 
community pharmacies in the South West of England.
Tentative comparisons with Sheridan’s 1995 survey suggest that the level of needle 
exchange provision from community pharmacies in the south west has fallen since 
1995. This is coupled with a decline in the number of pharmacies who were prepared to 
sell clean injecting equipment to drug misusers, and those who were prepared to sell 
but had not received any requests in the week before the questionnaire was completed.
These results raise concern about the overall availability of sterile injecting equipment 
through community pharmacies and suggest that urgent work is required to increase 
this availability in the light of rising levels of HCV infection amongst injecting drug 
users.
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6.1.3. Pharmacists’ Knowledge and Attitude on aspects of Drug Misuse
The level of knowledge of pharmacists who responded to the postal questionnaire 
varied, with those provided a needle exchange scheme having a significantly higher 
knowledge score than those who did not.
Importantly, whilst attitudes towards drug misusers and their treatment varied, those 
pharmacists who provided drug misuse services had significantly higher attitude scores 
than those who did not provide services, confirming the link made by Matheson in 
1999.
In addition to this finding, a positive correlation between attitude and knowledge was 
found to exist. This is the first time that such a link has been demonstrated and 
reiterates the importance of training in influencing attitudes towards drug misusers.
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6.2. DEVELOPING COMMUNITY PHARMACY SERVICES TO DRUG 
MISUSERS
Qualitative, semi-structured interviews with community pharmacists and service users 
revealed multi-dimensional experiences associated with providing drug misuse services 
(pharmacists) and using such services (service users). Important barriers and 
opportunities to developing services were identified as a result of the analysis of the 
interviews.
6.2.1. Information Sharing
A difficulty in sharing information about clients was perceived as a barrier to providing 
drug misuse services.
Crucially, participants’ experience of communication with drug treatment services 
varied with many suggesting that there was a lack of communication on the part of the 
drug services. This was often discussed in the context of confidentiality with some 
participants suggesting that confidential client information that they regarded as having 
an impact on the standard of care that they provided, was withheld from the 
pharmacists.
Service users recognised that certain information needed to be shared between their 
GP/ drugs worker and the pharmacist, and whilst some were happy for information to 
be freely shared between healthcare professionals involved in their care, others
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questioned why pharmacists needed to know more than the information that a 
prescription would provide.
In some areas where an ‘agreement’ between pharmacist, drug worker, GP and client 
existed it was perceived that this helped to define the role of each individual in the 
treatment of the client, however, the use of this agreement as a form of role 
clarification was not universal.
6.2.2. Support to Provide Services
The perception of the level and quality of support that participants received in order to 
provide drug misuse services varied with support being defined as communication, 
remuneration and training.
Interestingly, participants who were actively engaged with the drug treatment services 
were critical of pharmacists who complained that there was a lack of support. These 
pharmacists were all similar in that they had actively sought support in order to provide 
drug misuse services, and were all interested in the subject of drug misuse.
Whilst interest in providing drug misuse services is likely to be a motivator in actively 
seeking support, there must also be support mechanisms in place for those who are 
more passive in their support seeking.
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6.2.3. Training and Attitude
The importance of training pharmacists to provide drug misuse services is underpinned 
by the link between training and level of service provision first defined by Matheson 
(1999) and the link between knowledge, service provision and attitude demonstrated as 
a result of the work presented in this thesis.
Providing adequate and relevant training to pharmacists who provide services was 
discussed by both pharmacist and service user interviewees. Pharmacists felt that drug 
misuse training should include an understanding of the evidence behind the treatment 
of drug misuse and a clarification of their role within the drug misuse team, whilst 
service users felt that pharmacists should have an understanding of the impact on drug 
misuse on the life of the user in order to raise the pharmacists’ awareness of the issues 
and problems faced by people who misuse drugs.
Service users tended to view pharmacists as ‘dispensers of medication’ rather than as 
potential experts in the field of drug misuse. Service user participants recognised that 
pharmacists were a source of general healthcare advice, but seemed less confident in 
asking advice about aspects of their drug misuse. Similarly, when asked about their 
views of pharmacist prescribing, many recognised the benefits in terms of increasing 
the availability of substitute medication; however, this was tempered by concern about 
the level of the pharmacist’s knowledge and the impact of this on the safety of 
methadone prescribing.
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In view of this, training that is seen as relevant by both pharmacists and service users is 
vital in ensuring that new services such as pharmacist prescribing of substitute 
medication is accepted as a viable and safe alternative to traditional prescribing 
methods.
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6.3. METHODOLOGICAL LEARNINGS
Both quantitative and qualitative methods were used to explore the objectives of this 
thesis and were felt to have been relevant in producing the results on which the 
discussions of the objectives are based.
Methodological learnings were made during the course of the research and these are 
summarised below.
6.3.1. Quantitative Postal Questionnaire
Two versions of the postal questionnaire were used in order to maximise the response 
rate of pharmacies included in the research. The use of an abridged version in the forth 
mailing of the questionnaire was successful in increasing the response rate from 60% to 
78% overall. The abridged version was designed to ensure that maximum data on the 
extent of drug misuse service provision was obtained; however the use of two versions 
of the questionnaire resulted in challenges when the data were subsequently analysed 
and interpreted. It was important to ensure that it was clear whether the results had been 
obtained from analysis of the first three mailings or from all four mailings.
The questionnaire attempted to test the level of pharmacists’ knowledge on aspects of 
drug misuse and revealed a range of knowledge levels among respondents. The 
interpretation of these results would have had greater relevance if the questions 
designed to test knowledge had been tested on pharmacist ‘experts’ in the field of drug
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misuse in order to provide consensus on questions with a range of correct answers and 
to provide a baseline on which to compare the data from the respondents.
6.3.2. Qualitative Semi-Structured Interviews
Thirty-one interviews were conducted with pharmacists. However, when the transcripts 
of these interviews were analysed, it was clear that the themes resulting from the 
interviews had been saturated after 15 transcripts were included in the analysis. The 
remaining 16 transcripts were therefore not included.
It is acknowledged that had the transcripts been analysed as the research progressed it 
may have been possible to avoid conducting interviews which did not add to the 
development of resulting themes.
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6.4. THE PLACE OF THE RESEARCH
Since the start of this research in 2003, there have been a number of developments with 
regard to the place of pharmacy in the treatment of drug misuse. These will be 
considered in terms of the context of this research.
6.4.1. Updated Model of Care
In July 2006, the NT A published an update to the original Model of Care for Treatment 
of Adult Drug Misusers which was published in 2002.
The original document was criticised in section 1.3.4 for lacking specific information 
about pharmacy services to drug misusers and it’s failure to recognise the pharmacist as 
part of the drug misuse team. However, the recent update goes some way to redressing 
this.
The update now recognises the pharmacist as a part of the multidisciplinary team in 
both the in- and out-patient treatment of drug misusers. The unique role of the 
pharmacist in the provision of needle syringe exchange schemes and supervised 
consumption is given attention with a recommendation that pharmacists providing 
‘extended’ services such as interactive needle exchange and supervised consumption be 
trained to a suitable level of competence in line with the Drug and Alcohol National 
Occupational Standards (DANOS) competencies.
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This recognition and subsequent training suggestions goes some way to addressing the 
concerns raised following the postal questionnaire and interviews with pharmacists 
who provide drug misuse services conducted as part of this thesis. Both these pieces of 
research highlighted the need for suitable training in order to provide drug misuse 
services. The interviews with pharmacists revealed that they often do not feel part of 
the drug misuse team and suggested that suitable training was the main way of 
providing them with support.
The unique property of the community pharmacy in its ability to provide open access 
healthcare to drug misusers is mentioned in the update. Access and availability was 
discussed by service users as the most beneficial property of services such as needle 
exchange and supervised consumption. Unfortunately, the update does not discuss 
strategies for increasing service such as needle exchange in pharmacies which appear to 
have possibly remained static since the last survey was carried out in 1995.
Non-medical supplementary prescribing by pharmacists is mentioned in the update. 
The recent extension of prescribing rights to include pharmacists has the potential to 
impact positively on the availability of substitute prescribing for those who wish to 
address their drug use in this manner. However, the interviews with service users in this 
thesis suggest that further work is required to increase the acceptability of this 
alternative to doctor prescribing. Interviewees recognised that pharmacist prescribing 
could increase the availability of methadone but were concerned with the safety of this 
alternative and the potential ease of abuse of pharmacist prescribing. It was suggested
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that maintenance prescribing could be undertaken by pharmacists but that those new to 
treatment should continue to obtain methadone through doctor prescribing.
The updated Model of Care does not, however, refer to the non-medical ‘holistic’ role 
that several of the pharmacist interviewees in this study referred to when asked about 
the role that they played in the care of drug misusers. Similarly, a recent paper by 
Roberts and Hunter (2004) describing a system of pharmaceutical care in Glasgow pays 
close attention to reducing harm through the provision of needle exchange and 
supervised methadone consumption, but does not mention the social role that the
pharmacist plays in the care of people who misuse drugs.
Both the NTA’s updated Model of Care and Roberts and Hunter’s description of 
pharmaceutical care for the dispensing and supervision of methadone follow Hepler 
and Strand’s original definition that is discussed in section 2.7.1.
However, this definition does not describe the additional roles of providing needle 
exchange to drug misusers or the more holistic, social role described by the pharmacist 
interviewees that develops with the frequent visits of the client to the pharmacy. This 
social role which has so far been under described in the literature on pharmaceutical 
care of drug misusers, holds importance for both provider and service user and can 
positively impact on the care of the drug misuser through feedback to the key worker/
prescriber on the overall well being of the client.
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The original definition of pharmaceutical care fails to address the importance of the 
patient’s concerns and expectations (Barber, 2000). In the treatment of dependence, the 
expectations of the patient should be at the centre of any treatment plan in order to 
maximise the patient’s compliance with the treatment regime. For example, imposing a 
detoxification regime onto a patient who is not ready to become drug free is likely to 
result in failure. Detoxification from opioids could be classified as an ‘outcome’ 
according to Hepler and Strand’s definition, but unless it is an outcome with which the 
patient is in agreement, it is unlikely to succeed.
Barber’s criticism of Hepler and Strand’s definition (section 2.7.1.) holds true in the 
example of pharmaceutical care for drug misusers, as the non-medical social role 
focuses on the patient rather than the patient’s disease.
The treatment and reduction of harm associated with opioid addiction has focussed on 
medical model of treatment through the prescribing of substitute medication. The 
interviews with pharmacists and service users for this study clearly show an additional, 
non-medical role for the pharmacists which is not described by Hepler and Strand’s 
definition.
A new definition of pharmaceutical care for drug misusers is now proposed, which 
takes into account this newly described social role and the need for the individual 
patient’s input.
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“The provision of drug therapy, harm reduction measures and non-medical social care 
which takes into consideration the expectations of the client, in order to reduce drug 
related harm and improve the patient’s quality of life.”
6.4.2. Guide for Commissioners and Providers of Pharmacy Services
In February 2006, the NTA published the document entitled ‘Best Practice Guidance 
for Commissioners and Providers of Pharmaceutical Services for Drug Users’. This 
was produced in conjunction with the Royal Pharmaceutical Society of Great Britain 
and the Pharmacy Misuse Advisory Group (PharMAG) which enables pharmacists with 
an interest in substance misuse to share ideas and best practice. It has been written by 
Marion Walker who is now employed by the NTA as a pharmacist on the clinical team 
and who was previously responsible for the development of the Berkshire 4-Way 
agreement.
The document provides a comprehensive guide to pharmacy services including needle 
exchange and supervised consumption both from the point of view of those who 
commission services and those who provide the services. It gives detailed service 
specifications for needle exchange and supervised consumption.
It describes pharmacy services to drug misusers in the context of the new pharmacy 
contract for England and Wales and describes both how pharmacists are paid for NHS 
services and potential issues with payment to pharmacies
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Most importantly, the document serves to clarify the current and future roles of the 
pharmacist, including a description of the role of ‘Pharmacist with Special Interest 
(PhwSI)’ in drug misuse.
This publication answers the previous criticism of the NTA in underestimating the 
impact of pharmacy on drug treatment services. It is a comprehensive review of 
pharmacy service with an eye to the future role of the specialist pharmacist. It 
reinforces the vital role of the pharmacist within the drug misuse team which has been 
recognised by individuals with an interest in the area but not, until now in detail in 
official documents by the organisation responsible for drug treatment in England. It 
remains to be seen, however, how this document will impact on services on the ground.
6.4.3. Implications for Pharmacy Practice
The work presented in this thesis further demonstrates the clear need for community 
pharmacy to be actively involved in the care of drug misusers. There is a need for 
services to the expanded in order to meet the needs of the drug misusing population in 
terms of the availability of sterile injecting equipment.
There are opportunities for the pharmacy profession to develop its role as non-medical 
prescribers in the area of substance misuse, such development will enhance the service 
that the profession provides to the drug misusing population by increasing the 
availability of substitute medication and by providing an additional avenue of advice 
and support to those who wish to address their drug dependence.
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7.1. RECOMMENDATIONS
7.1.1. Increase the number of Pharmacy Based Needle Exchanges
The provision of a needle/ syringe exchange service through community pharmacies 
appears not to have increased since the last survey of community pharmacies was 
conducted. Participants who were not currently providing a needle exchange service 
commonly gave the reason that there was already a needle exchange available locally.
Analysis of the postal questionnaire conducted for this study suggested that 
pharmacists may be willing to provide services if an additional need were demonstrated 
and if adequate funding was available. Clearly, Parson’s work (Parsons, 2002) strongly 
suggests additional need for clean injecting equipment and it should therefore be a 
priority of commissioning bodies to demonstrate this additional need in order to secure 
funding and increase the number of pharmacy based needle exchange outlets.
In addition, as the recent audit on needle exchange provision conducted by the NTA 
(NTA, 2006) suggested that the provision of injecting paraphernalia through 
community pharmacies was lower than through specialist drug services, commissioning 
bodies should review the content of needle exchange packs to ensure that there is an 
appropriate level of paraphernalia provision.
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7.1.2. Review the level of Supervised Consumption in Individual Locations
The results of the postal questionnaire suggested a variation in the extent of supervised 
consumption of methadone across the South West. There are anecdotal reports of 
saturation of such services in individual locations and interviews with service users 
suggest that supervised consumption may be a blanket policy in some locations.
DAT’s and local Shared Care Monitoring Groups should be encouraged to review the 
criteria for supervised consumption within their areas to ensure that local resources of 
this service are utilised appropriately.
7.1.3. Multi-disciplinary Group Training
Interviews with pharmacists have revealed the importance of training as a way of 
providing support. Those who had experienced face to face training sessions with other 
pharmacists and healthcare professionals involved in the care of drug misusers 
described forming both formal and informal support networks. Therefore, multi­
disciplinary group training for healthcare professionals involved in the care of drug 
misusers should be a requirement of accreditation to provide drug misuse services. 
These training sessions should involve current service users whenever possible.
-278-
Chapter Seven - Recommendations
7.2. FUTURE WORK
7.2.1. Increasing the Availability of Injecting Equipment
As stated above, the analysis of the postal questionnaire has revealed an apparent 
reduction in the numbers of pharmacies providing needle and syringe exchange. This is 
coupled with an apparent reduction in the numbers of pharmacists in the South West of 
England who are prepared to sell clean injecting equipment. The reason for the 
reduction in ‘willing sellers’ is unknown, but may be related to a lack of disposal 
facilities.
In order to increase the availability of clean injecting equipment, further work should 
be conducted in order to examine whether providing community pharmacies with 
disposal facilities for used equipment increases selling activity.
7.2.2. Criteria for Supervising Consumption
Data obtained on the number of methadone clients who received their daily dose by 
supervised consumption revealed differences across the South West. Avon, 
Gloucestershire and Wiltshire had a higher incidence of supervised consumption than 
Dorset and Somerset; and the South West Peninsula Strategic Health Authority areas. 
The reason for this apparent difference is unknown and may be a result of chance.
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However, interviews conducted with service users has revealed that in some locations, 
supervised consumption is a ‘blanket policy’ with some individuals reporting being 
supervised for several years despite being on a stable, maintenance dose of methadone.
This finding is concerning, and is at odds with guidance from the Department of Health 
and the ACMD which suggests supervised consumption for the first three to six months 
of treatment.
Further work should be conducted to understand the reasons why clients are supervised 
for longer periods of time and the criteria used to assess an individuals’ suitability for 
‘take home’ doses.
7.2.3. Provision and Availability of Leaflets
The results from the postal questionnaire suggest that the provision of leaflets by 
pharmacists on drug misuse and blood borne disease is limited. More pharmacists 
reported giving face to face advice on issues surrounding drug misuse than providing 
leaflets on the topic.
Whilst it is encouraging that face to face advice does occur, analysis of the interviews 
with service users suggest that many may not be willing to ask for advice about their 
drug misuse. In these cases, the availability of relevant leaflets on topics such as safer 
injecting and local treatment services represent a way of obtaining advice in an 
anonymous fashion.
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Ways of improving leaflet provision in community pharmacies should therefore be 
researched, along with an assessment of the quality of such publications.
7.2.4. Pharmacists’ Training
Adequate training of pharmacists involved in the care of drug misusers has been 
demonstrating as being a factor in promoting positive attitudes towards drug misusers 
and their treatment.
Pharmacist and service user interviewees had differing views of important topics to 
include in a training package however, both views should be considered when 
designing training for pharmacists and their staff.
The content of such training should be examined to ensure it is relevant to both 
pharmacists and drug misusers’ expectations, and is up to date with the latest evidence 
in treatment.
7.2.5. The ‘Pharmacist with Special Interest’
The Pharmacist with Special Interest (PhwSI) is defined as “Someone who 
supplements their core generalist role by delivering an additional, high-quality service 
to meet the needs of patients. Working principally in the community, they deliver a 
clinical service beyond the scope of their core professional role or may undertake 
advanced interventions not normally undertaken by their peers. They will have
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demonstrated appropriate skills and competencies to deliver those services without 
direct supervision.”
The recent NTA document ‘Best practice guidance for commissioners and providers of 
pharmaceutical services for drug users’ suggests that pharmacists who have completed 
Part 2 of the Royal College of General Practitioners certificate in the management of 
drug misuse in Primary Care are an untapped resource with whom commissioners and 
DATs should be encouraged to make contact. Such pharmacists may become PhwSI’s 
within the framework published by the Department of Health.
The existence and roles of PhwSI’s within the area of drug misuse should be examined 
to provide information on the impact of such pharmacists on drug treatment and 
pharmacy service provision in general.
7.2.6. Impact of NTA Document ‘Best practice guidance for commissioners and 
providers of pharmaceutical services for drug users’
As described in 6.4.2 above, this document is a comprehensive guide to pharmacy 
services for drug misusers.
The impact of this document on local services should be assessed to ensure that the 
recommendations and standards contained within it are being followed in order to 
ensure high quality and standardised pharmaceutical care to drug misusers.
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APPENDICES
APPENDIX ONE
COMMUNITY PHARMACY SERVICES TO DRUG MISUSERS: 
POSTAL QUESTIONNAIRE FOR COMMUNITY PHARMACISTS
Study Number:
Community Pharmacy Services to Drug 
Misusers
A Postal Questionnaire for Community Pharmacists
Instructions for Completion
This questionnaire should take between 15 and 20 minutes to complete
• Please answer all sections. However, if you do not currently dispense methadone to drug 
misusers, you do not need to answer Part TWO.
• Please tick one box for each question unless otherwise specified.
• If there is insufficient space provided for you to answer some of the questions, or you wish 
to expand an answer more fully, then please continue on a separate piece of paper, 
indicating the question number clearly.
• All answers will be treated with the strictest of confidence. When the questionnaire is 
completed, please return it in the enclosed pre-pay envelope.
The next planned stage of the research is to conduct one-to-one interviews, local focus groups 
(group discussions around topics from the questionnaire) and observational work with willing 
pharmacists. If you would like to participate further, please indicate which studies you would 
like to participate in on the form at the end of the questionnaire._________________________
THANK YOU FOR TAKING PART IN THIS QUESTIONNAIRE. YOUR TIME IS MUCH
APPRECIATED.
Community Pharmacists and the Treatment of Drug Misuse
Community Pharmacists and the treatment of Drug Misuse
FIRSTLY, please provide some brief details about YOU and the PHARMACY in which you work.
1 Age in years:________
3 Number o f years registered:_________
4 Number o f years at present pharmacy:













6 Type o f business: 
Single outlet
Small Multiple (2-9 branches)
□
□
Large Multiple (>9 branches) □ 
Health Centre □
Do you have responsibility for making decisions about services for drug misusers?
YES -  sole responsibility 














Part ONE: This section aims to gather information on your level o f  involvement with drug 
misusers. Please complete this section even i f  you have never had any involvement with drug 
misusers.
9 Are there any OTCproducts that you believe YES □
are being misused in your local area? NO (go to 11) □
DON’T KNOW (go to 11) □
If YES, which products do you believe are being misused?_________________________________
10 I f  you answered YES to question 9, does this affect your sales policy YES □
for these products? NO □
Rachel Britton, Department o f Pharmacy and Pharmacology, University of Bath
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If YES please explain in what way:___________
If NO please explain why not:
11 Approximately how many individuals (excluding diabetics) have asked to Nil □




12 Are you prepared to sell needles or syringes YES, currently do □
to known or suspected drug addicts/misusers? YES, but no demand □
NO □
Please give reasons(s):
13 Do you provide a syringe/needle exchange scheme YES (go to 13a,b,c,d&e) □
at present? NO (go to 13f&g) □
a) If YES, please estimate the number of people who use the service (per week):______
b) If YES, what was your motivation for providing such a scheme___________________________
c) If YES, please list the types of drugs you suspect are being injected by the people using the 
syringe/needle exchange scheme_________________________________________________
d) If YES, are you and your staff vaccinated against Hepatitis B? YES □
NO □
e) If YES, have you and your staff had any formal training on the management YES □
of the syringe/needle exchange scheme? NO □
(Please go to Q. 14)
f) If NO please give reason(s) for not providing a syringe/needle exchange
Rachel Britton, Department o f Pharmacy and Pharmacology, University o f Bath
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g) If NO, what (if anything) would encourage you to provide a needle/ syringe exchange scheme?
14 Are you currently dispensing any drugs to any person who is YES □
being prescribed these drugs for dependence? NO □
If YES, which drugs do you dispense at present?________________________________________
15 Do you dispense methadone to any person being YES □
prescribed it for drug dependence? NO (no demand) □
NO (not willing to) □
If you have ticked NO (not willing to) please state reason(s):_______________________________
If you answered YES to question 15 please continue with part TWO. 
If you answered NO, please go to part THREE and then part FOUR.
Rachel Britton, Department o f Pharmacy and Pharmacology, University o f Bath
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Part TWO: Methadone Dispensing (Please look at this week’s prescriptions for methadone while 
completing this section)_____________________________________________________________
16 Is your pharmacy part o f a formal ‘shared care scheme’ for the YES □
treatment o f people dependent on drugs such as heroin? NO □
DON’T KNOW □
If YES, which organisation organises the shared care scheme?_____________________________
If YES, what support do you (as a Pharmacist) get from the organisers of the shared care scheme?
17 How many drug misusers do you currently dispense methadone
for in total? (Where currently is defined as the number of different people
for whom you have dispensed methadone in the past week.) ___
18 For this total number o f people, please indicate the dispensing interval and source o f 
prescription in the following table. I f  there is none in any category, please put nil:
DisDensing Interval Number of FP10 tad) 
forms (blue)
Number of HosDital/ 









19 How many o f those clients mentioned in question 17 would you describe
as regular clients? (where regular is defined as clients receiving their ________
prescription consistently from your pharmacy for one month or longer)
20 For any o f those that receive a dose daily, do you supervise YES (go to 20a and b)D
the consumption o f methadone on your pharmacy premises? NO (go to 20c and d) □
a) I f  YES for how many do you supervise the consumption o f methadone
on the premise at present? _______
b) Do you check they have swallowed the dose? YES □
NO (go to 21) □
If YES, how do you check that the dose has been swallowed?_______________________________
 (go to 21)
Rachel Britton, Department o f Pharmacy and Pharmacology, University o f Bath
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c) T/’NO, would you be prepared to supervise the consumption YES □
o f controlled drugs (CDs) for the treatment o f drug dependence? NO □
UNSURE □
If you answered NO or UNSURE above, please give reason(s):
d) What, i f  anything, would encourage you to supervise the consumption o f
methadone?
21 Have you ever had to stop dispensing methadone to a particular drug YES □
misuser for any reason? NO □
If YES, please give details:__________________________________________________________
22 Have you ever withheld a dose o f methadone from a client? YES □
NO □
If YES, please give details:
23 Do you supervise the consumption o f any other drugs used YES □
to treat dependence? NO □
If YES, please list which drug(s):
24 Do you have a private area in which to supervise consumption o f YES □
drugs used to treat dependence? NO □
If YES, do you always offer this to the drug users? YES □
NO □
If NO, has any drug misuser ever commented that they would like to be supervised YES □
in a private area? NO □
25 Have you ever contacted the prescriber about concerns over a particular YES □
drug user or their treatment? NO □
If YES, what type of concerns have you raised with the prescriber. Please describe.
Rachel Britton, Department o f Pharmacy and Pharmacology, University o f Bath
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26 Does your pharmacy have a written Standard Operating Procedure (SOP)
a) .. ..for the dispensing of CDs for the treatment of dependence? YES □
NO □
b) ... .for the supervision of consumption of CDs for the treatment of dependence? YES □
NO □
27 In general do you: (Please tick the appropriate box)
always sometimes never
a) lay down ground rules for a new person
with a prescription for methadone? □ □ □
b) have a written contract with drug misusers? □ □ □
c) ask drug misusers for identification on their first visit? □ □ □
d) ask for identification each time they collect a supply? □ □ □
e) make up prescriptions in advance? □ □ □
f) provide plastic measures with prescriptions which 
are taken away?
□ □ □
g) supply information leaflets concerning drug misuse 
to new drug misusing clients?
□ □ □
h) supply information leaflets concerning methadone 
to new clients who present a prescription for methadone?
□ □ □
i) supply information leaflets concerning HTV prevention 
to new drug misusing clients?
□ □ □
j) offer face to face advice on the management of drug misuse? □ □ □
k) offer face to face advice concerning methadone? □ □ □
1) offer face to face advice on HTV prevention? □ □ □
m) treat drug misusers the same as other customers? □ □ □
Ifvou supervise consumption o f CDs do vou: 
n) provide water after the dose is swallowed? □ □ □
o ) .... in a disposable cup? □ □ □
Please go to Part THREE
Rachel Britton, Department of Pharmacy and Pharmacology, University o f Bath
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Part THREE: Knowledge and Trainins
The aim of this section is to understand the level of knowledge and training that Community 
Pharmacists’ possess with regard to drug misuse and treatment. Please answer the questions 
without reference to texts. If  you do not know the answers, please tick ‘Unsure’.___________
28 Please tick true or false to the following statements:
a) 5mg of methadone could be fatal to an opioid naive adult. TD F D
b) Taking benzodiazepines with methadone will help with withdrawal. TD F D
c) lOmg of methadone could kill a child. TD F D
d) Opiate overdose may cause respiratory depression, coma and death. TD F D
How long (days) on average does a person’s 1 day D
tolerance methadone decrease to a point where 2 days D




> 30 seconds □
30 secs-lmin □
1 -2  mins □
Until tablet has dissolved □ 
Unsure □
A drug user arrives at your pharmacy Give out his methadone as
for his daily dose o f methadone usual D
showing obvious signs o f alcohol Refuse to dispense his
intoxication. What do you do? methadone
Tell him to come back
D
when sober 




32 People who misuse heroin may ask to buy citric acid Why is this?
33 Please list three signs o f opiate intoxication:
34 Please list three symptoms o f opiate withdrawal:
30 When supervising consumption o f
Subutex (buprenorphine) how long does it 
take for the fu ll dose to be absorbed 
from the mouth?
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Have you ever had any professional training on drug misuse? YES □
NO □
If YES please indicate type of training: undergraduate course □
(Please tick all that apply) Postgraduate training □
CPPE distance learning □
local branch meeting □
other
Would you like further professional training on drug misuse? YES □
NO □
If YES please indicate the format of the training
you think would be useful:






give details of the topics you think would be useful:
37 Have you ever had any professional training on the prevention YES □
o f blood borne diseases (e.g. HIV/ hepatitis)? NO □
If YES please indicate type of training: undergraduate course □
(Please tick all that apply) Postgraduate training □
CPPE distance learning □
local branch meeting □
other
38 Would you like training on prevention o f blood borne diseases? YES □
NO □
If YES please indicate the format of the training
you think would be useful:






Please go to Part FOUR
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Part FOUR: Please indicate your opinions on the following issues concerning drug misusers and 
the role o f the community pharmacist in managing drug misuse. Please answer even i f  you do 
not currently have any drug misusers visiting your pharmacy. (Note by ‘drug m isuser’we mean people  
who participate in drug misuse and who, in the pharmacy setting, are often referred to as ‘drug addicts ’).
39 I believe that prescribing maintenence1 
doses of a CD2 to a drug misuser will 
improve their quality of life.
(Please tick the appropriate box) 
strongly agree uncertain disagree strongly 
agree disagree
□ □ □ □ □
40 I believe that providing drug misusers
maintenance doses of CDs will stop them 
using street drugs
□ □ □ □ □
41 I believe drug misusers should only be 
prescribed CDs if it is in reducing doses 
to help them ‘come o ff drugs
□ □ □ □ □
42 I believe providing maintenance doses of 
CDs to drug misusers is a waste of NHS 
resources.
□ □ □ □ □
43 I believe that CDs should be dispensed to □ □ □ □ □
drug misusers through a central' clinic
rather than community pharmacies.
44 I believe that community pharmacists have □ □ □ □ □
a duty provide services to drug misusers
in order to protect the wider community from 
the consequences of drug misuse.
45 I believe that dispensing maintenance doses □ □ □ □ □
CDs to drug misusers is part of a
pharmacist’s professional duty.
46 I believe that my staff would rather not □ □ □ □ □
have to deal with drug misusers.
47 I believe that drug misusers visiting my □ □ □ □ □
pharmacy endanger the safety
of my staff.
48 I believe that drug misusers visiting my □ □ □ □ □
premises have a damaging effect
on business.
'Maintenence refers to the deliberate prescribing of products such as methadone in regular doses. The aim of this approach in the 
management of drug misuse is to reduce the associated risks.
Controlled Drug (Schedule 2 or 3, Misuse of Drugs Act, 1971)
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strongly agree uncertain disagree strongly 
agree disagree
49 I believe that drug misusers who visit □ □ □ □ □
my pharmacy are treated by us as ‘normal’ 
members of the public.
50 I believe it is a persons’ own fault 
if they become addicted to drugs.
□ □ □ □ □
51 I believe that syringes/ needles 
should only be supplied as part 
of a needle exchange scheme.
□ □ □ □ □
52 I believe that drug addiction is an 
illness not a vice.
□ □ □ □ □
53 I believe that all drug misusers □ □ □ □ □
should be encouraged to ‘come
o ff drugs altogether.
54 I believe that selling syringe/ □ □ □ □ □
needles encourages illicit drug
misuse.
55 I believe that drug misusers are □ □ □ □ □
taking some responsibility for
their health if they ask to buy 
syringes/needles.
56 I believe it is unethical to sell □ □ □ □ □
drug misusers’ needles or syringes
without having a means of disposing 
of them.
57 I believe the community pharmacy □ □ □ □ □
is an appropriate place for a
syringe/needle exchange scheme.
58 I believe that I would never supervise □ □ □ □ □
the consumption of doses of CDs by drug
misusers on my pharmacy premises.
59 I believe supervising consumption of CDs □ □ □ □ □
by drug misusers on the pharmacy premises.
is an inappropriate role for the community 
pharmacist.
60 I believe supervising the consumption of □ □ □ □ □
CDs by drug misusers prevents the illicit
selling of these CDs on the street.
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strongly agree uncertain disagree strongly
61 I believe that a drug misuser should 
have a private area in the pharmacy 
when (s)he is being supervised consuming 
a dose of a CD.
62 I believe that a drug misuser is embarrassed 
when they have to consume their dose of a 
CD in front of a member of staff, or whilst 
other customers are looking on.
63 I believe that a written contract between the 
pharmacist and drug misuser would help 
develop trust between the two individuals.
64 I believe it is appropriate for pharmacists to 
provide advice (verbal or written) to drug 
misusers on the management of drug misuse.
65 I believe that I have sufficient knowledge □ □ □ □ □
about drug misuse to be able to provide advice 
to drug misusers on the management of their 
drug use.
66 I believe that I would never provide advice □ □ □ □ □
(written or verbal) on safer injecting to 
intravenous drug misusers.
67 I believe that it is the responsibility of the □ □ □ □ □
pharmacist to provide information on CD’s 
used in the treatment of drug misuse to a drug 
misuser.
68 I believe it is ethical to sell □ □ □ □ □
drug misusers’ needles or syringes.
69 I believe that I am adequately supported □ □ □ □ □
by the local Primary Care Trust in 
providing services to drug misusers.
70 I believe that the reason services are □ □ □ □ □
provided for drug users is to improve 
the quality of life of that individual, 
rather than the community as a whole
Please check you have completed every question, 
and see over the page!
agree disagree
□ □ □ □ □
□ □ □ □ □
□ □ □ □ □
□ □ □ □ □
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WOULD YOU LIKE TO PARTICIPATE FURTHER?
The aim o f this study is to produce a model o f community pharmaceutical care for drug misusers. 
In order to achieve this, I  need to understand more about why pharmacists do, or do not provide 
services to drug misusers, and watch pharmacists and dispensary staff in action so that I  can 
understand a model o f care might look like.
Iam  also planning to interview drug misusers who use community pharmacies, so that I  can 
understand what is important to them about the service that they receive from pharmacies.
The next planned stage o f the research is to conduct one-to-one interviews, local focus groups 
(group discussions around topics from the questionnaire) and observational work with willing 
pharmacists.
The one-to-one interviews and observational work will be carried out within the pharmacy in 
which you work, at a time and date to suit you.
The focus groups will be carried out during the evening at a local venue, and should last 
around one and a half hours. Refreshments will be available on the night, and travel expenses 
will be paid.
All the data gathered from these studies will remain confidential.
Please indicate which study you would like to participate in...
1. One to One interview □
2. Focus Group □
3. Observational Study □
4. All the above □
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APPENDIX TWO
COMMUNITY PHARMACY SERVICES TO DRUG MISUSERS: A 
POSTAL QUESTIONNAIRE FOR COMMUNITY PHARMACISTS 
(Shortened Version)
ICommunity Pharmacy Services to Drug Misusers]
A Postal Questionnaire for Community Pharmacists
Instructions for Completion
• Please tick one box for each question unless otherwise specified.
• All answers will be treated with the strictest of confidence. When the 
questionnaire is completed, please return it in the enclosed pre-pay envelope.
1 Approximately how many individuals (excluding diabetics) have asked to 






YES,currently do □ 
YES, but no demand □ 
NO □
YES (go to 3a,b&c) □ 
NO (go to 4) □
a) If YES, please estimate the number of people who use the service (per week): _______
b) If YES, are you and your staff vaccinated against Hepatitis B? YES □
NO □
c) If YES, have you and your staff had any formal training on the management of the 
syringe/needle exchange scheme? YES □
NO □
4 Are you currently dispensing any drugs to any person who is
being prescribed these drugs for dependence? YES □
NO □
5 How many drug misusers do you currently dispense methadone
for in total? (Where currently is defined as the number of different people
for whom you have dispensed methadone in the past week.) _______
2 Are you prepared to sell needles or syringes 
to known or suspected drug addicts/misusers?
3 Do you provide a syringe/needle exchange scheme 
at present?
6 For this total number o f people, please indicate the dispensing interval and source o f  
prescription in the following table. I f  there is none in any category, please put nil:
Dispensing Interval Number of FP10 fad) 
forms (blue)
Number of Hospital/ 









1 How many o f those clients mentioned in question 5 would you describe
as regular clients? (where regular is defined as clients receiving their prescription 
consistently from your pharmacy for one month or longer) ______
8 For any o f those that receive a dose daily, do you supervise
the consumption o f methadone on your pharmacy premises? YES □
NO □
a) I f  YES for how many do you supervise the consumption o f methadone
on the premise at present?
9 Does your pharmacy have a written Standard Operating Procedure (SOP)
a ) .. ..for the dispensing of CDs for the treatment of dependence? YES □
NO □
b) .. ..for the supervision of consumption of CDs for the treatment
of dependence? YES □
NO □
10 Have you ever had any professional training on drug misuse? YES □
NO □
THANK YOU FOR COMPLETING MY QUESTIONNAIRE. 
PLEASE RETURN IT IN THE FREEPOST ENVELOPE.
Study Number:
APPENDIX THREE
LETTER OF ETHICAL APPROVAL FOR PHARMACIST INTERVIEWS
APPENDIX FOUR
SEMI-STRUCTURED INTERVIEW SCHEDULE (PHARMACISTS)
One to One Interview Schedule (Pharmacists)
> Thank you for agreeing to take part in this interview. In a moment I will start 
the tape. If at anytime you wish me to stop, just let me know. I ’m going to 
start the tape now, OK?
START TAPE
Role of the Pharmacist
> Firstly, I am going to ask you some questions about the role of community 
pharmacy in the treatment of drug misuse
1. What role do you think the pharmacist plays in the treatment of drug 
misuse?
2. How do your staff feel about providing services to drug misusers?
Service Provision
>  OK, now for some questions on the way that you provide services to drug 
misusers. Firstly, do you provide a supervised methadone service? (If YES, 
go to Q3, If NO, go to Q5)
3. Do you use contracts for supervised methadone? (If YES -  where did you 
get your contact from?)
4. Do you find them useful?
PROMPT -  in what way?
Why not?




6. What would encourage you to provide needle exchange?
7. What do you see as the potential risks in running needle exchange?
8. How could these risks be minimised?
9. What are you views on selling syringes to drug users?
Knowledge
> I would like to ask you some general questions about drug misuse services 
in England.... OK?
10. Do you think all addicts should attend ‘specialist centres’ for treatment? 
PROMPT - Why?
Why not?
11. What are the key benefits from you providing services to drug misusers?
12. Do you think that prescribing opiate substitutes to addicts is an appropriate 
way to treat opiate addiction?
PROMPT - Why?
Why not?
What do you think the answer is?
Problems and Positives
> My initial survey indicated that pharmacists and their staff sometimes come 
up against problems when providing drug misuse services. I ’d like to ask 
you about this....
13. What difficulties do you face in your day to day practice with regard to drug 
misusers?
PROMPT -  ' making up Rx’s in advance 
Inappropriate behaviour
14. How could you overcome these difficulties?
15. If these difficulties could be over come -  would you get more involved than 
you currently are?
16. Have you had any experiences which have put you off providing services to 
drug misusers?
17. Would you be willing to share these?
18. Reflecting on these experiences -  could anything be implemented or done 
differently to avoid this happening again?
19. What positive experiences have you had in your professional interaction 
with drug misusers?
20. Have these encouraged you?
Support
> Pharmacists who replied to my services had mixed views about the support 
that they received to provide drug misuse services. I ’d like to ask you about 
this....
21. What support do you receive (to provide services to drug misusers)? 
PROMPT - training?
Financial
22. Is this support helpful in your day to day practice?
PROMPT- If yes, how?
If not, why not?
23. What support would you find helpful?
Recognition




How can this be changed?
25. At present there is no specific ‘Model of Care’ for pharmacy services to drug 
misusers -  what do you think such a model should contain?
Thank you very much, that is the end of the interview, is there anything else 
that you would like to add?
STOP TAPE
APPENDIX FIVE
LETTER OF ETHICAL APPROVAL FOR SERVICE USER INTERVIEWS
APPENDIX SIX
SEMI-STRUCTURED INTERVIEW SCHEDULE (SERVICE USERS)
One to One Interview Topic Guide
> Thank you for agreeing to take part in this interview. In a moment I will start 
the tape. If at anytime you wish me to stop, just let me know. I’m going to 
start the tape now, OK?
START TAPE
Experience of Pharmacy Services
> Firstly, I am going to ask you some questions about your experiences of 
using a pharmacy.
1. What do you think about the services you get from the pharmacy?
PROMPT -  supervised methadone, needle exchange, advice from pharmacist
2. Would you like to see anything done differently? Why?
3. What do you think about drinking your methadone on the premises?
4. In general, what do you think about the way the pharmacy staff are with you?
5. Is there any other service that you would like from your pharmacy that you do 
not get now?
PROMPT -  minor illness advice, safer injecting
6. Have you had any past experiences of different pharmacies?
- have you noticed any changes over the time you have been in treatment?
- have you noticed differences in the pharmacists? In what way?
7. Why might someone miss a dose of methadone?
8. Why do you think a pharmacist might have to withhold a dose of methadone? 
(use vignette)
Model of Care
>  I have interviewed a number of pharmacists about how they provide 
services like supervised methadone and needle exchange. I would like to 
know what you think about some of the suggestions they made.
1. Some pharmacists told me that they would like more information about clients 
and their treatment so that they can give more support
- what information do you think a pharmacist should have?
- do you think pharmacists should tell the doctor if someone misses a dose?
2. Pharmacists have told me that prescriptions can be a headache for them -  
what do you know about the law around prescriptions and do you think 
anything could be changed?
3. Some clients are asked to sign contracts when they start on supervised 
consumption. What do you think about contracts? What should they contain?
4. Some pharmacists told me that they felt embarrassed for their clients when 
they are made to drink methadone on the premises.
- What do you think about this?
- Can it be made better?
PROMPT -  use of private areas, wait until shop is empty
5. Some pharmacists told me that they wanted more training around drugs and 
drug misuse -  what training do you think they need?
6. How do you rate the pharmacist in relation to other healthcare professionals 
(doctors, nurses, drugs worker)
7. In the future, some pharmacists will be able to prescribe drugs like methadone 
and Subutex. What do you think about this?
APPENDIX SEVEN
EN1: ENHANCED SERVICE SPECIFICATION - SUPERVISED 
ADMINISTRATION (CONSUMPTION OF MEDICATION)
NHS Community Pharmacy Contractual Framework
Enhanced Service -  Supervised Administration 
(Consumption of Prescribed Medicines)
1. Service description
1.1 This service will require the  pharm acist to supervise the  
consum ption of prescribed medicines a t  the  point of 
dispensing in the  pharm acy, ensuring th a t  the  dose has 
been adm inistered to the  patient.
1.2 Pharm acies will offer a user-friendly, non-judgm ental, client- 
centred  and confidential service.
1.3 The pharm acy will provide support and advice to the  patient, 
including referral to primary care or specialist cen tres  where 
appropria te .
1.4 Examples of medicines which m ay have consum ption 
supervised include m ethadone  and o ther  medicines used for 
the  m an ag em en t of opiate  dependence , and medicines used 
for the  m an ag em en t  of mental health conditions or 
tuberculosis.
2. Aims and intended service outcomes
2.1 To ensu re  compliance with the  agreed  t re a tm e n t  plan by:
♦ dispensing in specified instalments1 (doses may be dispensed for the 
patient to take away to cover days when the pharmacy is closed),
♦ ensuring each supervised dose is correctly consumed by the patient 
for whom it was intended.
2.2 To reduce the  risk to  local com m unities of:
♦ over u sage  or under u sage  of medicines;
♦ diversion of prescribed medicines onto the  illicit drugs 
m arket; and
♦ accidental exposure  to  the  supervised medicines.
2.3 To provide service users  with regular contact with health 
care  professionals and to help them  access further advice or 
assistance . The service use r  will be referred to specialist 
t re a tm e n t  cen tres  or o ther  health and social care 
professionals w here appropriate .
3. Service outline
3.1 The part of the  pharm acy used for provision of the  service
provides a sufficient level of privacy and safety  and m ee ts  
o ther  locally ag reed  criteria.
1 In th is Service  Specification  it is a ssu m ed  th at instalm ent d isp en sing  is provided for by th e  
provisions o f th e  D ispensing or R epeat D ispensing Essential S erv ices. If th is is not th e  c a se  for a 
particular m edicine which m ay be included in th e  serv ice , local arran gem ents will need  to  be  
d ev e lo p ed .
3.2 The pharm acy will p resen t the  medicine to the  service use r  
in a suitable receptacle  and will provide th e  service u se r  with 
w a ter  to  facilitate administration an d /o r  reduce th e  risk of 
doses  being held in the  m outh.
3.3 Term s of a g re em e n t  a re  se t  up betw een the  p resc r ib es  
pharm acist and patien t (a th ree-w ay  ag reem en t)  to ag ree  
how th e  service will opera te , w hat constitu tes acceptable  
behaviour by the  client, and w hat action will be taken  by the  
GP and pharm acist if the  u se r  does not comply with the  
ag reem en t.  A 'four-w ay ' ag reem en t  could also be developed 
which would include the  specialist centre.
3 .4 The pharm acy contractor has a duty to ensu re  th a t  
pharm acists  and staff involved in the  provision of the  service 
have relevant knowledge and a re  appropriately trained  in 
the  operation of the  service.
3.5 The pharm acy contractor has a duty to ensu re  th a t  
pharm acists  and staff involved in the  provision of the  service 
a re  aw are  of and op e ra te  within local protocols.
3.6  The pharm acy should maintain appropria te  records to 
ensu re  effective ongoing service delivery and audit.
3.7 Pharm acists will sha re  re levant information with o ther  health 
care  professionals and agencies, in line with locally 
determ ined confidentiality a rrangem en ts .
3.8 The PCO should a rrang e  a t  least one contractor m eeting per 
year  to prom ote service developm ent and upda te  the  
knowledge of pharm acy staff.
3.9 The PCO will need to  provide a fram ework for the  recording 
of relevant service information for th e  purposes of audit and 
th e  claiming of paym ent.
3 .10 The PCO will need to provide details of relevant referral 
points which pharm acy staff can use  to signpost service 
users  who require fu rther  assistance .
3.11 The PCO should consider obtaining or producing health 
promotion material re levant to the  service users and making 
this available to pharm acies.
4. Suggested Quality Indicators
4.1 The pharm acy has appropria te  PCO provided health 
promotion material available for th e  u se r  group and 
prom otes its uptake.
4 .2  The pharm acy reviews its s tandard  operating procedures 
and th e  referral pa thw ays for the  service on an annual basis.
4 .3  The pharm acy can d e m o n s tra te  th a t  pharm acists  and staff 
involved in the  provision of th e  service have undertaken  CPD 
relevant to this service.
4 .4  The pharm acy participates in an annual PCO organised audit 
of service provision.
4 .5  The pharm acy co-opera tes  with any locally agreed  PCO-led 
a s se s sm e n t  of service use r  experience.
Background information -  not part of the service specification
Current guidelines2 recom m end ail new tre a tm e n t  of opiate 
dependence  be sub ject to supervised consum ption for the  first th ree  
m onths or a period considered appropria te  by th e  prescriber. The 
rationale for this recom m endation is to provide routine and 
s truc tu re  for th e  client, helping to prom ote a move away from 
chaotic and risky behaviour.
Supervision of the  consum ption of medicines used in the  t rea tm e n t  
of people with mental illness can in a similar way help to reduce 
chaotic and risky behaviour. Regular contact with the  pharm acist 
and pharm acy staff can help to reduce the  social isolation felt by 
m any people with mental illness. Pharm acists and their staff are  
well placed to spo t the  deterioration of a person 's  mental s ta te  and 
alert o ther  m em bers  of th e  health care team  to  the  person 's  need 
for fu rther support if appropriate .
Tuberculosis is becoming an increasing problem in m any parts  of 
th e  country, especially am ong socially d isadvantaged groups such 
a s  the  hom eless. The effective t re a tm e n t  of tuberculosis and the  
prevention of acquired drug resistance relies on full compliance with 
medication t re a tm e n t  regim ens. 'Directly Observed Therapy 
Schem es ' (DOTS) have been used in m any countries to improve 
compliance. A comparison of self t re a tm e n t  versus various forms of 
DOT has shown th a t  completion of t re a tm e n t  is significantly higher 
when the  t re a tm e n t  is superv ised .3
An exam ple  c laim /audit form and 'th ree -w ay ' ag reem en t form are  
provided with this service specification which could be adopted 
locally by PCOs.
Background information for Drug Action Team  (DAT) 
comm issioners:
Service Specification Tier (2 or 3), Pharmaceutical Services for Drug 
Users, National T rea tm en t Agency for Substance  Misuse, 2005, 
w w w .nta.nhs.uk
2 'Drug m isu se  and d ep en d en ce: gu id elin es on clinical m an agem en t' D epartm ent o f Health (1 9 9 9 )
3 Chaulk CP, Kazandjian VA. Directly observed  therapy for trea tm en t com pletion  o f pulm onary  
tuberculosis: c o n se n su s sta te m en t o f th e  Public Health Tuberculosis G uidelines Panel. JAMA 1998;  
2 7 9 : 9 4 3 -9 4 8
CPPE training which may support this service:
Opiate t rea tm en t:  Supporting pharm acists  for improved patien t care  
open learning
Public Health -  drug users , harm  reduction workshop 
Mental health workshop series
APPENDIX EIGHT
EN2: ENHANCED SERVICE SPECIFICATION -  NEEDLE AND SYRINGE 
EXCHANGE
NHS Community Pharmacy Contractual Framework 
Enhanced Service -  Needle & Syringe Exchange
1. Service description
1.1 Pharm acies will provide access  to  sterile needles and 
syringes, and sha rps  containers for return of used 
equipm ent. W here agreed  locally, associated  m aterials , for 
exam ple  condom s, citric acid and sw abs, to prom ote  safe 
injecting practice and reduce transm ission of infections by 
subs tance  m isusers  will be provided.
1.2 Pharm acies will offer a user-friendly, non-judgm ental, client- 
centred and confidential service.
1.3 Used equ ipm en t is normally returned by the  service u se r  for 
safe disposal.
1.4 The service u se r  will be provided with appropria te  health 
promotion materials.
1.5 The pharm acy will provide support and advice to th e  user, 
including referral to o th e r  health and social care  
professionals and specialist drug and alcohol t re a tm e n t  
services w here  appropria te .
1.6 The pharm acy will prom ote safe practice to the  user,
including advice on sexual health and STIs, HIV and 
Hepatitis C transm ission  and Hepatitis B immunisation.
2. Aims and intended service outcomes
2.1 To ass is t  th e  service users  to  remain healthy until they  a re
ready and willing to cease  injecting and ultimately achieve a 
drug-free  life with appropria te  support
2.2 To protect health and reduce the  ra te  of blood-borne 
infections and drug related dea th s  am ong service, users:
♦ by reducing the  ra te  of sharing and o th er  high risk 
injecting behaviours;
♦ by providing sterile injecting equipm ent and o ther  
support;
♦ by promoting safer injecting practices; and
♦ by providing and reinforcing harm  reduction m essag es  
including safe  sex  advice and advice on overdose  
prevention (e.g . risks of poly-drug use and alcohol use).
2.3 To improve th e  health of local comm unities by preventing
th e  sp read  of blood-borne infections by ensuring th e  safe 
disposal of used injecting equipm ent.
2 .4  To help service users  access  t rea tm e n t  by offering referral
to  specialist drug and alcohol t re a tm e n t  cen tres  and health 
and social care  professionals where appropriate .
2.5 To aim to maximise the  access and retention of all injectors, 
especially the  highly socially excluded.
2 .6  To help service u sers  access o ther  health and social care 
and to  ac t a s  a ga tew ay  to o ther  services (e.g. key working, 
prescribing, hepatitis B immunisation, hepatitis and HIV 
screening, primary care services etc).
3. Service outline
3.1 The part of the  pharm acy used for provision of the  service 
provides a sufficient level of privacy and safety  and m ee ts  
o ther  locally ag reed  criteria.
3 .2 The pharm acy contractor has a duty to ensu re  th a t
pharm acists  and staff involved in th e  provision of the  service
have relevant knowledge and a re  appropriately trained in 
the  operation of th e  service.
3.3 The pharm acy contractor has a duty to ensu re  th a t
pharm acists  and staff involved in the  provision of the  service
are  aw are  of and o pe ra te  within local protocols.
3 .4  The pharm acy will allocate a safe place to s to re  equipm ent 
and re tu rns for safe onward disposal. The s to rage  containers 
provided by the  PCO commissioned clinical w aste  disposal 
service will be used to s to re  returned  used equipm ent.
3 .5 The pharm acy contractor should ensu re  th a t  their  staff a re  
m ade  aw are  of th e  risk associated  with the  handling of 
re turned  used equ ipm ent and the  correct procedures used to 
minimise those  risks. A needle stick injury procedure should 
be in place.
3 .6  The pharm acy should maintain appropria te  records to 
ensure  effective ongoing service delivery and audit.
3 .7  Appropriate protective equipm ent, including gloves, overalls 
and m aterials to deal with spillages, should be readily 
available close to th e  s to rage  site.
3 .8  The pharm acy should clearly display the  national schem e 
logo or a local logo indicating participation in th e  service.
3.9 Staff involved in th e  delivery of this service should be 
offered immunisation for Hepatitis B.
3 .10  Pharm acists will sha re  relevant information with o ther  health 
care  professionals and agencies, in line with locally 
determ ined confidentiality a rrangem en ts .
3.11 The PCO should a rrange  a t  least one contractor m eeting per 
y ear  to prom ote service developm ent and update  the  
knowledge of pharm acy staff.
3 .12  The PCO will provide th e  exchange packs and associated 
m aterials and will commission a clinical w aste  disposal 
service for each participating pharm acy. The frequency of 
w aste  collection should be agreed  to ensu re  the re  is not an
unacceptable  build up of clinical w aste  on th e  pharm acy 
prem ises.
3.13 The PCO will need to provide a fram ework for th e  recording 
of re levant service information for th e  purposes of audit and 
the  claiming of paym ent.
3 .14  The PCO will need to provide details of relevant referral 
points which pharm acy staff can use  to signpost service 
users  who require fu rther assistance .
3 .15 The PCO should consider obtaining or producing health 
promotion material relevant to the  service users  and making 
this available to  pharm acies.
4. Suggested Quality Indicators
4.1 The pharm acy has appropria te  PCO provided health
promotion material available for the  use r  group and 
prom otes its uptake.
4 .2  The pharm acy reviews its s tandard  operating procedures
and the  referral pa thw ays for the  service on an annual basis.
4.3  The pharm acy can dem o n s tra te  th a t  pharm acists  and staff
involved in th e  provision of the  service have undertaken  CPD 
relevant to this service.
4 .4  The pharm acy can d em o ns tra te  th a t  the  ra te  of return of
used equipm ent m ee ts  locally ag reed  ta rge ts .
4 .5  The pharm acy participates in an annual PCO organised audit
of service provision.
4 .6  The pharm acy co -opera tes  with any locally agreed  PCO-led
a sse ssm e n t  of service use r  experience.
Background information -  not part of the service specification
The National Treatment Agency for Substance Misuse service specification for 
Needle Exchange and Harm Reduction sets out a series of objectives for needle 
exchange services generally, these apply to services commissioned from 
community pharmacy and are reflected within the service specification:
• To offer user-friendly, non-judgmental, client-centred and confidential 
services;
• To ass is t  the  service u sers  to  rem ain healthy until they  are  
ready and willing to cease  injecting and ultimately achieve a 
drug-free  life with appropria te  support;
• To reduce th e  ra te  of sharing and o ther  high risk injecting 
behaviours by providing sterile injecting equ ipm ent and o ther  
support;
• To reduce th e  ra te  of blood-borne infections am ong drug 
users;
• To reduce drug-rela ted  d ea th s  (Im mediate dea th  through 
overdose and long-term  such a s  blood borne infections);
• To prom ote safer injecting practices;
• To provide focused harm  reduction advice and initiatives, 
including advice on overdose  prevention (e.g. risks of poly­
drug use  and alcohol use);
• To provide and reinforce harm  reduction m essages;
• To help service users  access  drug t re a tm e n t  to refer to o ther  
specialist drug (and alcohol) t re a tm e n t  services;
• To help service users  access  o ther  health and social care and 
to act a s  a ga tew ay  to  o th er  services (e.g. key working, 
prescribing, hepatitis B immunisation, hepatitis and HIV 
screening, primary care  services etc);
• To facilitate access to  primary care w here relevant;
• To ensu re  the  safe disposal of used injecting equipm ent;
• To prevent initiation into injecting and to encourage  
a lternatives to injecting;
• To aim to maximise the  access and retention of all injectors, 
especially the  highly socially excluded, through the  low- 
threshold  nature  of service delivery and interventions 
provided; and
• To improve the  health of local com m unities by preventing the  
spread  of blood-borne viruses and by reducing the  ra te  of 
discarded used injecting equipm ent.
There is good evidence th a t  com m unity pharm acy based  needle 
exchange  services can com plem ent and support o th er  needle 
exchange and harm  minimisation initiatives commissioned by drug 
t re a tm e n t  agencies.
Background information for Drug Action Team  (DAT) 
com m issioners:
Service Specification Tier (2 or 3), Pharmaceutical Services for Drug 
Users, National T rea tm en t Agency for Substance  Misuse, 2005, 
w w w .nta.nhs.uk
National schem e 
logo:
CPPE training which may support this service:
Opiate trea tm en t:  Supporting pharm acists  for improved patien t care  
open learning
Public Health -  drug users, harm  reduction workshop
APPENDIX NINE
ABSTRACTS OF POSTER PRESENTATIONS
1. INTERATIONAL CONFERENCE ON THE REDUCTION OF DRUG
RELATED HARM. BELFAST, 2005.
Levels of Pharmacy Based Needle Exchange (PBNX) in South West England -  
cause for concern?
Background and Objectives
In 1995, Sheridan et at (1996) surveyed a sample of community pharmacies in 
England and Wales. They reported that 18.9% of pharmacies who responded 
participated in a needle exchange scheme. This study aims to quantify current levels 
of needle exchange in community pharmacies in the South West of England.
Design
A self completion postal questionnaire was sent to all community pharmacies in the 
strategic health authority areas of Avon, Gloucestershire and Wiltshire; Dorset and 
Somerset; and South West Peninsula (n=903). Descriptive data were collected on 
demography and drug misuse services provided.
Results
A response rate of 77.9% was achieved. Ninety-seven pharmacies (17.9%) who 
replied to the questionnaire provided PBNX to an average of 22.1 clients per week. 
The most common reason given for providing the service was ‘harm reduction’. 
52.3% of pharmacies currently sold or were willing to sell needles and syringes to 
drug misusers, but only 161 drug misusers had asked to buy needles and syringes in 
the week prior to the questionnaire being filled out.
Conclusion
It is concerning that levels of PBNX appear to have remained static since the last 
survey of community pharmacists was carried out and few drug misusers seem 
willing to buy injecting equipment from pharmacies. The availability of a 
community pharmacy on ‘every high street’ makes them valuable resource in the 
fight against blood borne diseases. Further work is required to understand how 
pharmacists can be encouraged to provide needle exchange services.
2. HEALTH SERVICES RESEARCH AND PHARMACY PRACTICE 
CONFERENCE. BATH, 2006
Facilitators and Barriers to a Community Pharmacy Model of Care for the 
provision of services to drug misusers -  a qualitative study.
Britton. R.M. and Scott. J.
Clinical Pharmacy and Pharmacy Practice Group, Department of Pharmacy and 
Pharmacology, University of Bath, BATH, BA2 7AY, UK. (prprmw@bath.ac.uk)
Introduction
In 2002, the National Treatment Agency for Substance Misuse (NTA) published its 
‘Models of Care’ document which described the range of services that should be 
available in every drug action team (DAT) area in England. The Models of Care 
document advocates primary care based treatment services for drug misusers and 
mentions community pharmacy based services such as needle exchange and 
supervised methadone consumption but does not discuss the standards by which 
these services should be provided. This research aims to inform a community 
pharmacy ‘Model of Care’ and is part of a larger project employing both 
quantitative and qualitative methods. The study reported here was preceded by a 
large postal questionnaire which was sent to 903 community pharmacies in the 
South West of England. On the basis of the questionnaire findings, qualitative 
interviews were then undertaken to further explore the key factors identified in the 
questionnaire. In order to propose a new ‘Model of Care’ it is important to 
understand what would facilitate the models use and what may inhibit community 
pharmacists from using it.
Method
This was a semi-structured interview study that was designed to understand the 
experiences of community pharmacists who provide drug misuse services. Approval 
was gained from the Central and South Bristol Research Ethics Committee before 
commencement of the study. Community pharmacists were recmited as a result of 
their indication of willingness to participate in further research in their replies to the 
preceding postal questionnaire. Thirty one interviews were carried out between 
September 2004 and January 2005. All were transcribed verbatim and read. The 
first 20 transcripts were included in the final analysis as no new themes or points for 
discussion was found in the remaining transcripts. Analysis was carried out using 
the software program ‘NVivo’ and themes were generated using Interpretative 
Phenominological Analysis (IPA).
Results
Nine major themes were identified from the analysis of the interview transcripts. 
One of these themes was named ‘Perceived facilitators and barriers to a Pharmacy 
Model of Care’ and this abstract focuses on this theme. Participants felt that 
training, teamwork and the new pharmacy contract would help facilitate a Model of 
Care whilst identifying that the attitude of pharmacists and their staff towards drug 
misusers, the perceived effect of drug misusers on the pharmacy business, a lack of 
training and wider understanding of drug misuse, a lack of understanding of the 
pharmacists’ role in caring for drug misusers by other healthcare professionals and a 
lack of two-way information sharing between prescriber/ key worker and
pharmacists were potential barriers to the successful implementation of a Model of 
Care.
Conclusion
This qualitative study has provided some important considerations for the proposal 
and implementation of a Model of Care for community pharmacy services to drug 
misusers. One important facilitator is training, as a lack of training was also 
identified as a potential barrier. The Model of Care should therefore contain a list of 
training needs for pharmacists who provide drug misuse services. The other barriers 
must be considered and ways of limiting their impact on the implementation of the 
Model of Care will be considered in future work.
APPENDIX TEN
ABSTRACTS FOR CONFERENCE PRESENTATIONS
1. NATIONAL DRUG TREATMENT CONFERENCE. LONDON, 2005.
-Working with drug users : dangers, myths and reality & Supervised 
consumption with dignity: an impossibility?'
Community pharmacies are becoming increasingly involved in dispensing 
methadone for the treatment of heroin addiction. In addition, current guidelines 
suggest that in the early stages of treatment (3-6 months) a methadone prescription 
should be dispensed daily, with a requirement that the client be supervised taking 
their medication. Therefore, the community pharmacist may often be the healthcare 
professional who is most regular contact with an individual on a methadone script 
and in some cases may be the only healthcare professional that an individual not 
receiving treatment sees, (via needle syringe exchange schemes)
Working with drug misusers can be challenging; the extra workload required to 
dispense sometimes fairly large quantities of Controlled Drugs, the storage 
arrangements for needle exchange packs and having a confidential area for 
supervised consumption as well as dealing with and trying to understand the 
problems that drug users face.
Some drug users shoplift and others are abusive and threatening, whilst other drug 
users write letters of thanks for your help at Christmas and name their new-bom 
baby after you. Working with drug users can be very frustrating but at times 
immensely rewarding.
Whatever your view of providing services to drug users -  one thing is clear, and 
that is that as a profession we must ensure that our practice in this area is of a high 
standard with the needs of the client paramount.
In this meeting we will discuss and debate how best we can provide pharmaceutical 
services to drug users as well as hearing about the reality of working these clients in 
a community setting.
2. NATIONAL DRUG TREATMENT CONFERENCE. GLASGOW, 2006
Drug Treatment and the Role of the Pharmacist
Pharmacists play an important part in the care of drug misusers, be it by providing 
needle exchange services or by dispensing and supervising consumption of 
methadone or other substitute treatments.
In their updated guidance on the use of methadone for the treatment of opioid 
dependence in primary care, the Royal College of General Practitioners stresses the 
importance of the multidisciplinary team, with the pharmacist included in this team. 
They state, ‘Pharmacists are key individuals in the success o f methadone treatment. 
They will see the patient much more often than the prescriber and can provide 
additional important support. Close liaison with pharmacists should be 
maintained. ’
It follows, therefore, that in order to operate a successful treatment program, there 
must be clear lines of communication between pharmacist, prescriber and other 
relevant health and social care professionals, as well structured support mechanisms 
for pharmacists involved in providing substance misuse treatment.
This parallel session will review research on pharmacists’ (based in the South West 
of England) experiences of support services and communication with prescribers. 
The recommendations contained in the Scottish Executive document “Prevention 
and Treatment of Substance Misuse. Delivering the Right Medicine: A Strategy for 
Pharmaceutical Care in Scotland” will be outlined with specific examples drawn 
from developments in Addiction Services in Glasgow. Finally, the role of the 
Scottish specialist pharmacist in substance misuse will be discussed.
APPENDIX ELEVEN
BIOGRAPHICAL DETAILS OF INTERVIEWEES
Pharmacist Interviewees
Pseudonym Age Years on 
Register
Location StHA area
Harry 42 20 Small Town DS
Nigel 38 17 Urban AGW
Ellie 30 8 City Centre AGW
Simon 48 26 Urban AGW
Adam 26 4 Small Town AGW
Greg 57 36 Small Town SWP
Donald 54 33 Small Town DS
Wilma 47 16 Village AGW
Alf 33 12 Village AGW
Rachel 52 30 Urban AGW
Kath 50 28 Urban DS
Carmel 50 27 Urban AGW
Lottie 29 8 City Centre AGW
George 47 24 Small Town AGW
Jackie 26 5 City Centre SWP
Sandra 44 20 Rural DS
Mike 36 10 Rural DS
Paul 50 29 Small Town DS
Maxwell 48 25 Urban SWP
Brad 36 15 Small Town DS
Vicky 49 25 Village SWP
Ken 51 30 Small Town AGW
Jack 30 8 Village SWP
Norman 29 5 Urban SWP
Harriet 39 15 Urban SWP
Grant 32 7 Urban SWP
David 31 9 Small Town SWP
Nick 62 39 Small Town DS
Malcolm 48 25 Small Town DS
Greg 53 30 City Centre SWP
Service User Interviewees




Sarah 24 3 Small Town AGW
Cheryl 34 12 City Centre SWP
Adam 43 15 Urban AGW
Kate 39 10 ' City Centre SWP
Michelle 40 1 Suburban DS
Marcus 29 6 Suburban DS
John 38 7 Small Town DS
Emily 21 3 Urban AGW
Patrick 52 >20 Urban AGW
Pamela 32 11 Suburban DS
Michael 27 4 Small Town AGW
Alex 40 8 Urban AGW
Natalie 18 <1 Urban AGW
Helen 16 <1 City Centre SWP
Sam 29 7 Small Town DS
* AGW -  Avon, Gloucestershire and Wiltshire,!DS -  Dorset and Somerset,
SWP -  South West Peninsula Strategic Health Authority (StHA)
